_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
503384125,7/15/2014 23:12:49,,1323898103,7/15/2014 23:12:39,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],observed between,N/A,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/15/2014 23:14:47,,1323899243,7/15/2014 23:14:33,instagc,1,28301350,GBR,O4,Torquay,89.241.101.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],between,N/A,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/15/2014 23:17:30,,1323900655,7/15/2014 23:16:49,clixsense,1,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],observed,N/A,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/15/2014 23:24:50,,1323904903,7/15/2014 23:24:02,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],TUBERCULIN,N/A,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/16/2014 00:16:17,,1323934163,7/16/2014 00:15:12,neodev,1,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],observed between,n/a,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/16/2014 00:25:51,,1323939004,7/16/2014 00:25:10,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was similarly observed between,[DIAGNOSE_BY_TEST_OR_DRUG],6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/16/2014 00:33:46,,1323942890,7/16/2014 00:32:46,sendearnings,1,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],similarly observed,n/a,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/16/2014 00:39:49,,1323945748,7/16/2014 00:38:05,elite,1,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and ......,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/16/2014 00:40:08,,1323945897,7/16/2014 00:39:03,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,[PREVENTS],[PREVENTS],low risk differential similarly observed,N/A,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/16/2014 01:13:03,,1323964526,7/16/2014 01:12:52,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PART_OF],[PART_OF],TUBERCULOSIS TUBERCULIN NEGATIVE,N/A,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/16/2014 01:20:46,,1323969232,7/16/2014 01:19:46,instagc,1,28519532,USA,IA,Honey Creek,12.73.110.160,[OTHER],[OTHER],NEGATIVE,n/a,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/16/2014 02:20:03,,1323997242,7/16/2014 02:19:43,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],differential,Na,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/16/2014 02:52:40,,1324008607,7/16/2014 02:51:54,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[SYMPTOM] [IS_A] [OTHER],"[SYMPTOM]
[IS_A]
[OTHER]",TUBERCULOSIS was observed TUBERCULIN NEGATIVE,N/A,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/16/2014 03:33:46,,1324022551,7/16/2014 03:33:07,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULOSIS TUBERCULIN NEGATIVE,n/a,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384125,7/16/2014 03:44:36,,1324027436,7/16/2014 03:44:03,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULOSIS TUBERCULIN NEGATIVE,n/a,6,68,17,87,1,RO-may_diagnose,906819-FS1,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
503384126,7/15/2014 23:11:00,,1323897205,7/15/2014 23:10:46,elite,1,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES],[CAUSES],TRICHURIASIS caused by TRICHURIS TRICHIURA,N/A,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/15/2014 23:16:37,,1323900080,7/15/2014 23:14:41,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],caused,N/A,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/15/2014 23:20:38,,1323902525,7/15/2014 23:20:17,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",Treatment caused by,N/A,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/15/2014 23:24:57,,1323904951,7/15/2014 23:24:49,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],caused by,N/A,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/15/2014 23:25:08,,1323905050,7/15/2014 23:24:51,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],caused by,N/A,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/15/2014 23:26:01,,1323905532,7/15/2014 23:25:39,instagc,1,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],caused by,N/A,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/15/2014 23:35:32,,1323910475,7/15/2014 23:33:12,clixsense,1,15189335,GBR,H9,London,188.29.165.200,[CAUSES],[CAUSES],caused by,Na,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/16/2014 00:39:41,,1323945703,7/16/2014 00:38:07,prodege,1,15287417,CAN,ON,Maple,99.248.137.57,[CAUSES],[CAUSES],caused by,N/A,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/16/2014 01:36:05,,1323976902,7/16/2014 01:35:32,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[CAUSES],[CAUSES],caused by,na,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/16/2014 02:21:53,,1323997948,7/16/2014 02:21:35,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[PART_OF],[PART_OF],(whipworm.,Na,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/16/2014 02:32:20,,1324002181,7/16/2014 02:31:51,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES],[CAUSES],caused,n/a,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/16/2014 03:37:08,,1324023966,7/16/2014 03:36:21,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TRICHURIASIS TRICHURIS TRICHIURA,n/a,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/16/2014 05:24:34,,1324066060,7/16/2014 05:24:12,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],caused by,N/A,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/16/2014 05:34:19,,1324068699,7/16/2014 05:33:39,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[CAUSES],[CAUSES],caused by,N/A,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384126,7/16/2014 06:05:36,,1324077893,7/16/2014 06:05:15,neodev,1,14861092,GBR,H9,London,90.194.156.173,[CAUSES],[CAUSES],caused by,N/A,61,30,79,42,1,RO-has_causative_agent,903707-FS1,9  Trichuriasis  Treatment of TRICHURIASIS   +    caused by  TRICHURIS TRICHIURA  (whipworm.,TRICHURIS TRICHIURA,TRICHURIASIS
503384127,7/15/2014 23:12:26,,1323897947,7/15/2014 23:11:42,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",treated with,N/A,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/15/2014 23:25:17,,1323905146,7/15/2014 23:24:52,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/15/2014 23:26:00,,1323905529,7/15/2014 23:25:29,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],patients treated,N/A,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/15/2014 23:39:02,,1323912336,7/15/2014 23:38:12,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[LOCATION],[LOCATION],in,N/A,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/15/2014 23:58:54,,1323922584,7/15/2014 23:58:08,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[SYMPTOM],[SYMPTOM],previously treated with,Na,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/16/2014 00:00:17,,1323923294,7/16/2014 00:00:04,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],Anderson et,asd,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/16/2014 01:00:31,,1323956979,7/16/2014 00:59:42,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",HUMAN INSULIN] in IDDM and NIDDM patients,N/A,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/16/2014 01:16:23,,1323966511,7/16/2014 01:16:11,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/16/2014 05:39:34,,1324070134,7/16/2014 05:37:01,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],patients previously treated with,N/A,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/16/2014 07:06:15,,1324098587,7/16/2014 07:05:41,instagc,1,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],Immunologic effects of PRO (B29 HUMAN INSULIN] in IDDM patients,N/a,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/16/2014 07:32:39,,1324107742,7/16/2014 07:31:45,prodege,1,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],effects of,N/A,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/16/2014 08:04:22,,1324116823,7/16/2014 08:03:59,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],treated,N/A,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/16/2014 09:14:26,,1324137121,7/16/2014 09:14:15,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/16/2014 10:22:40,,1324182008,7/16/2014 10:21:54,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[TREATS],[TREATS],treated,n/a,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384127,7/16/2014 10:50:27,,1324194452,7/16/2014 10:49:43,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],and,N/A,123,95,126,118,1,RO-may_treat,907870-FS1,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
503384128,7/15/2014 23:15:03,,1323899391,7/15/2014 23:14:49,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[TREATS],[TREATS],treatment,N/A,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/15/2014 23:19:44,,1323902037,7/15/2014 23:19:37,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],determined,n/a,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/15/2014 23:22:25,,1323903389,7/15/2014 23:22:15,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],treatment with,N/A,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/15/2014 23:29:07,,1323907115,7/15/2014 23:28:56,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/15/2014 23:29:35,,1323907395,7/15/2014 23:29:22,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],treatment with,N/A,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/15/2014 23:59:40,,1323922952,7/15/2014 23:57:22,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],PYRIDOXINE DEPENDENT SEIZURES,asd,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/16/2014 00:23:25,,1323937863,7/16/2014 00:22:26,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",was determined before treatment with,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/16/2014 00:51:14,,1323951267,7/16/2014 00:51:02,tremorgames,1,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],treatment,N/A,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/16/2014 00:52:51,,1323952194,7/16/2014 00:52:15,clixsense,1,21917173,CAN,"","",24.71.41.51,[CAUSES],[CAUSES],PYRIDOXINE DEPENDENT SEIZURES,n/a,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/16/2014 01:02:03,,1323957833,7/16/2014 01:01:08,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],PYRIDOXINE DEPENDENT SEIZURES CSF GABA treatment with PYRIDOXINE,N/A,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/16/2014 04:07:20,,1324038520,7/16/2014 04:06:28,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[TREATS],[TREATS],PYRIDOXINE DEPENDENT SEIZURES CSF GABA PYRIDOXINE,n/a,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/16/2014 04:16:41,,1324043082,7/16/2014 04:16:06,clixsense,1,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],determined before treatment,N/A,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/16/2014 05:25:32,,1324066366,7/16/2014 05:25:07,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],was determined before treatment with,N/A,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/16/2014 07:56:28,,1324113998,7/16/2014 07:56:12,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,[TREATS],[TREATS],treatment with,n/a,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384128,7/16/2014 07:59:10,,1324114869,7/16/2014 07:58:58,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],treatment,N/A,26,26,54,36,1,RO-may_treat,908322-FS1,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
503384129,7/15/2014 23:10:33,,1323896958,7/15/2014 23:09:37,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],is the treatment,N/A,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/15/2014 23:45:38,,1323915555,7/15/2014 23:45:21,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],is the drug of choice for the treatment of,n/a,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/15/2014 23:47:41,,1323916721,7/15/2014 23:46:38,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],the,asd,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/15/2014 23:48:08,,1323916888,7/15/2014 23:47:41,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],for the treatment of,N/A,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/16/2014 00:12:28,,1323931417,7/16/2014 00:12:11,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],drug of choice for the treatment,n/a,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/16/2014 00:14:57,,1323933119,7/16/2014 00:14:20,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],ALL TRANS RETINOIC ACID (ATRA) drug choice treatment ACUTE PROMYELOCYTIC LEUKEMIA (APL),Treats,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/16/2014 00:33:11,,1323942634,7/16/2014 00:32:55,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[TREATS],[TREATS],is the drug of choice for the treatment of,N/A,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/16/2014 01:12:34,,1323964279,7/16/2014 01:12:23,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],treatment,N/A,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/16/2014 02:01:43,,1323987648,7/16/2014 02:01:24,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],treatment,none,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/16/2014 04:03:54,,1324036590,7/16/2014 04:03:21,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[TREATS],[TREATS],ALL TRANS RETINOIC ACID (ATRA) ACUTE PROMYELOCYTIC LEUKEMIA (APL),n/a,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/16/2014 04:44:00,,1324050853,7/16/2014 04:43:35,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[TREATS],[TREATS],ALL TRANS RETINOIC ACID drug choice treatment ACUTE PROMYELOCYTIC LEUKEMIA,N/A,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/16/2014 05:11:12,,1324061783,7/16/2014 05:10:47,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],treatment of,N/A,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/16/2014 05:43:36,,1324071209,7/16/2014 05:42:48,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],drug of choice for the treatment of,N/A,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/16/2014 07:33:59,,1324108145,7/16/2014 07:33:28,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],the drug of choice,N/A,74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384129,7/16/2014 08:17:45,,1324120812,7/16/2014 08:17:09,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[TREATS],[TREATS],is the drug of choice for the treatment,is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),74,0,107,30,1,RO-may_treat,908323-FS1,ALL TRANS RETINOIC ACID (ATRA) is the drug of choice for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA (APL),ACUTE PROMYELOCYTIC LEUKEMIA (APL),ALL TRANS RETINOIC ACID (ATRA)
503384130,7/15/2014 23:10:19,,1323896850,7/15/2014 23:10:10,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],safe,N/A,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/15/2014 23:19:04,,1323901667,7/15/2014 23:18:59,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],conventional,n/a,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/15/2014 23:22:59,,1323903733,7/15/2014 23:22:48,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],therapy with,N/A,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/15/2014 23:26:23,,1323905724,7/15/2014 23:26:02,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],conventional therapy,N/A,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/16/2014 00:24:34,,1323938408,7/16/2014 00:24:02,prodege,1,9636318,USA,HI,Wailuku,72.234.78.171,[TREATS],[TREATS],indicating the importance of overnight gastric acidity in the pathogenesis of,n/a,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/16/2014 00:27:30,,1323939775,7/16/2014 00:26:42,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],indicating the importance of overnight gastric acidity in the pathogenesis of,[DIAGNOSE_BY_TEST_OR_DRUG],191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/16/2014 00:32:29,,1323942322,7/16/2014 00:32:01,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[TREATS],[TREATS],effective as conventional therapy with,N/A,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/16/2014 00:41:43,,1323946618,7/16/2014 00:39:42,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],in the pathogenesis,N/A,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/16/2014 00:57:01,,1323954876,7/16/2014 00:56:03,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[TREATS],[TREATS],therapy with RANITIDINE,na,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/16/2014 02:00:35,,1323986997,7/16/2014 01:59:59,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],conventional therapy with,na,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/16/2014 06:42:19,,1324090012,7/16/2014 06:42:05,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],conventional therapy,n/a,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/16/2014 09:24:01,,1324143550,7/16/2014 09:23:14,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],conventional therapy,N/A,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/16/2014 10:20:06,,1324181005,7/16/2014 10:19:36,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[TREATS],[TREATS],therapy with,n/a,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/16/2014 10:51:12,,1324194683,7/16/2014 10:50:28,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],indicating the importance of overnight gastric acidity in the pathogenesis,N/A,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384130,7/16/2014 12:01:21,,1324218396,7/16/2014 12:00:53,paiddailysurveys,1,11786001,USA,NC,Charlotte,71.28.89.238,[TREATS],[TREATS],therapy with,N/A,191,102,212,112,1,RO-may_prevent,907235-FS1,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
503384131,7/15/2014 23:18:38,,1323901385,7/15/2014 23:17:40,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[CONTRAINDICATES],[CONTRAINDICATES],ingestion,N/A,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/15/2014 23:23:33,,1323904102,7/15/2014 23:23:07,instagc,1.0,13763729,USA,"","",75.182.89.225,[CONTRAINDICATES],[CONTRAINDICATES],warfarin embryopathy,N/A,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/15/2014 23:23:52,,1323904346,7/15/2014 23:22:47,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",is a result of,N/A,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/15/2014 23:28:20,,1323906752,7/15/2014 23:27:00,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],fetal exposure,N/A,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/15/2014 23:54:43,,1323920235,7/15/2014 23:53:55,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[CONTRAINDICATES],[CONTRAINDICATES],fetal exposure maternal ingestion of,Na,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/16/2014 00:04:09,,1323925746,7/16/2014 00:03:29,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],(coumadin) embryopathy,asd,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/16/2014 00:25:31,,1323938844,7/16/2014 00:25:10,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[ASSOCIATED_WITH],[ASSOCIATED_WITH],during,n/a,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/16/2014 00:46:56,,1323948942,7/16/2014 00:45:36,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[SIDE_EFFECT],[SIDE_EFFECT],result,n/a,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/16/2014 00:52:10,,1323951740,7/16/2014 00:51:34,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,WARFARIN during PREGNANCY,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/16/2014 01:15:06,,1323965722,7/16/2014 01:14:53,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ingestion WARFARIN,N/A,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/16/2014 05:05:30,,1324059757,7/16/2014 05:03:03,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[ASSOCIATED_WITH] [SIDE_EFFECT],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",warfarin embryopathy rare condition result fetal exposure maternal ingestion WARFARIN,N/A,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/16/2014 06:00:36,,1324076461,7/16/2014 06:00:11,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[CONTRAINDICATES],[CONTRAINDICATES],result of fetal exposure,N/A,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/16/2014 10:53:25,,1324195270,7/16/2014 10:52:23,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SIDE_EFFECT],[SIDE_EFFECT],Fetal warfarin syndrome to maternal ingestion WARFARIN during PREGNANCY,N/A,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/16/2014 11:51:25,,1324215032,7/16/2014 11:51:07,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[CAUSES],[CAUSES],as a result of,N/A,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384131,7/16/2014 12:00:51,,1324218180,7/16/2014 12:00:13,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],as a result,N/A,140,156,147,165,1,RO-contraindicated_drug,901253-FS1,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
503384132,7/15/2014 23:06:27,,1323894555,7/15/2014 23:05:08,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],was,N/A,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 00:16:02,,1323933944,7/16/2014 00:14:58,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION] [ASSOCIATED_WITH],"[LOCATION]
[ASSOCIATED_WITH]","SOLITARY BONE METASTASIS no metastases to appendicular bone, PATHOLOGIC FRACTURES",Location / Associated With,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 00:27:56,,1323939958,7/16/2014 00:26:01,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],more likely in patients with,N/A,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 00:51:49,,1323951508,7/16/2014 00:51:30,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],to,N/A,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 01:01:29,,1323957547,7/16/2014 01:00:53,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[NONE],[NONE],na,there is no relation mentioned,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 02:16:13,,1323995326,7/16/2014 02:15:54,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],no,Na,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 03:10:05,,1324014669,7/16/2014 03:09:18,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER] [PART_OF],"[PART_OF]
[OTHER]",SOLITARY BONE METASTASIS PATHOLOGIC FRACTURES,N/A,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 03:26:34,,1324020048,7/16/2014 03:25:39,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SOLITARY BONE METASTASIS PATHOLOGIC FRACTURES,n/a,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 05:16:01,,1324063413,7/16/2014 05:14:59,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],and patients with,N/A,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 12:00:53,,1324218206,7/16/2014 11:59:39,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[CAUSES],[CAUSES],performance,N/A,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 12:08:18,,1324220896,7/16/2014 12:07:06,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],"appendicular bone,",N/A,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 12:50:49,,1324237273,7/16/2014 12:50:19,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],"use of systemic chemotherapy,",n/a,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 12:56:24,,1324239835,7/16/2014 12:54:56,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,just similar bone problems that can occur,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 13:02:35,,1324242304,7/16/2014 13:02:03,instagc,1,14378608,USA,NY,Brooklyn,24.189.101.95,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]","favorable FRACTURES systemic chemotherapy,",it causes the growth of it,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384132,7/16/2014 13:12:14,,1324246216,7/16/2014 13:11:43,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],patients with,na,149,81,168,105,-1,RO-disease_may_have_finding,902860-FS1,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
503384133,7/15/2014 23:02:54,,1323892162,7/15/2014 23:02:32,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[ASSOCIATED_WITH],[ASSOCIATED_WITH],majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,N/A,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/15/2014 23:20:49,,1323902656,7/15/2014 23:20:42,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],majority,n/a,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/15/2014 23:22:03,,1323903236,7/15/2014 23:21:42,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/15/2014 23:25:49,,1323905439,7/15/2014 23:25:08,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/16/2014 00:19:20,,1323935956,7/16/2014 00:18:44,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",have been found in,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/16/2014 00:28:23,,1323940204,7/16/2014 00:28:10,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/16/2014 00:46:16,,1323948633,7/16/2014 00:45:58,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],and,N/A,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/16/2014 00:51:36,,1323951407,7/16/2014 00:50:47,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",found in the majority of,N/A,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/16/2014 00:53:51,,1323952948,7/16/2014 00:53:41,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/16/2014 03:59:34,,1324034495,7/16/2014 03:58:31,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA KEARNS SAYRE SYNDROME,n/a,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/16/2014 05:35:32,,1324069041,7/16/2014 05:35:12,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,UNRELATED CONDITIONS,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/16/2014 07:54:45,,1324113485,7/16/2014 07:54:20,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/16/2014 09:09:41,,1324135443,7/16/2014 09:09:31,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/16/2014 10:32:04,,1324185282,7/16/2014 10:31:01,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],found in,n/a,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384133,7/16/2014 10:47:10,,1324193192,7/16/2014 10:46:41,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],and,N/A,93,134,128,155,-1,RO-has_manifestation,906425-FS1,Mitochondrial DNA (mtDNA) deletions have been found in the majority of patients with chronic PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA and KEARNS SAYRE SYNDROME,PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA,KEARNS SAYRE SYNDROME
503384134,7/15/2014 23:23:41,,1323904196,7/15/2014 23:23:27,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NICOTINE WITHDRAWAL NICOTINE,N/A,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/15/2014 23:34:17,,1323909878,7/15/2014 23:33:20,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Animal models,N/A,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 00:04:33,,1323926022,7/16/2014 00:03:40,quickrewards,1,20452113,USA,NY,Port Henry,108.176.206.207,[SYMPTOM],[SYMPTOM],NICOTINE WITHDRAWAL,N/A,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 00:18:08,,1323935268,7/16/2014 00:16:58,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"reward, withdrawal and craving.",n/a,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 00:33:47,,1323942902,7/16/2014 00:33:24,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",NICOTINE WITHDRAWAL,N/A,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 00:43:16,,1323947326,7/16/2014 00:42:31,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],indicate involvement,N/A,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 00:43:45,,1323947569,7/16/2014 00:41:50,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,[LOCATION] [SIDE_EFFECT],"[LOCATION]
[SIDE_EFFECT]",NICOTINE WITHDRAWAL in NICOTINE,N/A,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 00:48:28,,1323949787,7/16/2014 00:46:57,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,n/a,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 02:04:19,,1323988912,7/16/2014 02:03:45,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],indicate involvement,n/a,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 02:54:13,,1324009047,7/16/2014 02:53:27,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[SYMPTOM] [ASSOCIATED_WITH] [SIDE_EFFECT],"[SYMPTOM]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",NICOTINE WITHDRAWAL in NICOTINE,N/A,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 04:35:02,,1324048517,7/16/2014 04:32:42,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[SIDE_EFFECT],[SIDE_EFFECT],"NICOTINE WITHDRAWAL indicate striatal serotonin systems NICOTINE reward, withdrawal",N/A,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 05:19:58,,1324064707,7/16/2014 05:19:33,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],NICOTINE NICOTINE,N/A,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 05:53:23,,1324074077,7/16/2014 05:53:02,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[CAUSES],[CAUSES],withdrawal and craving.,N/A,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 06:41:29,,1324089704,7/16/2014 06:41:08,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],NICOTINE,n/a,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384134,7/16/2014 07:36:18,,1324108729,7/16/2014 07:34:37,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[PREVENTS],[PREVENTS],"reward,",N/A,17,17,24,36,-1,RO-has_causative_agent,903555-FS1,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
503384135,7/15/2014 23:08:16,,1323895550,7/15/2014 23:08:06,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients,N/A,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/15/2014 23:08:45,,1323895818,7/15/2014 23:08:23,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[NONE],[NONE],N/A,Different patient types,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/15/2014 23:22:12,,1323903273,7/15/2014 23:21:38,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",was investigated,N/A,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/15/2014 23:22:29,,1323903409,7/15/2014 23:22:05,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MIGRAINE and HEADACHE FREE CONTROLS.,N/A,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/15/2014 23:24:15,,1323904522,7/15/2014 23:23:50,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was investigated,N/A,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/15/2014 23:36:27,,1323910865,7/15/2014 23:35:33,clixsense,1.0,15189335,GBR,H9,London,188.29.165.200,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/15/2014 23:44:10,,1323914748,7/15/2014 23:42:31,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[NONE],[NONE],N/A,Headache free controls are unrelated to migraine sufferers - they are used as controls within the study only,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/15/2014 23:58:19,,1323922249,7/15/2014 23:56:51,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They are both controls in the same study but aren't related to each other.,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/16/2014 00:04:00,,1323925606,7/16/2014 00:03:40,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],investigated,n/a,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/16/2014 00:47:38,,1323949312,7/16/2014 00:47:18,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],and,N/A,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/16/2014 01:16:10,,1323966375,7/16/2014 01:15:56,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MIGRAINE HEADACHE,N/A,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/16/2014 02:53:26,,1324008834,7/16/2014 02:52:41,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A] [OTHER],"[IS_A]
[OTHER]",MIGRAINE and HEADACHE FREE CONTROLS.,N/A,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/16/2014 03:24:21,,1324019304,7/16/2014 03:23:36,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MIGRAINE 17 HEADACHE FREE CONTROLS.,n/a,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/16/2014 05:18:19,,1324064131,7/16/2014 05:17:24,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],investigated in patients with,N/A,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384135,7/16/2014 06:02:35,,1324077044,7/16/2014 06:00:32,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[OTHER],[OTHER],CONTROLS.,n/a,191,160,212,168,-1,RO-has_definitional_manifestation,904644-FS1,"Blink reflex R2 amplitude was investigated in seven patients with cervicogenic headache (CEH), 12 patients with chronic tension type headache, 23 patients with MIGRAINE (10 with aura) and 17 HEADACHE FREE CONTROLS.",HEADACHE FREE CONTROLS,MIGRAINE
503384136,7/15/2014 23:09:43,,1323896478,7/15/2014 23:09:17,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LYMPHOEPITHELIAL LYMPHOMAS,N/A,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/15/2014 23:19:41,,1323901976,7/15/2014 23:18:59,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",lymphomas appearing,N/A,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/15/2014 23:32:53,,1323909200,7/15/2014 23:31:03,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",grade MALT lymphomas appearing MALT LYMPHOMAS,Symptom / Manifestation,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/16/2014 00:09:12,,1323929162,7/16/2014 00:08:10,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],appearing in,[DIAGNOSE_BY_TEST_OR_DRUG],115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/16/2014 00:49:22,,1323950346,7/16/2014 00:47:48,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM] [MANIFESTATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]",based on the presence or absence of,N/A,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/16/2014 01:15:07,,1323965727,7/16/2014 01:14:20,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LYMPHOEPITHELIAL LESIONS appearing in low grade MALT LYMPHOMAS,N/A,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/16/2014 06:02:46,,1324077087,7/16/2014 06:02:11,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[MANIFESTATION],[MANIFESTATION],appearing in low grade,N/A,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/16/2014 07:56:57,,1324114148,7/16/2014 07:56:28,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/16/2014 10:24:10,,1324182524,7/16/2014 10:22:41,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],presence and appearing in,n/a,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/16/2014 10:58:57,,1324196931,7/16/2014 10:58:24,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],classified in three groups,N/A,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/16/2014 11:51:06,,1324214905,7/16/2014 11:50:49,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],appearing in,N/A,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/16/2014 11:56:38,,1324216753,7/16/2014 11:55:43,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],appearing,N/A,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/16/2014 12:54:21,,1324238851,7/16/2014 12:53:45,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],three groups based on the presence,n/a,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/16/2014 12:54:36,,1324238968,7/16/2014 12:53:50,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],appearing in,n/a,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384136,7/16/2014 12:58:03,,1324240556,7/16/2014 12:57:25,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[CAUSES] [SYMPTOM] [ASSOCIATED_WITH],"[CAUSES]
[SYMPTOM]
[ASSOCIATED_WITH]",groups based presence absence low grade component,It is related due to the presence of the low grade component,115,200,138,214,-1,RO-disease_may_have_finding,902863-FS1,High grade lymphomas were classified in three groups based on the presence or absence of a low grade component and LYMPHOEPITHELIAL LESIONS (LELs): 1) high grade MALT lymphomas appearing in low grade MALT LYMPHOMAS (LG/HG MALT lymphoma); 2) large cell lymphoma with LELs composed of large cells (high grade LELs) but without a low grade component (HG MALT lymphoma); and 3) diffuse large cell lymphoma without a low grade MALT lymphoma component or LELs (DLCL.,LYMPHOEPITHELIAL LESIONS,MALT LYMPHOMAS
503384137,7/15/2014 23:08:27,,1323895644,7/15/2014 23:07:19,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],HYPERTENSION Oral: studies using benazepril/AMLODIPINE dosages,Treats,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/15/2014 23:10:09,,1323896720,7/15/2014 23:09:59,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],HYPERTENSION,N/A,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/15/2014 23:11:24,,1323897382,7/15/2014 23:09:25,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],using,N/A,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/15/2014 23:23:56,,1323904366,7/15/2014 23:23:41,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],Therapy for HYPERTENSION using benazepril/AMLODIPINE,N/A,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/15/2014 23:28:59,,1323907034,7/15/2014 23:28:21,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],Therapy,N/A,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/15/2014 23:45:20,,1323915379,7/15/2014 23:43:28,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],using benazepril/AMLODIPINE fixed combination,n/a,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/15/2014 23:56:01,,1323920878,7/15/2014 23:55:33,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],Therapy,asd,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/16/2014 00:18:42,,1323935615,7/16/2014 00:17:27,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],In studies using,[DIAGNOSE_BY_TEST_OR_DRUG],62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/16/2014 00:48:44,,1323949920,7/16/2014 00:48:30,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],using,N/A,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/16/2014 00:55:38,,1323954034,7/16/2014 00:54:45,elite,1.0,27788262,USA,"","",172.163.6.138,[TREATS],[TREATS],Therapy for,N/A,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/16/2014 02:20:59,,1323997613,7/16/2014 02:20:48,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],Therapy,Na,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/16/2014 03:07:34,,1324013772,7/16/2014 03:05:02,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],Therapy HYPERTENSION benazepril/AMLODIPINE,N/A,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/16/2014 05:21:42,,1324065260,7/16/2014 05:21:11,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],Fixed combination Therapy,N/A,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/16/2014 05:58:58,,1324075916,7/16/2014 05:58:38,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],Fixed combination Therapy,N/A,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384137,7/16/2014 06:05:09,,1324077748,7/16/2014 06:04:10,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[TREATS],[TREATS],Therapy for,n/a,62,111,73,121,1,RO-may_treat,907516-FS1,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
503384138,7/15/2014 23:06:49,,1323894749,7/15/2014 23:06:36,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[TREATS],[TREATS],ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,N/A,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 00:31:46,,1323941992,7/16/2014 00:31:23,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[OTHER] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[OTHER]",patients who were in and receiving,N/A,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 00:46:51,,1323948939,7/16/2014 00:46:10,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[PREVENTS],[PREVENTS],did not occur in patients receiving,N/A,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 00:50:33,,1323950966,7/16/2014 00:50:18,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],receiving,N/A,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 00:57:42,,1323955202,7/16/2014 00:57:03,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[NONE],[NONE],na,there is no relation mentioned,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 01:17:31,,1323967107,7/16/2014 01:17:20,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],receiving,N/A,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 01:37:13,,1323977320,7/16/2014 01:36:46,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[TREATS],[TREATS],receiving,na,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 02:11:29,,1323992537,7/16/2014 02:11:05,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],and receiving,na,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 02:20:47,,1323997536,7/16/2014 02:20:34,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],receiving,Na,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 02:31:50,,1324002003,7/16/2014 02:31:11,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],receiving,n/a,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 03:11:56,,1324015340,7/16/2014 03:11:23,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATRIAL FIBRILLATION WARFARIN ANTICOAGULATION.,n/a,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 05:41:28,,1324070648,7/16/2014 05:41:13,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],and receiving,N/A,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 06:07:05,,1324078390,7/16/2014 06:06:09,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",receiving,n/a,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 06:41:07,,1324089616,7/16/2014 06:40:55,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],receiving,n/a,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384138,7/16/2014 07:00:45,,1324096212,7/16/2014 07:00:30,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],and receiving WARFARIN,N/a,54,88,72,112,1,RO-may_treat,908209-FS1,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
503384139,7/15/2014 23:23:17,,1323903928,7/15/2014 23:23:09,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/15/2014 23:27:47,,1323906461,7/15/2014 23:27:20,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],from patients with and patients with,N/A,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 00:32:54,,1323942492,7/16/2014 00:32:30,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",from patients with,N/A,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 02:57:12,,1324010033,7/16/2014 02:56:19,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN),N/A,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 04:13:18,,1324041687,7/16/2014 04:11:46,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[NONE],[NONE],N/A,"Really there may be a common denominator, as they are tested together",123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 05:17:57,,1324064008,7/16/2014 05:17:13,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[OTHER],[OTHER],and patients with,N/A,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 06:35:06,,1324087647,7/16/2014 06:34:43,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MEMBRANOUS GLOMERULOPATHY,n/a,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 07:53:54,,1324113283,7/16/2014 07:53:09,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and from patients with,n/a,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 08:09:54,,1324118327,7/16/2014 08:09:00,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Eleven renal biopsy specimens from patients with and with primary,"because of the part ""Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN)""",123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 10:51:57,,1324194864,7/16/2014 10:51:14,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],biopsy specimens from patients with and with primary,N/A,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 11:55:38,,1324216384,7/16/2014 11:54:46,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 12:03:47,,1324219376,7/16/2014 12:02:45,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[ASSOCIATED_WITH],[ASSOCIATED_WITH],from patients with patients with,N/A,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 12:52:32,,1324238084,7/16/2014 12:52:05,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],clinical data were available were examined quantitatively.,n/a,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 12:53:09,,1324238387,7/16/2014 12:52:09,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],MEMBRANOUS GLOMERULOPATHY,N/A,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384139,7/16/2014 12:56:54,,1324240051,7/16/2014 12:56:25,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,two different types of illnesses,123,49,156,80,-1,RO-cause_of,900168-FS1,"Eleven renal biopsy specimens from patients with LUPUS MEMBRANOUS GLOMERULOPATHY (LMGN) and 16 from patients with primary (NONLUPUS MEMBRANOUS GLOMERULOPATHY (NLMGN) for whom light, electron microscopy and immunofluorescence microscopy, and full clinical data were available were examined quantitatively.",NONLUPUS MEMBRANOUS GLOMERULOPATHY,LUPUS MEMBRANOUS GLOMERULOPATHY
503384140,7/15/2014 23:16:30,,1323900049,7/15/2014 23:15:29,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],increase nonspecific bronchial response METHACHOLINE mechanism BRONCHIAL HYPERREACTIVITY,Treats,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/15/2014 23:17:52,,1323900829,7/15/2014 23:17:10,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],response with,N/A,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/15/2014 23:25:41,,1323905341,7/15/2014 23:23:35,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/15/2014 23:34:43,,1323910092,7/15/2014 23:34:18,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],mechanism,N/A,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/16/2014 00:22:44,,1323937583,7/16/2014 00:22:26,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the mechanism of,n/a,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/16/2014 00:47:47,,1323949425,7/16/2014 00:46:52,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",would increase the response,N/A,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/16/2014 04:10:31,,1324040316,7/16/2014 04:09:33,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],METHACHOLINE BRONCHIAL HYPERREACTIVITY,n/a,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/16/2014 05:28:25,,1324067163,7/16/2014 05:27:42,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],and the mechanism of the,N/A,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/16/2014 06:31:44,,1324086711,7/16/2014 06:31:10,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],with,n/a,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/16/2014 08:04:47,,1324116867,7/16/2014 08:04:24,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],increase the nonspecific bronchial response with METHACHOLINE,N/A,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/16/2014 09:09:07,,1324135281,7/16/2014 09:08:56,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],METHACHOLINE BRONCHIAL HYPERREACTIVITY,n/a,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/16/2014 10:18:05,,1324180223,7/16/2014 10:17:04,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[TREATS],[TREATS],with,n/a,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/16/2014 12:03:08,,1324219071,7/16/2014 12:02:54,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[CAUSES],[CAUSES],response,N/A,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/16/2014 12:24:56,,1324226465,7/16/2014 12:24:16,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[TREATS],[TREATS],response with,N/A,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384140,7/16/2014 12:48:32,,1324236194,7/16/2014 12:48:05,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],response with and the mechanism of,n/a,137,99,161,111,1,RO-may_diagnose,906549-FS1,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503384141,7/15/2014 23:05:07,,1323893818,7/15/2014 23:03:47,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],examine,N/A,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/15/2014 23:10:17,,1323896829,7/15/2014 23:10:03,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURES and NON EPILEPTIC ATTACK DISORDER,N/A,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/15/2014 23:18:51,,1323901545,7/15/2014 23:18:37,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],DISORDER,n/a,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/15/2014 23:23:20,,1323904004,7/15/2014 23:22:52,clixsense,1.0,15189335,GBR,H9,London,188.29.165.232,[SYMPTOM],[SYMPTOM],portrayal,Na,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/15/2014 23:23:34,,1323904125,7/15/2014 23:22:39,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/15/2014 23:46:02,,1323915784,7/15/2014 23:45:43,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/16/2014 00:11:45,,1323930964,7/16/2014 00:11:08,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/16/2014 00:14:29,,1323932790,7/16/2014 00:12:03,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],produced over three quarters,[CAUSES],52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/16/2014 00:25:09,,1323938667,7/16/2014 00:24:35,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[SYMPTOM],[SYMPTOM],and,n/a,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/16/2014 00:42:16,,1323946837,7/16/2014 00:41:54,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,SEIZURES and NON EPILEPTIC ATTACK DISORDER,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/16/2014 02:15:49,,1323995085,7/16/2014 02:15:21,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/16/2014 02:20:33,,1323997467,7/16/2014 02:20:19,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[PART_OF],[PART_OF],and,Na,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/16/2014 03:13:43,,1324015934,7/16/2014 03:13:01,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURES NON EPILEPTIC ATTACK DISORDER,n/a,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/16/2014 03:46:41,,1324028439,7/16/2014 03:46:07,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURES NON EPILEPTIC ATTACK DISORDER,n/a,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384141,7/16/2014 06:31:09,,1324086568,7/16/2014 06:30:22,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,52,65,59,94,-1,RO-has_definitional_manifestation,904528-FS1,"In this review I examine the portrayal of epilepsy, SEIZURES and NON EPILEPTIC ATTACK DISORDER in 62 movies produced over three quarters of a century, across four continents, covering nine cinematic genres.",SEIZURES,NON EPILEPTIC ATTACK DISORDER
503384142,7/15/2014 23:11:14,,1323897326,7/15/2014 23:10:47,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],has the potential to detect,N/A,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/15/2014 23:14:41,,1323899195,7/15/2014 23:14:30,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],whole,n/a,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 00:21:29,,1323937012,7/16/2014 00:21:14,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],potential to detect,n/a,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 01:00:25,,1323956848,7/16/2014 00:59:30,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detect,na,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 01:32:40,,1323975653,7/16/2014 01:32:04,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[PART_OF],[PART_OF],with TUBERCULIN,na,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 02:08:04,,1323990661,7/16/2014 02:07:28,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detect,none,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 03:28:58,,1324020969,7/16/2014 03:27:53,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TUBERCULIN TUBERCULOSIS INFECTION,n/a,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 04:00:45,,1324035095,7/16/2014 04:00:10,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULIN TUBERCULOSIS INFECTION,n/a,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 05:01:57,,1324058497,7/16/2014 04:59:52,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TUBERCULIN potential detect TUBERCULOSIS INFECTION,N/A,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 05:41:18,,1324070595,7/16/2014 05:40:54,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],has the potential to detect,N/A,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 06:33:28,,1324087241,7/16/2014 06:33:03,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],potential to detect,n/a,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 08:05:01,,1324116931,7/16/2014 08:04:48,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detect,N/A,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 12:01:22,,1324218399,7/16/2014 12:01:10,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],potential to detect,N/A,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 12:23:34,,1324225965,7/16/2014 12:22:53,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[ASSOCIATED_WITH],[ASSOCIATED_WITH],potential to,N/A,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384142,7/16/2014 12:50:17,,1324237060,7/16/2014 12:49:50,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],potential to detect,n/a,143,104,164,114,1,RO-may_diagnose,906709-FS1,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
503384143,7/15/2014 23:20:42,,1323902566,7/15/2014 23:20:36,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],phenytoin,n/a,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/15/2014 23:24:12,,1323904511,7/15/2014 23:23:57,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],The effect of nimodipine alone and in combination with DIAZEPAM,N/A,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/15/2014 23:42:30,,1323913941,7/15/2014 23:40:45,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",was tested in,N/A,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/16/2014 00:37:38,,1323944723,7/16/2014 00:37:18,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],or phenytoin was tested in the electroshock induced mouse model of,N/A,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/16/2014 00:53:40,,1323952862,7/16/2014 00:53:25,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tested,N/A,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/16/2014 00:58:11,,1323955404,7/16/2014 00:57:13,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,model of STATUS EPILEPTICUS,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/16/2014 01:19:46,,1323968467,7/16/2014 01:18:41,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],DIAZEPAM was tested in STATUS EPILEPTICUS,N/A,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/16/2014 01:26:37,,1323972905,7/16/2014 01:25:37,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[TREATS],[TREATS],effect of,na,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/16/2014 04:19:33,,1324044083,7/16/2014 04:19:11,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],effect of,N/A,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/16/2014 06:06:11,,1324078068,7/16/2014 06:05:37,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],tested in,N/A,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/16/2014 06:58:11,,1324095249,7/16/2014 06:58:00,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],The effect of,N/a,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/16/2014 07:38:21,,1324109289,7/16/2014 07:37:47,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was tested in,n/a,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/16/2014 07:41:15,,1324110008,7/16/2014 07:40:33,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],effect with,N/A,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/16/2014 08:06:16,,1324117266,7/16/2014 08:05:51,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],effect,N/A,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384143,7/16/2014 10:34:05,,1324185935,7/16/2014 10:33:24,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[TREATS],[TREATS],effect of,n/a,131,55,148,63,1,RO-may_treat,908055-FS1,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
503384144,7/15/2014 23:11:08,,1323897278,7/15/2014 23:10:35,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/15/2014 23:11:27,,1323897428,7/15/2014 23:10:58,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[CAUSES],[CAUSES],associated with,N/A,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/15/2014 23:19:59,,1323902195,7/15/2014 23:19:54,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],the,n/a,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/15/2014 23:22:33,,1323903445,7/15/2014 23:22:05,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/15/2014 23:49:29,,1323917701,7/15/2014 23:48:28,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SYMPTOM],[SYMPTOM],LMNA,asd,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/16/2014 00:19:02,,1323935848,7/16/2014 00:18:34,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diseases associated with,n/a,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/16/2014 01:19:07,,1323968209,7/16/2014 01:18:27,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/16/2014 03:30:02,,1324021380,7/16/2014 03:29:04,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],PREMATURE AGING PROGERIA SYNDROME (HGPS),n/a,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/16/2014 04:07:56,,1324038856,7/16/2014 04:07:23,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],PREMATURE AGING PROGERIA SYNDROME (HGPS),n/a,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/16/2014 04:44:38,,1324051015,7/16/2014 04:44:01,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",are PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME,N/A,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/16/2014 07:57:57,,1324114474,7/16/2014 07:57:19,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[IS_A],[IS_A],disorders,N/A,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/16/2014 09:10:28,,1324135770,7/16/2014 09:10:15,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PREMATURE AGING PROGERIA SYNDROME,n/a,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/16/2014 10:21:02,,1324181425,7/16/2014 10:20:07,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[IS_A],[IS_A],are the disorders,n/a,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/16/2014 11:04:05,,1324198457,7/16/2014 11:03:16,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM] [OTHER],"[SYMPTOM]
[OTHER]",PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME,N/A,77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384144,7/16/2014 11:38:10,,1324210130,7/16/2014 11:37:11,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[PART_OF],[PART_OF],are the PREMATURE AGING disorders,"because,

 mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS)",77,122,91,146,-1,RO-has_manifestation,906273-FS1,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
503384145,7/15/2014 23:26:53,,1323905994,7/15/2014 23:25:49,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],X LINKED HYDROCEPHALUS MASA SYNDROME linked,n/a,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/15/2014 23:43:27,,1323914400,7/15/2014 23:43:07,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[MANIFESTATION],[MANIFESTATION],LINKED,n/a,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 00:30:46,,1323941431,7/16/2014 00:30:13,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",N/A,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 00:57:52,,1323955241,7/16/2014 00:57:22,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[NONE],[NONE],N/A,Same part,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 01:15:19,,1323965862,7/16/2014 01:15:07,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],X LINKED HYDROCEPHALUS MASA SYNDROME X,N/A,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 01:16:15,,1323966416,7/16/2014 01:15:09,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[IS_A],[IS_A],X LINKED HYDROCEPHALUS MASA SYNDROME X,N/A,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 02:05:22,,1323989356,7/16/2014 02:04:51,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],linked,none,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 03:47:31,,1324028821,7/16/2014 03:46:44,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],X LINKED HYDROCEPHALUS MASA SYNDROME X,n/a,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 04:16:17,,1324042920,7/16/2014 04:13:19,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",X LINKED HYDROCEPHALUS MASA SYNDROME X,N/A,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 05:05:50,,1324059947,7/16/2014 05:02:49,instagc,1,27770607,USA,TX,El Paso,72.183.248.75,[NONE],[NONE],LINKED HYDROCEPHALUS MASA SYNDROME,It is part of the same thing,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 06:04:04,,1324077425,7/16/2014 06:03:34,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[PART_OF],[PART_OF],X LINKED HYDROCEPHALUS MASA SYNDROME,n/a,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 06:25:19,,1324084628,7/16/2014 06:23:48,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],X LINKED HYDROCEPHALUS MASA SYNDROME X,n/a,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 07:38:54,,1324109469,7/16/2014 07:38:22,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[PART_OF],[PART_OF],LINKED HYDROCEPHALUS MASA SYNDROME,n/a,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 09:07:02,,1324134654,7/16/2014 09:06:48,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",caused by,n/a,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384145,7/16/2014 09:23:13,,1324142675,7/16/2014 09:21:33,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],"L1 syndrome,",N/A,0,23,21,36,-1,RO-has_manifestation,906399-FS1,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
503384146,7/15/2014 23:12:19,,1323897916,7/15/2014 23:12:08,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[IS_A],[IS_A],INFLAMMATORY BOWEL DISEASES ULCERATIVE COLITIS,N/A,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/15/2014 23:20:21,,1323902386,7/15/2014 23:20:15,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],"(e.g.,",n/a,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/15/2014 23:21:37,,1323903059,7/15/2014 23:21:04,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],produce,N/A,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/15/2014 23:28:40,,1323906872,7/15/2014 23:28:29,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],"(e.g.,",N/A,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/15/2014 23:30:50,,1323908085,7/15/2014 23:30:24,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES] [SYMPTOM] [MANIFESTATION],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]","produce inflammatory diarrhea,",N/A,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/15/2014 23:38:43,,1323912188,7/15/2014 23:37:56,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[IS_A],[IS_A],"Typically,",Na,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/15/2014 23:42:48,,1323914103,7/15/2014 23:42:20,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[PART_OF],[PART_OF],"(e.g.,",n/a,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/16/2014 00:02:14,,1323924466,7/16/2014 00:01:00,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SIDE_EFFECT],[SIDE_EFFECT],"Typically, INFLAMMATORY",asd,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/16/2014 00:32:00,,1323942065,7/16/2014 00:31:47,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[IS_A],[IS_A],"(e.g.,",N/A,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/16/2014 00:50:17,,1323950829,7/16/2014 00:50:04,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],"(e.g.,",N/A,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/16/2014 01:23:25,,1323971051,7/16/2014 01:22:55,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[IS_A],[IS_A],"(e.g.,",na,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/16/2014 01:57:25,,1323984949,7/16/2014 01:56:35,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[MANIFESTATION],[MANIFESTATION],"(e.g.,",na,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/16/2014 02:02:02,,1323987831,7/16/2014 02:01:44,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[CAUSES],[CAUSES],produce,none,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/16/2014 02:21:34,,1323997807,7/16/2014 02:21:19,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(e.g.,",Na,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384146,7/16/2014 02:57:57,,1324010220,7/16/2014 02:57:14,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[MANIFESTATION] [IS_A],"[MANIFESTATION]
[IS_A]","INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS",N/A,44,79,70,97,1,RO-disease_has_primary_anatomic_site,902198-FS1,"29  Inflammatory bowel disease   Typically, INFLAMMATORY BOWEL DISEASES (e.g., ULCERATIVE COLITIS and Crohn disease) produce inflammatory diarrhea, with blood and pus in the stool.",INFLAMMATORY BOWEL DISEASES,ULCERATIVE COLITIS
503384147,7/15/2014 23:12:48,,1323898094,7/15/2014 23:12:31,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[LOCATION],[LOCATION],in the,N/A,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/15/2014 23:55:30,,1323920625,7/15/2014 23:55:16,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],evaluation,asd,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 00:23:35,,1323937913,7/16/2014 00:23:20,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include staging of,n/a,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 00:25:07,,1323938645,7/16/2014 00:24:14,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[LOCATION] [ASSOCIATED_WITH],"[LOCATION]
[ASSOCIATED_WITH]",include staging of localization,[LOCATION] [ASSOCIATED_WITH],37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 00:38:05,,1323944875,7/16/2014 00:35:55,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],staging of,N/A,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 00:56:33,,1323954660,7/16/2014 00:56:23,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],include,N/A,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 01:14:13,,1323965135,7/16/2014 01:14:08,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],STOMACH,N/A,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 01:52:20,,1323982901,7/16/2014 01:51:51,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],include staging of,na,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 02:05:10,,1323989311,7/16/2014 02:04:20,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",include staging,n/a,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 03:08:47,,1324014199,7/16/2014 03:08:15,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],STOMACH include GASTRIC CARCINOMA,N/A,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 05:07:03,,1324060355,7/16/2014 05:06:29,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],in the,N/A,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 05:33:30,,1324068528,7/16/2014 05:32:21,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],include staging of localization,N/A,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 05:55:25,,1324074756,7/16/2014 05:55:01,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[LOCATION],[LOCATION],include staging of,N/A,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 07:02:02,,1324096672,7/16/2014 07:01:38,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],in the STOMACH include staging of GASTRIC CARCINOMA,N/a,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384147,7/16/2014 07:53:09,,1324113064,7/16/2014 07:52:43,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[SYMPTOM],[SYMPTOM],include staging of,n/a,37,64,43,81,1,RO-disease_has_primary_anatomic_site,902110-FS1,"Applications of endoscopic US in the STOMACH include staging of GASTRIC CARCINOMA localization and characterization of nonmucosal gastric masses, detection and evaluation of gastric varices, and evaluation of gastric lymphoma.",STOMACH,GASTRIC CARCINOMA
503384148,7/15/2014 23:05:21,,1323893908,7/15/2014 23:04:59,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[OTHER],[OTHER],VASCULAR HEADACHES MIGRAINE,Unclear,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/15/2014 23:21:59,,1323903204,7/15/2014 23:21:49,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],VASCULAR HEADACHES MIGRAINE,N/A,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/15/2014 23:24:22,,1323904623,7/15/2014 23:24:01,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],VASCULAR HEADACHES MIGRAINE,N/A,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/15/2014 23:56:25,,1323921092,7/15/2014 23:55:25,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[NONE],[NONE],N/A,Nothing in the passage specifies a relationship between the two.,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/15/2014 23:59:04,,1323922680,7/15/2014 23:58:21,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[MANIFESTATION],[MANIFESTATION],&gt;,n/a,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/16/2014 00:26:28,,1323939275,7/16/2014 00:26:02,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],&gt;,N/A,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/16/2014 00:35:18,,1323943722,7/16/2014 00:35:08,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH],[ASSOCIATED_WITH],&gt;,N/A,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/16/2014 00:50:45,,1323951061,7/16/2014 00:50:00,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],&gt;,N/A,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/16/2014 00:50:49,,1323951106,7/16/2014 00:50:34,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],&gt;,N/A,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/16/2014 01:29:42,,1323974330,7/16/2014 01:29:12,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[IS_A],[IS_A],&gt;,na,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/16/2014 01:47:45,,1323980906,7/16/2014 01:46:40,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],Prescribing,none,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/16/2014 02:22:15,,1323998122,7/16/2014 02:21:54,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],&gt;,Na,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/16/2014 02:30:41,,1324001634,7/16/2014 02:29:55,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",Prescribing Maximum 30 mg 24 hour period.,n/a,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/16/2014 03:02:46,,1324012122,7/16/2014 03:02:12,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A],[IS_A],VASCULAR HEADACHES MIGRAINE,N/A,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384148,7/16/2014 04:56:05,,1324055511,7/16/2014 04:53:23,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[IS_A],[IS_A],VASCULAR HEADACHES MIGRAINE Oral: Maximum 30,N/A,31,57,48,65,-1,RO-has_definitional_manifestation,904531-FS1,1  Prescribing Limits  Adults  VASCULAR HEADACHES  >     MIGRAINE  Oral:  Maximum 30 mg in any 24 hour period.,VASCULAR HEADACHES,MIGRAINE
503384149,7/15/2014 23:11:35,,1323897545,7/15/2014 23:11:17,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[NONE],[NONE],N/A,Different conditions,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/15/2014 23:12:06,,1323897791,7/15/2014 23:11:55,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[LOCATION],[LOCATION],psychogenic,N/A,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/15/2014 23:19:03,,1323901658,7/15/2014 23:18:40,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[OTHER],[OTHER],plus true,N/A,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/15/2014 23:20:13,,1323902303,7/15/2014 23:20:07,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],non,n/a,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/15/2014 23:20:42,,1323902601,7/15/2014 23:20:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],SEIZURES,N/A,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/15/2014 23:23:18,,1323903937,7/15/2014 23:22:42,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],seizures,N/A,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/16/2014 00:27:03,,1323939597,7/16/2014 00:26:29,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],had,N/A,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/16/2014 00:30:47,,1323941442,7/16/2014 00:30:01,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]",four of whom had psychogenic non epileptic seizures plus,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [MANIFESTATION],141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/16/2014 00:44:53,,1323948008,7/16/2014 00:43:46,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PSYCHOGENIC NON EPILEPTIC SEIZURES plus true EPILEPTIC SEIZURES,N/A,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/16/2014 01:13:46,,1323964909,7/16/2014 01:13:34,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NON EPILEPTIC EPILEPTIC,N/A,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/16/2014 01:20:28,,1323968965,7/16/2014 01:19:46,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM] [PART_OF],"[SYMPTOM]
[PART_OF]",EEG recordings 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES,N/A,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/16/2014 01:55:18,,1323984014,7/16/2014 01:54:26,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two different things,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/16/2014 04:00:07,,1324034763,7/16/2014 03:59:37,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PSYCHOGENIC NON EPILEPTIC SEIZURES EPILEPTIC SEIZURES,n/a,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/16/2014 05:19:00,,1324064343,7/16/2014 05:18:20,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],SEIZURES SEIZURES,N/A,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384149,7/16/2014 05:24:23,,1324066006,7/16/2014 05:22:27,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],seizures plus true,N/A,141,157,174,175,-1,RO-has_definitional_manifestation,904653-FS1,"Depending on video EEG recordings and witnessed accounts, 18 of the patients had no seizures recorded, 160 had epileptic seizures and 18 had PSYCHOGENIC NON EPILEPTIC SEIZURES four of whom had psychogenic non epileptic seizures plus true EPILEPTIC SEIZURES",PSYCHOGENIC NON EPILEPTIC SEIZURES,EPILEPTIC SEIZURES
503384150,7/15/2014 23:34:17,,1323909875,7/15/2014 23:33:54,clixsense,1,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared,N/A,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/15/2014 23:56:59,,1323921413,7/15/2014 23:56:42,clixsense,1,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],QUINIDINE controlling,asd,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 00:33:03,,1323942546,7/16/2014 00:32:27,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",in controlling ventricular couplets,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH] [TREATS],86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 00:37:01,,1323944434,7/16/2014 00:36:47,bitcoinget,1,21614812,USA,"","",73.39.136.3,[TREATS],[TREATS],in controlling,N/A,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 03:09:16,,1324014362,7/16/2014 03:08:48,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],QUINIDINE controlling VENTRICULAR TACHYCARDIA (VT),N/a,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 03:30:52,,1324021576,7/16/2014 03:30:07,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[PREVENTS],[PREVENTS],QUINIDINE VENTRICULAR TACHYCARDIA,n/a,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 05:06:28,,1324060131,7/16/2014 05:05:57,vivatic,1,25451531,GBR,"","",83.67.28.193,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",in controlling,N/A,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 05:18:37,,1324064239,7/16/2014 05:17:58,elite,1,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],in controlling,N/A,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 06:23:45,,1324084081,7/16/2014 06:22:06,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],efficacy,n/a,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 08:00:54,,1324115659,7/16/2014 08:00:38,prodege,1,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],efficacy,N/A,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 08:13:50,,1324119389,7/16/2014 08:13:05,clixsense,1,27969116,NLD,04,Veendam,185.12.216.74,[TREATS],[TREATS],The efficacy of mexiletine and QUINIDINE,"I think because of:

The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT)",86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 09:13:24,,1324136781,7/16/2014 09:13:12,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 10:37:45,,1324187103,7/16/2014 10:37:11,bitcoinget,1,28222930,USA,IL,Charleston,67.58.235.205,[TREATS],[TREATS],efficacy of,n/a,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 10:47:46,,1324193469,7/16/2014 10:47:11,neodev,1,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],in controlling ventricular couplets and VENTRICULAR TACHYCARDIA,N/A,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384150,7/16/2014 11:57:43,,1324217170,7/16/2014 11:56:52,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],efficacy controlling,N/A,86,31,113,40,1,RO-may_prevent,907007-FS1,The efficacy of mexiletine and QUINIDINE in controlling ventricular couplets (VC) and VENTRICULAR TACHYCARDIA (VT) was compared in 156 trials (78 for each drug) in 114 consecutive patients.,VENTRICULAR TACHYCARDIA (VT),QUINIDINE
503384151,7/15/2014 23:04:57,,1323893680,7/15/2014 23:04:40,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[TREATS],[TREATS],RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor disease,N/A,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/15/2014 23:21:39,,1323903071,7/15/2014 23:19:26,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],for,N/A,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/15/2014 23:37:07,,1323911246,7/15/2014 23:36:43,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for,N/A,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/15/2014 23:38:01,,1323911752,7/15/2014 23:37:09,neodev,1,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS,Treats,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/15/2014 23:45:18,,1323915382,7/15/2014 23:44:56,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[TREATS],[TREATS],LATERAL,asd,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/16/2014 00:02:13,,1323924459,7/16/2014 00:01:46,zapbux,1,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],for,n/a,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/16/2014 01:13:10,,1323964587,7/16/2014 01:13:04,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],for,N/A,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/16/2014 02:06:21,,1323989800,7/16/2014 02:05:54,prodege,1,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],for,none,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/16/2014 03:14:19,,1324016168,7/16/2014 03:13:48,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],RILUZOLE AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor,n/a,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/16/2014 04:18:57,,1324043852,7/16/2014 04:16:19,neodev,1,20929875,USA,MA,Allston,71.174.190.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RILUZOLE AMYOTROPHIC LATERAL SCLEROSIS,N/A,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/16/2014 05:59:44,,1324076161,7/16/2014 05:59:27,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],for,N/A,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/16/2014 07:04:19,,1324097709,7/16/2014 07:04:06,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS,N/a,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/16/2014 07:54:19,,1324113378,7/16/2014 07:54:02,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],for,N/A,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/16/2014 09:12:35,,1324136461,7/16/2014 09:12:23,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RILUZOLE (MND.,n/a,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384151,7/16/2014 10:52:21,,1324194988,7/16/2014 10:51:57,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],for,N/A,13,0,41,8,1,RO-may_treat,907922-FS1,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
503384152,7/15/2014 23:09:33,,1323896371,7/15/2014 23:09:08,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[OTHER],[OTHER],CENTRE FOR SEVERE SKIN DISEASES TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME),Organization doing testing on that specific condition,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/15/2014 23:12:16,,1323897914,7/15/2014 23:12:08,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],DISEASES,N/A,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/15/2014 23:13:37,,1323898628,7/15/2014 23:13:15,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[OTHER],[OTHER],"attempting comprehensive, country wide documentation",N/A,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/15/2014 23:20:06,,1323902264,7/15/2014 23:20:01,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],DISEASES,n/a,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/15/2014 23:21:02,,1323902750,7/15/2014 23:20:39,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"comprehensive, documentation",N/A,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/16/2014 00:19:53,,1323936252,7/16/2014 00:19:29,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],"attempting comprehensive, country wide documentation of",n/a,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/16/2014 01:18:39,,1323967920,7/16/2014 01:17:38,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[LOCATION],[LOCATION],CENTRE FOR SEVERE SKIN DISEASES wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME),N/A,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/16/2014 02:05:53,,1323989516,7/16/2014 02:05:23,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],documentation,none,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/16/2014 02:22:31,,1323998224,7/16/2014 02:22:16,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],documentation,Na,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/16/2014 02:56:17,,1324009752,7/16/2014 02:55:17,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],CENTRE FOR SEVERE SKIN DISEASES documentation TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME),N/A,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/16/2014 06:29:17,,1324086095,7/16/2014 06:27:14,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[NONE],[NONE],n/a,talking about a venue,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/16/2014 07:08:09,,1324099571,7/16/2014 07:07:38,instagc,1.0,18960682,GBR,"","",86.29.147.112,[NONE],[NONE],N/a,Centre for skin diseases is a place,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/16/2014 07:40:10,,1324109801,7/16/2014 07:39:30,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[OTHER],[OTHER],documentation,n/a,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/16/2014 08:01:57,,1324115988,7/16/2014 08:01:21,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[OTHER],[OTHER],documentation,Company which researches skin disease,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384152,7/16/2014 09:11:07,,1324135927,7/16/2014 09:10:50,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CENTRE FOR SEVERE SKIN DISEASES which TOXIC EPIDERMAL NECROLYSIS,n/a,49,146,79,191,1,RO-disease_has_primary_anatomic_site,902119-FS1,"The only exception is the Freiburg Documentation CENTRE FOR SEVERE SKIN DISEASES which is attempting comprehensive, country wide documentation of TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME) and Stevens Johnson syndrome.",CENTRE FOR SEVERE SKIN DISEASES,TOXIC EPIDERMAL NECROLYSIS (LYELL'S SYNDROME)
503384153,7/15/2014 23:03:53,,1323892877,7/15/2014 23:03:32,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES],[CAUSES],SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,N/A,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/15/2014 23:14:32,,1323899097,7/15/2014 23:14:14,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[CAUSES],[CAUSES],because of,N/A,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/15/2014 23:22:13,,1323903275,7/15/2014 23:21:58,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],because of,N/A,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/15/2014 23:23:49,,1323904308,7/15/2014 23:23:08,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],history of,N/A,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/15/2014 23:26:49,,1323905962,7/15/2014 23:26:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],because of,N/A,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/15/2014 23:36:42,,1323910996,7/15/2014 23:35:58,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],because,N/A,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/15/2014 23:40:05,,1323912881,7/15/2014 23:39:42,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],because of,N/A,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/15/2014 23:46:02,,1323915772,7/15/2014 23:45:22,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],year,asd,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/15/2014 23:47:28,,1323916588,7/15/2014 23:47:08,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],because of,n/a,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/15/2014 23:58:04,,1323922073,7/15/2014 23:57:05,instagc,1,19602039,USA,WA,Bellevue,50.135.214.140,[SYMPTOM],[SYMPTOM],because of,na,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/16/2014 00:50:13,,1323950806,7/16/2014 00:49:47,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[CAUSES],[CAUSES],because of,n/a,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/16/2014 01:13:12,,1323964636,7/16/2014 01:12:21,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,N/A,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/16/2014 01:35:28,,1323976667,7/16/2014 01:34:51,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[CAUSES],[CAUSES],because of,na,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/16/2014 02:14:37,,1323994383,7/16/2014 02:14:04,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[CAUSES],[CAUSES],because,none,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384153,7/16/2014 02:16:19,,1323995410,7/16/2014 02:15:53,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],because of,na,70,90,77,128,1,RO-disease_may_have_finding,902637-FS1,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
503384154,7/15/2014 23:09:52,,1323896594,7/15/2014 23:09:18,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],with a specific form of,N/A,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/15/2014 23:28:54,,1323906992,7/15/2014 23:27:07,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/15/2014 23:56:57,,1323921399,7/15/2014 23:55:17,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[SYMPTOM],[SYMPTOM],specific form of,Na,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/16/2014 00:26:24,,1323939244,7/16/2014 00:25:56,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[PART_OF],[PART_OF],"epilepsy with myoclonic absences, a rare disorder with a specific form of absence",n/a,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/16/2014 01:15:31,,1323965987,7/16/2014 01:15:20,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],SEIZURES,N/A,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/16/2014 02:06:26,,1323989839,7/16/2014 02:05:38,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[MANIFESTATION],[MANIFESTATION],with specific form of,na,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/16/2014 02:17:25,,1323996003,7/16/2014 02:17:00,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],specific form,Na,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/16/2014 04:49:57,,1324052700,7/16/2014 04:47:35,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[ASSOCIATED_WITH] [IS_A] [PART_OF] [SIDE_EFFECT],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]",ABSENCE EPILEPSY with specific form absence SEIZURES,N/A,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/16/2014 07:54:22,,1324113381,7/16/2014 07:53:55,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[SYMPTOM],[SYMPTOM],specific form of,n/a,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/16/2014 09:08:22,,1324135062,7/16/2014 09:08:07,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",ABSENCE EPILEPSY SEIZURES,n/a,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/16/2014 09:21:32,,1324141256,7/16/2014 09:19:55,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[MANIFESTATION],[MANIFESTATION],with,N/A,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/16/2014 11:47:38,,1324213670,7/16/2014 11:47:23,clixsense,1,6621167,USA,IL,Round Lake,24.12.122.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,na,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/16/2014 12:02:12,,1324218793,7/16/2014 12:01:55,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],specific form,N/A,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/16/2014 12:51:41,,1324237683,7/16/2014 12:51:10,clixsense,1,6500439,AUS,02,Ingleburn,115.146.65.99,[PREVENTS],[PREVENTS],specific form of absence,n/a,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384154,7/16/2014 12:58:09,,1324240589,7/16/2014 12:57:40,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],specific form of absence,n/a,120,18,127,34,1,RO-has_definitional_manifestation,904936-FS1,"The final form of ABSENCE EPILEPSY is epilepsy with myoclonic absences, a rare disorder with a specific form of absence SEIZURES",SEIZURES,ABSENCE EPILEPSY
503384155,7/15/2014 23:03:46,,1323892791,7/15/2014 23:03:11,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],may include,N/A,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/15/2014 23:09:16,,1323896198,7/15/2014 23:09:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],Treatment of may include,N/A,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/15/2014 23:18:58,,1323901623,7/15/2014 23:18:52,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],kojic,n/a,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/15/2014 23:26:17,,1323905695,7/15/2014 23:26:08,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],Treatment Treatment of HYPERPIGMENTATION may include HYDROQUINONE,N/A,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/15/2014 23:36:27,,1323910872,7/15/2014 23:35:58,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],Treatment HYPERPIGMENTATION include HYDROQUINONE,Treats,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/16/2014 00:36:36,,1323944267,7/16/2014 00:36:24,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[CAUSES],[CAUSES],may include,N/A,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/16/2014 00:42:30,,1323946970,7/16/2014 00:41:44,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],may include,N/A,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/16/2014 00:44:06,,1323947666,7/16/2014 00:43:47,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],Treatment of,N/A,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/16/2014 01:02:38,,1323958155,7/16/2014 01:02:04,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],"Treatment of HYPERPIGMENTATION include HYDROQUINONE kojic acid,",N/A,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/16/2014 01:14:34,,1323965414,7/16/2014 01:14:28,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],Treatment,N/A,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/16/2014 02:16:27,,1323995482,7/16/2014 02:16:15,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],Treatment,Na,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/16/2014 03:11:34,,1324015138,7/16/2014 03:11:07,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],Treatment of HYPERPIGMENTATION include HYDROQUINONE,N/A,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/16/2014 06:10:20,,1324079358,7/16/2014 06:09:45,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[TREATS],[TREATS],Treatment of,n/a,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/16/2014 06:42:55,,1324090156,7/16/2014 06:42:43,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],Treatment,n/a,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384155,7/16/2014 07:47:38,,1324111711,7/16/2014 07:47:19,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[TREATS],[TREATS],Treatment of,n/a,24,54,40,66,1,RO-may_treat,907808-FS1,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
503384156,7/15/2014 23:13:32,,1323898564,7/15/2014 23:13:21,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],capable,n/a,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/15/2014 23:14:44,,1323899218,7/15/2014 23:13:26,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"HEMORRHAGIC FEVER WITH RENAL SYNDROME virus capable neutralizing HANTAAN VIRUS,",Associated With,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 02:11:23,,1323992499,7/16/2014 02:10:24,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],neutralizing,none,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 02:15:17,,1323994767,7/16/2014 02:14:13,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two different terms,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 04:24:03,,1324045545,7/16/2014 04:21:51,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"patients HEMORRHAGIC FEVER WITH RENAL SYNDROME were capable neutralizing HANTAAN VIRUS,",N/A,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 05:32:03,,1324068155,7/16/2014 05:31:12,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],patients with,N/A,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 06:04:08,,1324077454,7/16/2014 06:02:35,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[TREATS],[TREATS],neutralizing,n/a,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 07:44:36,,1324110858,7/16/2014 07:43:50,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[PREVENTS],[PREVENTS],were capable of neutralizing,n/a,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 08:03:37,,1324116578,7/16/2014 08:03:07,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[SYMPTOM],[SYMPTOM],antibody,N/A,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 11:50:48,,1324214829,7/16/2014 11:50:32,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[PREVENTS],[PREVENTS],capable of neutralizing,N/A,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 11:58:58,,1324217529,7/16/2014 11:57:27,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[ASSOCIATED_WITH],[ASSOCIATED_WITH],phase antibody,N/A,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 12:52:04,,1324237875,7/16/2014 12:51:42,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],capable of neutralizing,n/a,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 12:53:11,,1324238393,7/16/2014 12:52:25,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SIDE_EFFECT],[SIDE_EFFECT],having higher antibody titers Hantaan virus,n/a,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 12:58:17,,1324240655,7/16/2014 12:56:48,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[CAUSES],[CAUSES],higher antibody titers,N/A,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384156,7/16/2014 12:58:37,,1324240852,7/16/2014 12:58:03,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[CONTRAINDICATES] [PART_OF],"[CONTRAINDICATES]
[PART_OF]","patients HEMORRHAGIC FEVER WITH RENAL SYNDROME neutralizing HANTAAN VIRUS,",They were able to neutralize the action,209,43,221,80,1,RO-has_causative_agent,903692-FS1,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
503384157,7/15/2014 23:43:06,,1323914250,7/15/2014 23:42:49,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],in treatment of,n/a,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 00:55:17,,1323953852,7/16/2014 00:55:08,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[TREATS],[TREATS],treatment,N/A,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 05:07:27,,1324060561,7/16/2014 05:07:03,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],in treatment of,N/A,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 05:37:00,,1324069419,7/16/2014 05:35:31,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],in treatment of,N/A,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 05:40:54,,1324070491,7/16/2014 05:40:37,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],in treatment of,N/A,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 05:57:12,,1324075375,7/16/2014 05:56:57,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],treatment of,N/A,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 06:59:26,,1324095723,7/16/2014 06:59:17,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],in treatment,N/a,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 07:54:01,,1324113325,7/16/2014 07:53:45,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],treatment,N/A,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 07:55:09,,1324113638,7/16/2014 07:54:56,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[TREATS],[TREATS],in treatment of,n/a,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 10:33:23,,1324185742,7/16/2014 10:33:04,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[TREATS],[TREATS],treatment of,n/a,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 11:48:38,,1324214066,7/16/2014 11:48:16,clixsense,1.0,6621167,USA,IL,Round Lake,24.12.122.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in treatment,na,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 11:55:51,,1324216451,7/16/2014 11:55:39,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],treatment,N/A,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 12:24:14,,1324226209,7/16/2014 12:23:35,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[TREATS],[TREATS],treatment of,N/A,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 12:51:09,,1324237412,7/16/2014 12:50:50,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],in treatment of,n/a,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384157,7/16/2014 12:51:29,,1324237614,7/16/2014 12:51:17,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],in treatment of,n/a,41,14,52,24,1,RO-may_treat,907499-FS1,Aldactone and ACEBUTOLOL in treatment of HYPERTENSION,HYPERTENSION,ACEBUTOLOL
503384158,7/15/2014 23:02:05,,1323891581,7/15/2014 23:01:32,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],Intra articular application of Placenta in the arthritis of patients with,N/A,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/15/2014 23:09:11,,1323896127,7/15/2014 23:08:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared with,N/A,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/15/2014 23:11:49,,1323897657,7/15/2014 23:11:36,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[LOCATION],[LOCATION],JOINTS of patients with RHEUMATOID ARTHRITIS,N/A,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/15/2014 23:13:47,,1323898688,7/15/2014 23:13:40,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],JOINTS,n/a,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/15/2014 23:30:23,,1323907847,7/15/2014 23:29:56,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],results significant improvement,N/A,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/16/2014 00:16:57,,1323934535,7/16/2014 00:16:19,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[LOCATION],[LOCATION],of patients with,n/a,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/16/2014 00:48:06,,1323949586,7/16/2014 00:47:04,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,JOINTS of patients with RHEUMATOID ARTHRITIS,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/16/2014 00:56:22,,1323954552,7/16/2014 00:55:35,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],with,N/A,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/16/2014 03:23:30,,1324018990,7/16/2014 03:22:34,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[LOCATION] [TREATS],"[TREATS]
[LOCATION]",JOINTS RHEUMATOID ARTHRITIS,n/a,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/16/2014 06:22:29,,1324083655,7/16/2014 06:21:56,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[LOCATION],[LOCATION],in the arthritis JOINTS of patients with,"because ""  in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS """,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/16/2014 06:29:34,,1324086170,7/16/2014 06:29:18,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],in the arthritis JOINTS,n/a,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/16/2014 07:45:48,,1324111206,7/16/2014 07:45:25,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of patients with,n/a,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/16/2014 08:00:03,,1324115226,7/16/2014 07:59:42,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[IS_A],[IS_A],of patients with,Is a disease of the joints.,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/16/2014 09:08:38,,1324135153,7/16/2014 09:08:23,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[LOCATION],[LOCATION],arthritis JOINTS,n/a,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384158,7/16/2014 10:38:57,,1324187712,7/16/2014 10:37:47,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[LOCATION],[LOCATION],in the,n/a,57,81,62,101,1,RO-disease_has_primary_anatomic_site,902088-FS1,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
503384159,7/15/2014 23:03:31,,1323892595,7/15/2014 23:03:13,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[TREATS],[TREATS],IRON DEFICIENCY ANEMIA prevent recurrence of IRON,N/A,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/15/2014 23:10:34,,1323897005,7/15/2014 23:10:11,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[TREATS],[TREATS],replacement,N/A,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/15/2014 23:10:46,,1323897056,7/15/2014 23:09:53,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],DEFICIENCY,N/A,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/15/2014 23:26:42,,1323905902,7/15/2014 23:26:24,instagc,1.0,13763729,USA,"","",75.182.89.225,[PART_OF],[PART_OF],IRON DEFICIENCY ANEMIA IRON deficiency.,N/A,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/15/2014 23:32:15,,1323908873,7/15/2014 23:31:52,clixsense,1.0,15189335,GBR,H9,London,188.29.165.200,[TREATS],[TREATS],prevent,Na,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/15/2014 23:42:23,,1323913872,7/15/2014 23:42:05,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],IRON deficiency.,N/A,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/16/2014 00:57:21,,1323955035,7/16/2014 00:57:06,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],replacement,N/A,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/16/2014 01:01:07,,1323957313,7/16/2014 01:00:33,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],"IRON DEFICIENCY ANEMIA replacement of iron stores,",N/A,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/16/2014 03:05:00,,1324012904,7/16/2014 03:04:25,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],correction of IRON DEFICIENCY ANEMIA IRON,N/A,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/16/2014 05:30:06,,1324067630,7/16/2014 05:28:27,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],prevent the recurrence of,N/A,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/16/2014 06:59:46,,1324095833,7/16/2014 06:59:27,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],replacement of iron,N/a,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/16/2014 07:37:08,,1324108948,7/16/2014 07:36:19,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],replacement of iron,N/A,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/16/2014 08:05:50,,1324117159,7/16/2014 08:05:22,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],prevent the recurrence,N/A,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/16/2014 11:37:10,,1324209805,7/16/2014 11:36:27,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[PREVENTS],[PREVENTS],can prevent the recurrence,and it can prevent the recurrence of IRON deficiency.,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384159,7/16/2014 12:04:26,,1324219630,7/16/2014 12:03:49,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],recurrence of,N/A,96,96,117,100,1,RO-may_prevent,907379-FS1,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
503384160,7/15/2014 23:04:17,,1323893183,7/15/2014 23:03:54,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[MANIFESTATION],[MANIFESTATION],LEVODOPA in PARKINSON'S DISEASE,N/A,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/15/2014 23:10:52,,1323897133,7/15/2014 23:10:41,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SIDE_EFFECT],[SIDE_EFFECT],experience,N/A,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/15/2014 23:23:26,,1323904016,7/15/2014 23:23:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],in,N/A,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/15/2014 23:31:06,,1323908279,7/15/2014 23:30:42,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],experience with in,N/A,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/16/2014 00:29:16,,1323940664,7/16/2014 00:28:24,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[PART_OF],[PART_OF],in,n/a,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/16/2014 00:29:58,,1323941025,7/16/2014 00:29:20,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Long term experience with,[DIAGNOSE_BY_TEST_OR_DRUG],66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/16/2014 00:54:43,,1323953507,7/16/2014 00:53:02,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,LEVODOPA in PARKINSON'S DISEASE,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/16/2014 01:08:31,,1323961771,7/16/2014 01:07:32,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Long term experience with LEVODOPA in PARKINSON'S DISEASE,N/A,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/16/2014 01:19:41,,1323968445,7/16/2014 01:19:11,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[TREATS],[TREATS],Long term in,N/A,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/16/2014 02:05:55,,1323989544,7/16/2014 02:05:11,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],experience with,n/a,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/16/2014 02:15:53,,1323995119,7/16/2014 02:15:29,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],Long term experience,Na,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/16/2014 03:03:47,,1324012430,7/16/2014 03:03:14,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",LEVODOPA in PARKINSON'S DISEASE,N/A,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/16/2014 04:20:36,,1324044481,7/16/2014 04:20:18,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],Long term experience,N/A,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/16/2014 05:02:30,,1324058718,7/16/2014 05:01:58,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[PART_OF],[PART_OF],LEVODOPA in PARKINSON'S DISEASE,N/A,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384160,7/16/2014 05:04:03,,1324059294,7/16/2014 05:03:38,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,N/A,66,54,84,62,1,RO-may_treat,907899-FS1,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
503384161,7/15/2014 23:07:30,,1323895102,7/15/2014 23:06:55,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],includes,N/A,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/15/2014 23:19:07,,1323901690,7/15/2014 23:18:25,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosis of SCC,N/A,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/15/2014 23:19:52,,1323902143,7/15/2014 23:19:46,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],"keratoacanthoma,",n/a,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/15/2014 23:33:10,,1323909390,7/15/2014 23:32:47,clixsense,1.0,15189335,GBR,H9,London,188.29.165.200,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of includes,Na,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/16/2014 00:29:56,,1323941033,7/16/2014 00:29:26,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH],[ASSOCIATED_WITH],The differential diagnosis of SCC includes,N/A,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/16/2014 00:32:06,,1323942085,7/16/2014 00:31:44,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosis,n/a,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/16/2014 00:32:44,,1323942431,7/16/2014 00:31:58,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],includes and,n/a,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/16/2014 01:13:23,,1323964681,7/16/2014 01:13:10,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/16/2014 04:10:57,,1324040531,7/16/2014 04:10:33,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[PART_OF],[PART_OF],"VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS",n/a,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/16/2014 05:21:09,,1324065103,7/16/2014 05:19:58,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[OTHER] [PREVENTS],"[PREVENTS]
[OTHER]",The differential diagnosis of SCC includes,N/A,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/16/2014 05:59:27,,1324076100,7/16/2014 05:58:59,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,different consitions,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/16/2014 06:40:28,,1324089388,7/16/2014 06:40:03,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],differential diagnosis includes,n/a,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/16/2014 06:59:00,,1324095518,7/16/2014 06:58:41,instagc,1.0,18960682,GBR,"","",86.29.147.112,[OTHER],[OTHER],includes,N/a,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/16/2014 09:15:25,,1324137519,7/16/2014 09:14:49,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VERRUCOUS CARCINOMA HYPERTROPHIC ACTINIC KERATOSIS,n/a,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384161,7/16/2014 10:44:58,,1324191728,7/16/2014 10:44:09,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],includes,N/A,125,100,154,119,-1,RO-disease_has_finding,901795-FS1,"Differential diagnosis   The differential diagnosis of SCC includes keratoacanthoma, Bowen disease, VERRUCOUS CARCINOMA BCC, HYPERTROPHIC ACTINIC KERATOSIS and common warts.",HYPERTROPHIC ACTINIC KERATOSIS,VERRUCOUS CARCINOMA
503384162,7/15/2014 23:41:31,,1323913504,7/15/2014 23:41:12,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],lack of suppression,N/A,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/15/2014 23:53:38,,1323919749,7/15/2014 23:53:18,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 00:22:25,,1323937430,7/16/2014 00:22:10,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 00:31:04,,1323941654,7/16/2014 00:30:47,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 00:54:02,,1323953091,7/16/2014 00:52:08,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],with,N/A,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 01:18:22,,1323967778,7/16/2014 01:17:48,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[TREATS],[TREATS],doses,N/A,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 04:02:47,,1324035916,7/16/2014 04:01:36,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],HYPERCORTISOLISM DEXAMETHASONE,n/a,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 05:08:19,,1324060830,7/16/2014 05:07:28,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[PREVENTS],[PREVENTS],lack of suppression of,N/A,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 10:54:53,,1324195599,7/16/2014 10:54:13,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],"had undetectable of ACTH, lack of suppression of",nA,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 11:53:10,,1324215577,7/16/2014 11:52:47,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 12:00:11,,1324217945,7/16/2014 11:58:59,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[TREATS],[TREATS],suppression with,N/A,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 12:56:08,,1324239715,7/16/2014 12:55:32,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],undetectable levels with,n/a,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 12:56:47,,1324240005,7/16/2014 12:55:44,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],lack of suppression,N/A,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 12:59:25,,1324241184,7/16/2014 12:58:58,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],lack of suppression of with,n/a,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384162,7/16/2014 13:01:32,,1324241961,7/16/2014 13:00:23,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[PREVENTS] [MANIFESTATION],"[PREVENTS]
[MANIFESTATION]","of undetectable glands MRI,",It is the treatment of the cause.,124,146,139,159,1,RO-may_diagnose,906846-FS1,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
503384163,7/15/2014 23:08:22,,1323895608,7/15/2014 23:08:12,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE,N/A,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/15/2014 23:22:28,,1323903404,7/15/2014 23:22:14,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],HEADACHE,N/A,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/15/2014 23:25:38,,1323905327,7/15/2014 23:25:18,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],attack type headaches,N/A,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/15/2014 23:37:09,,1323911269,7/15/2014 23:36:28,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],"attack type headaches (migraine, CLUSTER HEADACHE EPISODIC TYPE HEADACHE",Is A,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/15/2014 23:45:23,,1323915424,7/15/2014 23:44:07,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[ASSOCIATED_WITH],[ASSOCIATED_WITH],combined,Na,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/16/2014 00:29:17,,1323940691,7/16/2014 00:28:15,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],focused on attack type headaches,[DIAGNOSE_BY_TEST_OR_DRUG],100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/16/2014 00:29:25,,1323940730,7/16/2014 00:28:55,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[OTHER],[OTHER],"(migraine, and and chronic or daily headaches",N/A,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/16/2014 01:22:11,,1323970128,7/16/2014 01:21:28,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[OTHER],[OTHER],type headaches,na,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/16/2014 01:22:13,,1323970186,7/16/2014 01:21:52,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PART_OF],[PART_OF],CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE,N/A,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/16/2014 01:53:11,,1323983231,7/16/2014 01:52:21,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two different things,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/16/2014 02:03:00,,1323988263,7/16/2014 02:02:20,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],and,none,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/16/2014 03:38:44,,1324024630,7/16/2014 03:37:56,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CLUSTER HEADACHE EPISODIC TENSION TYPE HEADACHE,n/a,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/16/2014 03:51:42,,1324030754,7/16/2014 03:50:58,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CLUSTER HEADACHE EPISODIC TENSION TYPE HEADACHE,n/a,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/16/2014 05:58:37,,1324075833,7/16/2014 05:58:05,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,different types of headache,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384163,7/16/2014 07:06:35,,1324098801,7/16/2014 07:06:16,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],"attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE",N/a,100,79,129,95,-1,RO-has_definitional_manifestation,904944-FS1,"The analysis of the data primarily focused on attack type headaches (migraine, CLUSTER HEADACHE and EPISODIC TENSION TYPE HEADACHE and chronic or daily headaches (chronic tension type headache and migraine combined with tension type headache.",EPISODIC TENSION TYPE HEADACHE,CLUSTER HEADACHE
503384164,7/15/2014 23:04:34,,1323893347,7/15/2014 23:04:18,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[OTHER],[OTHER],TENSION TYPE HEADACHE or MIGRAINE,Similar but not the same,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/15/2014 23:14:15,,1323898972,7/15/2014 23:14:04,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],HEADACHE,n/a,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/15/2014 23:18:03,,1323900957,7/15/2014 23:17:32,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",cause symptom,N/A,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/15/2014 23:21:17,,1323902886,7/15/2014 23:20:27,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/15/2014 23:54:07,,1323919955,7/15/2014 23:53:39,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They are each a type of headache but don't seem to be related to each other.,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/16/2014 00:30:12,,1323941167,7/16/2014 00:29:57,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[IS_A],[IS_A],or,N/A,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/16/2014 00:41:49,,1323946674,7/16/2014 00:39:41,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,[NONE],[NONE],N/a,The relationship is not between these two symptoms.,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/16/2014 01:24:01,,1323971379,7/16/2014 01:23:30,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[OTHER],[OTHER],or,na,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/16/2014 02:42:14,,1324005399,7/16/2014 02:41:41,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",but headache may be a symptom,n/a,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/16/2014 04:43:34,,1324050694,7/16/2014 04:43:08,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],cause usually TENSION TYPE HEADACHE or MIGRAINE,N/A,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/16/2014 06:03:33,,1324077283,7/16/2014 06:03:14,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,different consitions,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/16/2014 06:42:04,,1324089935,7/16/2014 06:41:46,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,n/a,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/16/2014 06:57:59,,1324095132,7/16/2014 06:57:50,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/a,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/16/2014 07:47:56,,1324111758,7/16/2014 07:47:38,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,n/a,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384164,7/16/2014 09:09:17,,1324135325,7/16/2014 09:09:08,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,n/a,59,84,79,92,-1,RO-has_definitional_manifestation,904704-FS1,"When pregnant women develop headache, the cause is usually TENSION TYPE HEADACHE or MIGRAINE but headache may be a symptom of a more serious neurologic or medical condition.",TENSION TYPE HEADACHE,MIGRAINE
503384165,7/15/2014 23:24:33,,1323904739,7/15/2014 23:23:53,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],should receive,N/A,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/15/2014 23:29:33,,1323907360,7/15/2014 23:29:00,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],should receive,N/A,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 00:35:07,,1323943628,7/16/2014 00:34:56,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[TREATS],[TREATS],should receive for,N/A,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 00:58:41,,1323955743,7/16/2014 00:58:13,elite,1.0,27788262,USA,"","",172.163.6.138,[TREATS],[TREATS],for,N/A,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 01:07:30,,1323960965,7/16/2014 01:06:54,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",PARACETAMOL for PAIN,N/A,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 01:12:23,,1323964215,7/16/2014 01:12:08,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],for,N/A,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 01:57:52,,1323985253,7/16/2014 01:57:26,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],receive for,na,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 02:54:42,,1324009164,7/16/2014 02:54:15,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],PARACETAMOL for PAIN,N/A,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 05:26:18,,1324066590,7/16/2014 05:25:55,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],should receive,N/A,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 07:33:26,,1324108014,7/16/2014 07:32:40,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],should receive,N/A,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 09:14:48,,1324137266,7/16/2014 09:14:37,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",for,n/a,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 10:33:03,,1324185598,7/16/2014 10:32:04,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[TREATS],[TREATS],receive for,n/a,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 10:59:36,,1324197091,7/16/2014 10:58:59,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],should receive PARACETAMOL for PAIN and fever,N/A,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 11:35:04,,1324209263,7/16/2014 11:34:17,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[TREATS],[TREATS],should receive for,"because:

should receive PARACETAMOL for PAIN and fever",76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384165,7/16/2014 11:52:30,,1324215370,7/16/2014 11:52:18,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],should receive,N/A,76,60,79,71,1,RO-may_treat,908195-FS1,Measles patients with an acute ear infection should receive PARACETAMOL for PAIN and fever and an antibiotic for the infection.,PAIN,PARACETAMOL
503384166,7/15/2014 23:09:07,,1323896108,7/15/2014 23:08:47,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Percutaneous aspiration of the GALLBLADDER performed to diagnosis ACUTE CHOLECYSTITIS,N/A,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/15/2014 23:22:05,,1323903247,7/15/2014 23:21:38,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/15/2014 23:24:34,,1323904744,7/15/2014 23:24:02,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/15/2014 23:51:37,,1323918817,7/15/2014 23:51:10,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],GALLBLADDER was,asd,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/16/2014 05:05:56,,1324059963,7/16/2014 05:04:04,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to establish,N/A,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/16/2014 07:53:44,,1324113220,7/16/2014 07:53:13,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],performed,N/A,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/16/2014 10:25:16,,1324182879,7/16/2014 10:24:12,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[LOCATION],[LOCATION],aspiration of,n/a,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/16/2014 10:48:52,,1324193933,7/16/2014 10:48:24,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],establish the diagnosis,N/A,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/16/2014 11:31:25,,1324208076,7/16/2014 11:30:44,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],establish the diagnosis,"because of 

most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient",31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/16/2014 11:51:44,,1324215152,7/16/2014 11:51:26,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[LOCATION],[LOCATION],of the,N/A,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/16/2014 11:52:15,,1324215287,7/16/2014 11:51:10,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],establish diagnosis,N/A,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/16/2014 12:21:46,,1324225316,7/16/2014 12:21:06,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[CAUSES],[CAUSES],the diagnosis,N/A,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/16/2014 12:48:03,,1324235957,7/16/2014 12:47:40,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],the diagnosis of,n/a,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/16/2014 12:51:53,,1324237776,7/16/2014 12:51:30,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Percutaneous aspiration of the GALLBLADDER was performed to establish the diagnosis ACUTE CHOLECYSTITIS,n/a,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384166,7/16/2014 12:59:57,,1324241376,7/16/2014 12:59:09,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",aspiration GALLBLADDER was performed hospitalized establish diagnosis ACUTE CHOLECYSTITIS,They must first test it,31,133,41,152,1,RO-has_finding_site,905242-FS1,"Percutaneous aspiration of the GALLBLADDER was performed for nine hospitalized patients, most commonly to establish the diagnosis of ACUTE CHOLECYSTITIS and its complications in the critically ill patient or patient with sepsis.",GALLBLADDER,ACUTE CHOLECYSTITIS
503384167,7/15/2014 23:13:00,,1323898220,7/15/2014 23:12:51,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],coumarin,N/A,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/15/2014 23:14:48,,1323899250,7/15/2014 23:14:42,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],prevention,n/a,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/15/2014 23:21:57,,1323903189,7/15/2014 23:21:39,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[PREVENTS],[PREVENTS],for the prevention of,N/A,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/15/2014 23:29:35,,1323907401,7/15/2014 23:29:22,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PART_OF],[PART_OF],versus,N/A,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/15/2014 23:30:40,,1323907966,7/15/2014 23:29:59,instagc,1.0,13763729,USA,"","",75.182.89.225,[PREVENTS],[PREVENTS],for the prevention of,N/A,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/15/2014 23:35:57,,1323910676,7/15/2014 23:35:17,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[PREVENTS],[PREVENTS],LOW MOLECULAR WEIGHT HEPARIN prevention RECURRENT VENOUS THROMBOEMBOLISM,Prevents,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/16/2014 00:00:45,,1323923500,7/15/2014 23:59:34,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,[PREVENTS],[PREVENTS],prevention of,na,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/16/2014 00:03:25,,1323925209,7/16/2014 00:02:18,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],WEIGHT HEPARIN,asd,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/16/2014 00:14:33,,1323932832,7/16/2014 00:13:52,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PREVENTS],[PREVENTS],prevention,n/a,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/16/2014 00:26:01,,1323939077,7/16/2014 00:25:30,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],for the prevention of,N/A,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/16/2014 00:34:20,,1323943186,7/16/2014 00:33:48,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],prevention,n/a,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/16/2014 00:51:01,,1323951171,7/16/2014 00:50:51,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PREVENTS],[PREVENTS],prevention,N/A,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/16/2014 01:14:27,,1323965283,7/16/2014 01:14:15,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PREVENTS],[PREVENTS],prevention,N/A,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/16/2014 01:22:44,,1323970496,7/16/2014 01:22:15,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PREVENTS],[PREVENTS],LOW MOLECULAR WEIGHT HEPARIN prevention of RECURRENT VENOUS THROMBOEMBOLISM,N/A,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384167,7/16/2014 01:46:11,,1323980457,7/16/2014 01:45:49,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[PREVENTS],[PREVENTS],prevention,none,69,0,100,28,1,RO-may_prevent,907025-FS1,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
503384168,7/15/2014 23:07:54,,1323895322,7/15/2014 23:07:36,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],atrioventricular,N/A,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/15/2014 23:10:57,,1323897193,7/15/2014 23:10:35,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[CAUSES],[CAUSES],triggering,N/A,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/15/2014 23:25:13,,1323905110,7/15/2014 23:24:38,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggesting a role of,N/A,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/15/2014 23:39:10,,1323912433,7/15/2014 23:38:44,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES],[CAUSES],triggering the clinical episodes,n/a,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/15/2014 23:39:32,,1323912627,7/15/2014 23:38:02,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],VENTRICULAR TACHYCARDIA suggesting role ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA triggering the,Is A,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/15/2014 23:44:48,,1323915075,7/15/2014 23:44:11,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES],[CAUSES],role of in triggering,N/A,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/16/2014 00:00:35,,1323923395,7/16/2014 00:00:21,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],VENTRICULAR ventricular,asd,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/16/2014 00:01:45,,1323924180,7/16/2014 00:01:23,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggesting a role of,n/a,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/16/2014 00:11:05,,1323930526,7/16/2014 00:10:35,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggesting a role,n/a,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/16/2014 00:19:38,,1323936130,7/16/2014 00:19:06,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[CAUSES],[CAUSES],suggesting a role,I did not select none,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/16/2014 00:24:12,,1323938204,7/16/2014 00:23:27,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],suggesting a role of,[DIAGNOSE_BY_TEST_OR_DRUG],234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/16/2014 01:15:43,,1323966061,7/16/2014 01:15:33,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],role,N/A,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/16/2014 01:30:19,,1323974624,7/16/2014 01:29:47,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[CAUSES],[CAUSES],triggering,na,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/16/2014 01:50:56,,1323982295,7/16/2014 01:49:49,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES] [PREVENTS],"[PREVENTS]
[CAUSES]",in triggering the clinical episodes of,na,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384168,7/16/2014 02:23:26,,1323998634,7/16/2014 02:23:12,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],role,Na,234,189,277,212,-1,RO-has_definitional_manifestation,904794-FS1,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
503384169,7/15/2014 23:13:25,,1323898480,7/15/2014 23:12:31,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A] [TREATS],"[TREATS]
[IS_A]",SIDS SIDS SUDDEN INFANT DEATHS,Is A,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/15/2014 23:53:18,,1323919607,7/15/2014 23:52:41,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[IS_A],[IS_A],"and, consequently, reduce the number of",n/a,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 00:06:51,,1323927459,7/16/2014 00:06:37,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],LQTS,asd,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 00:12:01,,1323931128,7/16/2014 00:11:22,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",reduce the number of unexplained,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [TREATS],41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 00:48:29,,1323949765,7/16/2014 00:48:10,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PREVENTS],[PREVENTS],reduce,N/A,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 00:51:52,,1323951514,7/16/2014 00:50:14,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[IS_A],[IS_A],SIDS SUDDEN INFANT DEATHS,n/a,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 02:16:43,,1323995660,7/16/2014 02:15:50,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"and,",none,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 02:23:53,,1323998844,7/16/2014 02:23:39,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],unexplained,Na,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 04:19:59,,1324044289,7/16/2014 04:19:34,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],mutations,N/A,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 05:26:54,,1324066755,7/16/2014 05:25:45,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],"and, consequently, reduce the number of unexplained",N/A,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 05:57:39,,1324075528,7/16/2014 05:57:14,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[IS_A],[IS_A],SIDS SUDDEN INFANT DEATHS,N/A,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 08:14:32,,1324119694,7/16/2014 08:13:51,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[PREVENTS],[PREVENTS],reduce the number of unexplained SUDDEN INFANT DEATHS,"because of:

 new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 09:11:41,,1324136128,7/16/2014 09:11:08,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",SIDS SUDDEN INFANT DEATHS,n/a,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 09:19:54,,1324139948,7/16/2014 09:18:00,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],SUDDEN INFANT DEATHS,N/A,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384169,7/16/2014 11:53:04,,1324215549,7/16/2014 11:52:24,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[CAUSES],[CAUSES],reduce unexplained,N/A,41,164,44,184,-1,RO-cause_of,900196-FS1,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
503384170,7/15/2014 23:09:16,,1323896191,7/15/2014 23:09:02,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[PART_OF],[PART_OF],THROMBOCYTHEMIA THROMBOCYTHEMIA,N/A,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/15/2014 23:35:28,,1323910450,7/15/2014 23:33:37,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],is,N/A,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/15/2014 23:55:24,,1323920601,7/15/2014 23:54:43,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],ESSENTIAL THROMBOCYTHEMIA (Essential Thrombocytosis; Primary THROMBOCYTHEMIA ESSENTIAL THROMBOCYTHEMIA,N/A,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/16/2014 00:49:37,,1323950473,7/16/2014 00:49:13,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],characterized,N/A,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/16/2014 00:54:33,,1323953421,7/16/2014 00:54:03,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],is characterized by,N/A,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/16/2014 02:41:14,,1324005099,7/16/2014 02:40:48,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]","characterized by an increased platelet count,",n/a,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/16/2014 02:50:25,,1324008012,7/16/2014 02:49:19,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A],[IS_A],ESSENTIAL THROMBOCYTHEMIA Primary THROMBOCYTHEMIA ESSENTIAL THROMBOCYTHEMIA is,N/A,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/16/2014 03:49:36,,1324029761,7/16/2014 03:48:45,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ESSENTIAL THROMBOCYTHEMIA THROMBOCYTHEMIA ESSENTIAL,n/a,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/16/2014 05:03:37,,1324059148,7/16/2014 05:02:43,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],THROMBOCYTHEMIA THROMBOCYTHEMIA,N/A,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/16/2014 07:01:37,,1324096508,7/16/2014 07:01:19,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],ESSENTIAL THROMBOCYTHEMIA,N/a,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/16/2014 10:57:23,,1324196439,7/16/2014 10:56:46,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],ESSENTIAL THROMBOCYTHEMIA THROMBOCYTHEMIA ESSENTIAL THROMBOCYTHEMIA,N/A,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/16/2014 11:50:15,,1324214686,7/16/2014 11:49:55,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(Essential Thrombocytosis;,N/A,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/16/2014 12:13:26,,1324222492,7/16/2014 12:12:21,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[PART_OF],[PART_OF],is characterized,N/A,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/16/2014 12:55:31,,1324239395,7/16/2014 12:54:59,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],characterized by,n/a,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384170,7/16/2014 12:57:39,,1324240412,7/16/2014 12:56:55,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],"is characterized by increased platelet count,",n/a,10,0,24,25,-1,RO-disease_has_finding,901683-FS1,"ESSENTIAL THROMBOCYTHEMIA  (Essential Thrombocytosis; Primary THROMBOCYTHEMIA  ESSENTIAL THROMBOCYTHEMIA is characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or thrombotic tendency.",THROMBOCYTHEMIA,ESSENTIAL THROMBOCYTHEMIA
503384171,7/15/2014 23:17:33,,1323900682,7/15/2014 23:16:26,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",with,N/A,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/15/2014 23:17:39,,1323900732,7/15/2014 23:17:23,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,N/A,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/15/2014 23:17:44,,1323900787,7/15/2014 23:16:38,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[LOCATION],[LOCATION],in,N/A,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/15/2014 23:19:19,,1323901820,7/15/2014 23:19:14,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],"AH,",n/a,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/15/2014 23:29:21,,1323907232,7/15/2014 23:28:57,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],with or without,N/A,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/16/2014 00:12:48,,1323931610,7/16/2014 00:12:01,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],Simvastatin with without EZETIMIBE FAMILIAL HYPERCHOLESTEROLEMIA,Treats,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/16/2014 00:25:30,,1323938824,7/16/2014 00:25:08,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],in,N/A,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/16/2014 00:30:35,,1323941344,7/16/2014 00:30:18,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[PART_OF],[PART_OF],in,n/a,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/16/2014 00:47:03,,1323948968,7/16/2014 00:46:41,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/16/2014 00:54:52,,1323953619,7/16/2014 00:54:02,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[NONE],[NONE],na,there is no relation mentioned,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/16/2014 01:28:28,,1323973791,7/16/2014 01:27:14,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[TREATS],[TREATS],with or without in,na,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/16/2014 02:04:49,,1323989152,7/16/2014 02:04:05,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],in,none,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/16/2014 03:33:01,,1324022312,7/16/2014 03:32:00,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],EZETIMIBE FAMILIAL HYPERCHOLESTEROLEMIA,n/a,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/16/2014 04:09:31,,1324039758,7/16/2014 04:08:38,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],EZETIMIBE FAMILIAL HYPERCHOLESTEROLEMIA,n/a,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384171,7/16/2014 05:58:04,,1324075654,7/16/2014 05:57:39,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[CAUSES],[CAUSES],in,N/A,125,112,153,121,1,RO-may_treat,907942-FS1,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503384172,7/15/2014 23:07:33,,1323895153,7/15/2014 23:07:00,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],is expected,N/A,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/15/2014 23:08:39,,1323895766,7/15/2014 23:08:18,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[SYMPTOM],[SYMPTOM],in patients,N/A,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/15/2014 23:11:34,,1323897536,7/15/2014 23:11:25,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],years,N/A,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/15/2014 23:21:31,,1323903011,7/15/2014 23:21:05,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS,N/A,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/15/2014 23:31:28,,1323908439,7/15/2014 23:31:04,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],expected,N/A,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/15/2014 23:32:55,,1323909222,7/15/2014 23:32:17,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],in patients with,N/A,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/15/2014 23:40:18,,1323912951,7/15/2014 23:39:56,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[SYMPTOM],[SYMPTOM],expected,Na,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/16/2014 00:13:40,,1323932178,7/16/2014 00:12:50,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",SEIZURE outcome patients with GANGLIOGLIOMAS,Manifestation / Associated With,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/16/2014 00:31:57,,1323942049,7/16/2014 00:30:11,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS] [MANIFESTATION],"[TREATS]
[MANIFESTATION]",expected,n/a,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/16/2014 02:20:30,,1323997449,7/16/2014 02:18:42,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[SYMPTOM],[SYMPTOM],Good outcome is expected in patients with,na,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/16/2014 02:24:17,,1323998977,7/16/2014 02:24:05,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],expected,Na,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/16/2014 03:58:28,,1324033958,7/16/2014 03:57:55,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],SEIZURE GANGLIOGLIOMAS,n/a,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/16/2014 05:22:26,,1324065444,7/16/2014 05:21:43,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],expected in patients with,N/A,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/16/2014 07:05:13,,1324098145,7/16/2014 07:04:42,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS,N/a,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384172,7/16/2014 07:40:45,,1324109928,7/16/2014 07:40:11,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with,n/a,5,50,11,64,1,RO-disease_may_have_finding,902773-FS1,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
503384173,7/16/2014 00:05:13,,1323926472,7/16/2014 00:04:14,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SEPSIS,asd,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 00:05:56,,1323926910,7/16/2014 00:04:43,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[CAUSES],[CAUSES],resulting,n/a,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 00:56:56,,1323954839,7/16/2014 00:56:34,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],resulting,N/A,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 01:21:24,,1323969615,7/16/2014 01:20:50,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[CAUSES],[CAUSES],resulting in,na,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 02:06:37,,1323989917,7/16/2014 02:05:56,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],may activate host inflammatory,n/a,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 02:21:41,,1323997850,7/16/2014 02:21:05,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],"may activate host inflammatory responses, resulting in the",na,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 05:08:54,,1324061051,7/16/2014 05:08:20,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],may activate,N/A,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 07:42:45,,1324110431,7/16/2014 07:42:19,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[CAUSES],[CAUSES],resulting in,n/a,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 08:01:20,,1324115781,7/16/2014 08:00:55,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"activate host inflammatory responses,",N/A,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 10:19:35,,1324180809,7/16/2014 10:18:55,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[CAUSES],[CAUSES],may activate,n/a,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 10:56:45,,1324196262,7/16/2014 10:56:06,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],"During GRAM NEGATIVE SEPSIS may activate host inflammatory responses, resulting in the",N/A,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 12:01:40,,1324218551,7/16/2014 12:01:23,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[CAUSES],[CAUSES],may activate,N/A,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 12:02:00,,1324218733,7/16/2014 12:01:23,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],During resulting,N/A,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 12:48:57,,1324236379,7/16/2014 12:48:34,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],resulting in the,n/a,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384173,7/16/2014 12:50:35,,1324237200,7/16/2014 12:49:52,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SIDE_EFFECT],[SIDE_EFFECT],resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,n/a,122,7,160,27,-1,RO-cause_of,900353-FS1,"During GRAM NEGATIVE SEPSIS endotoxin lipopolysaccharide (LPS) may activate host inflammatory responses, resulting in the SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the adult respiratory distress syndrome.",SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,GRAM NEGATIVE SEPSIS
503384174,7/15/2014 23:28:56,,1323906993,7/15/2014 23:28:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],characterized by,N/A,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/15/2014 23:53:53,,1323919859,7/15/2014 23:53:21,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[SYMPTOM],[SYMPTOM],characterized by,Na,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/15/2014 23:56:18,,1323921027,7/15/2014 23:56:04,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],nodules with,asda,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/16/2014 00:03:39,,1323925369,7/16/2014 00:02:06,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[SYMPTOM],[SYMPTOM],disorder characterized by,N/A,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/16/2014 00:13:50,,1323932319,7/16/2014 00:13:28,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],LYMPHOMATOID PAPULOSIS,n/a,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/16/2014 00:15:21,,1323933450,7/16/2014 00:14:31,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",cutaneous disorder characterized by recurrent eruptions,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/16/2014 00:26:00,,1323939054,7/16/2014 00:25:10,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",characterized by,N/A,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/16/2014 00:31:41,,1323941963,7/16/2014 00:31:20,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[SYMPTOM],[SYMPTOM],a cutaneous disorder characterized by recurrent eruptions of self healing,n/a,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/16/2014 02:31:10,,1324001822,7/16/2014 02:30:42,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[PART_OF],[PART_OF],small nodules,n/a,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/16/2014 05:40:53,,1324070492,7/16/2014 05:39:35,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],characterized by recurrent,N/A,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/16/2014 06:33:02,,1324087147,7/16/2014 06:32:42,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],characterized by,n/a,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/16/2014 07:00:07,,1324095936,7/16/2014 06:59:46,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],recurrent eruptions of self healing PAPULES,N/a,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/16/2014 07:44:59,,1324110973,7/16/2014 07:44:37,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[SYMPTOM],[SYMPTOM],characterized by,n/a,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/16/2014 08:07:13,,1324117567,7/16/2014 08:06:56,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[SYMPTOM],[SYMPTOM],characterized,N/A,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384174,7/16/2014 11:00:55,,1324197494,7/16/2014 11:00:20,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],histologic features of LYMPHOMATOID PAPULOSIS PAPULES,N/A,164,67,170,89,1,RO-disease_may_have_finding,902774-FS1,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
503384175,7/15/2014 23:06:59,,1323894847,7/15/2014 23:06:28,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",treatment of,N/A,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/15/2014 23:09:38,,1323896423,7/15/2014 23:09:30,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],"paroxetine,",N/A,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/15/2014 23:12:30,,1323897962,7/15/2014 23:11:31,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],"paroxetine, clomipramine placebo treatment PANIC DISORDER: PAROXETINE",Treats,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/15/2014 23:33:19,,1323909442,7/15/2014 23:32:53,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",comparison of treatment,N/A,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/16/2014 00:15:10,,1323933299,7/16/2014 00:14:35,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],treatment,n/a,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/16/2014 00:22:25,,1323937423,7/16/2014 00:21:47,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[TREATS],[TREATS],in the treatment of,[TREATS],112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/16/2014 00:41:53,,1323946705,7/16/2014 00:41:10,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/16/2014 00:46:49,,1323948930,7/16/2014 00:46:17,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],in the treatment of,N/A,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/16/2014 00:52:13,,1323951777,7/16/2014 00:51:53,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[TREATS],[TREATS],treatment,n/a,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/16/2014 00:54:30,,1323953379,7/16/2014 00:54:18,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],Collaborative,N/A,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/16/2014 02:09:01,,1323991214,7/16/2014 02:08:34,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],treatment,none,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/16/2014 02:18:41,,1323996663,7/16/2014 02:18:03,zoombucks,1,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/16/2014 05:06:07,,1324060041,7/16/2014 05:05:31,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[TREATS],[TREATS],"paroxetine, treatment PANIC DISORDER:",N/A,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/16/2014 05:35:10,,1324068944,7/16/2014 05:34:41,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],in the treatment of,N/A,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384175,7/16/2014 07:46:27,,1324111462,7/16/2014 07:45:49,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[OTHER],[OTHER],Collaborative Panic Study Investigators.,n/a,112,142,125,152,1,RO-may_treat,907829-FS1,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
503384176,7/15/2014 23:07:59,,1323895386,7/15/2014 23:07:41,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES],[CAUSES],IMMUNOSUPPRESSIVE MEDICATIONS monitor DRUG SIDE EFFECTS,N/A,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/15/2014 23:12:15,,1323897899,7/15/2014 23:11:50,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[SIDE_EFFECT],[SIDE_EFFECT],SIDE EFFECTS,N/A,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/15/2014 23:15:53,,1323899762,7/15/2014 23:15:16,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],monitor for,N/A,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/15/2014 23:28:38,,1323906868,7/15/2014 23:28:06,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],antibiotic therapy,N/A,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/15/2014 23:37:21,,1323911371,7/15/2014 23:35:28,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SIDE_EFFECT],[SIDE_EFFECT],monitor,N/A,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/16/2014 00:13:08,,1323931792,7/16/2014 00:12:49,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],monitor for,n/a,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/16/2014 00:28:08,,1323940070,7/16/2014 00:27:46,prodege,1,9636318,USA,HI,Wailuku,72.234.78.171,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],An ophthalmologist for ocular involvement and to monitor,n/a,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/16/2014 00:49:46,,1323950605,7/16/2014 00:48:29,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[ASSOCIATED_WITH],[ASSOCIATED_WITH],end.,n/a,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/16/2014 01:56:34,,1323984494,7/16/2014 01:55:18,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two different things,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/16/2014 02:23:11,,1323998525,7/16/2014 02:22:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],management,Na,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/16/2014 02:29:54,,1324001356,7/16/2014 02:29:17,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",involvement monitor,n/a,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/16/2014 03:02:11,,1324011908,7/16/2014 03:01:21,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],IMMUNOSUPPRESSIVE MEDICATIONS for DRUG SIDE EFFECTS,N/A,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/16/2014 04:43:07,,1324050513,7/16/2014 04:41:48,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[SIDE_EFFECT] [OTHER],"[SIDE_EFFECT]
[OTHER]",antibiotic therapy IMMUNOSUPPRESSIVE MEDICATIONS ocular involvement monitor DRUG SIDE EFFECTS should be consulted depending on the nature severity end.,N/A,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/16/2014 06:03:13,,1324077194,7/16/2014 06:02:47,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[CAUSES],[CAUSES],involvement and to monitor for,N/A,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384176,7/16/2014 07:02:55,,1324097009,7/16/2014 07:02:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],and to monitor for DRUG SIDE EFFECTS,N/a,147,240,175,257,-1,RO-has_causative_agent,903594-FS1,"? An infectious disease specialist for management of prophylactic antibiotic therapy and concomitant infections due to Wegener's granulomatosis or IMMUNOSUPPRESSIVE MEDICATIONS ? An ophthalmologist for ocular involvement and to monitor for DRUG SIDE EFFECTS such as cataracts from prednisone ? A neurologist for management of new neurologic complications ? Physical and occupational therapists to improve strength and function in patients with vasculitis and neurologic complications  Rationale: ? Organ specific specialists in fields such as otolaryngology, pulmonology, dermatology, neurology, and nephrology should be consulted depending on the nature and severity of end.",IMMUNOSUPPRESSIVE MEDICATIONS,DRUG SIDE EFFECTS
503384177,7/15/2014 23:03:43,,1323892743,7/15/2014 23:02:49,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],and intestinal biopsy in the diagnosis,N/A,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/15/2014 23:16:44,,1323900183,7/15/2014 23:15:55,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in the diagnosis of,N/A,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/15/2014 23:32:16,,1323908877,7/15/2014 23:31:46,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/15/2014 23:32:18,,1323908898,7/15/2014 23:31:54,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CONTRAINDICATES],[CONTRAINDICATES],excludes,N/A,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/15/2014 23:58:06,,1323922114,7/15/2014 23:57:35,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[TREATS],[TREATS],3 month GLUTEN challenge,Na,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/16/2014 00:11:20,,1323930736,7/16/2014 00:10:39,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],challenge (as described above) excludes,[DIAGNOSE_BY_TEST_OR_DRUG],173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/16/2014 00:18:12,,1323935299,7/16/2014 00:17:19,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[NONE],[NONE],none,no associaton,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/16/2014 00:23:19,,1323937830,7/16/2014 00:22:46,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],challenge (as described above) excludes,n/a,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/16/2014 00:38:08,,1323944908,7/16/2014 00:37:39,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[CONTRAINDICATES] [CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[CONTRAINDICATES]
[ASSOCIATED_WITH]",excludes,N/A,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/16/2014 00:44:49,,1323947977,7/16/2014 00:44:06,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in the diagnosis of,N/A,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/16/2014 01:05:19,,1323959672,7/16/2014 01:04:16,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],3 month GLUTEN challenge excludes COELIAC DISEASE.,N/A,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/16/2014 02:22:48,,1323998316,7/16/2014 02:22:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],diagnosis,Na,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/16/2014 08:13:04,,1324119130,7/16/2014 08:12:17,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[NONE],[NONE],N/A,N/A,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/16/2014 09:08:54,,1324135225,7/16/2014 09:08:39,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",challenge excludes,n/a,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384177,7/16/2014 10:21:53,,1324181760,7/16/2014 10:21:03,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],results suggest,n/a,173,220,178,235,1,RO-has_causative_agent,903990-FS1,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
503384178,7/15/2014 23:26:17,,1323905696,7/15/2014 23:25:11,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],have been linked,N/A,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 00:00:57,,1323923633,7/16/2014 00:00:38,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],CCBs a induced,asd,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 00:28:13,,1323940168,7/16/2014 00:27:32,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have been linked with,[ASSOCIATED_WITH],104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 01:12:50,,1323964419,7/16/2014 01:12:35,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,N/A,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 01:33:22,,1323975878,7/16/2014 01:32:45,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[IS_A],[IS_A],in the,na,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 05:19:12,,1324064438,7/16/2014 05:18:38,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],been linked with,N/A,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 05:56:02,,1324074991,7/16/2014 05:55:26,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[IS_A],[IS_A],distinct cutaneous subset in the,N/A,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 06:08:27,,1324078751,7/16/2014 06:07:07,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,[PART_OF],[PART_OF],subset,n/a,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 07:05:39,,1324098371,7/16/2014 07:05:14,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],"distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE),",N/a,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 08:06:55,,1324117488,7/16/2014 08:06:33,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[OTHER],[OTHER],LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,N/A,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 10:17:03,,1324179726,7/16/2014 10:15:57,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[PART_OF],[PART_OF],in the,n/a,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 10:45:59,,1324192593,7/16/2014 10:44:59,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],subset the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,N/A,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 11:52:17,,1324215307,7/16/2014 11:52:03,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,same,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 12:06:07,,1324220195,7/16/2014 12:05:09,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[ASSOCIATED_WITH],[ASSOCIATED_WITH],linked with,N/A,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384178,7/16/2014 12:47:38,,1324235778,7/16/2014 12:47:01,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],subset in,n/a,104,89,141,103,-1,RO-cause_of,900484-FS1,"In the last several years, CCBs have been linked with a distinct cutaneous subset in the LUPUS SPECTRUM SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE), and we describe a case induced by verapamil.",SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS SPECTRUM
503384179,7/15/2014 23:12:29,,1323897957,7/15/2014 23:12:19,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],ANTIPYRINE,N/A,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/15/2014 23:12:29,,1323897959,7/15/2014 23:12:16,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[TREATS],[TREATS],temporary relief,N/A,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/15/2014 23:13:39,,1323898640,7/15/2014 23:13:33,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],fixed,n/a,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/15/2014 23:28:03,,1323906572,7/15/2014 23:27:54,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],for the temporary relief,N/A,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/16/2014 00:22:09,,1323937336,7/16/2014 00:21:56,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[TREATS],[TREATS],for the temporary relief,n/a,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/16/2014 00:44:21,,1323947779,7/16/2014 00:43:49,elite,1.0,27788262,USA,"","",172.163.6.138,[TREATS],[TREATS],for the temporary relief of,N/A,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/16/2014 00:49:13,,1323950273,7/16/2014 00:49:01,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[TREATS],[TREATS],relief,N/A,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/16/2014 01:09:21,,1323962306,7/16/2014 01:08:31,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",Pain Used with ANTIPYRINE for relief of EAR PAIN,N/A,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/16/2014 01:12:07,,1323964073,7/16/2014 01:11:42,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],relief,N/A,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/16/2014 02:33:09,,1324002484,7/16/2014 02:32:21,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/16/2014 02:55:15,,1324009351,7/16/2014 02:54:43,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],ANTIPYRINE for EAR PAIN (OTALGIA EARACHE,N/A,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/16/2014 05:09:46,,1324061257,7/16/2014 05:07:17,prodege,1,24636399,USA,CA,Los Angeles,76.168.160.92,[OTHER],[OTHER],ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE,Antipyrine is used to treat ear pain.,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/16/2014 05:37:46,,1324069630,7/16/2014 05:37:26,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],for the temporary relief of,N/A,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/16/2014 06:35:44,,1324087853,7/16/2014 06:35:25,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],for temporary relief,n/a,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384179,7/16/2014 07:01:18,,1324096399,7/16/2014 07:01:04,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],ANTIPYRINE for the temporary relief of,N/a,93,54,117,64,1,RO-may_treat,907711-FS1,"r  Otic Pain  Used alone or in fixed combination with ANTIPYRINE for the temporary relief of EAR PAIN (OTALGIA EARACHE associated with otitis media of various causes; however, single ingredient preparations no longer commercially available in the US.",EAR PAIN (OTALGIA EARACHE,ANTIPYRINE
503384180,7/15/2014 23:08:51,,1323895857,7/15/2014 23:08:42,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],and,N/A,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/15/2014 23:18:30,,1323901247,7/15/2014 23:18:05,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/15/2014 23:23:08,,1323903864,7/15/2014 23:23:00,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/15/2014 23:50:39,,1323918237,7/15/2014 23:49:33,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were both,asd,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/16/2014 00:31:22,,1323941811,7/16/2014 00:31:05,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",and risk of,N/A,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/16/2014 00:39:01,,1323945324,7/16/2014 00:38:08,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both associated with,N/A,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/16/2014 00:51:28,,1323951356,7/16/2014 00:51:15,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/16/2014 01:16:37,,1323966593,7/16/2014 01:16:16,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with ELEVATED BP and risk of HYPERTENSION,N/A,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/16/2014 01:51:50,,1323982664,7/16/2014 01:50:57,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],and risk of,na,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/16/2014 05:39:50,,1324070196,7/16/2014 05:37:48,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],and risk of,N/A,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/16/2014 06:29:56,,1324086251,7/16/2014 06:29:35,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and risk of,n/a,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/16/2014 07:04:39,,1324097888,7/16/2014 07:04:20,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were both associated with ELEVATED BP and risk of HYPERTENSION,N/a,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/16/2014 11:36:26,,1324209590,7/16/2014 11:35:47,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[CAUSES],[CAUSES],and risk of,because associated with ELEVATED BP and risk of HYPERTENSION,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/16/2014 12:01:08,,1324218315,7/16/2014 12:00:54,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384180,7/16/2014 12:05:05,,1324219835,7/16/2014 12:04:27,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],risk of,N/A,62,86,72,98,-1,RO-has_definitional_manifestation,904720-FS1,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
503384181,7/15/2014 23:09:00,,1323896018,7/15/2014 23:08:52,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],"neoplastic,",N/A,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/15/2014 23:28:29,,1323906810,7/15/2014 23:27:38,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATED,N/A,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/15/2014 23:41:26,,1323913472,7/15/2014 23:40:08,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a HEMOPHAGOCYTOSIS,Is A,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/16/2014 00:46:06,,1323948535,7/16/2014 00:44:54,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,[MANIFESTATION],[MANIFESTATION],VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) with prominent HEMOPHAGOCYTOSIS,N/A,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/16/2014 00:54:01,,1323953079,7/16/2014 00:52:53,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[CAUSES],[CAUSES],VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME,n/a,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/16/2014 03:50:55,,1324030427,7/16/2014 03:50:08,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) HEMOPHAGOCYTOSIS,n/a,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/16/2014 05:53:44,,1324074247,7/16/2014 05:53:25,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[CAUSES],[CAUSES],with prominent,N/A,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/16/2014 06:06:07,,1324078047,7/16/2014 06:05:10,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[SYMPTOM],[SYMPTOM],associated with,n/a,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/16/2014 07:02:28,,1324096811,7/16/2014 07:02:03,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is a histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with,N/a,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/16/2014 07:58:31,,1324114691,7/16/2014 07:57:58,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/16/2014 10:48:23,,1324193741,7/16/2014 10:47:48,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],with prominent HEMOPHAGOCYTOSIS,N/A,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/16/2014 11:46:17,,1324213170,7/16/2014 11:45:54,clixsense,1.0,6621167,USA,IL,Round Lake,24.12.122.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,na,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/16/2014 11:52:02,,1324215220,7/16/2014 11:51:45,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[SYMPTOM],[SYMPTOM],generalized,N/A,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/16/2014 11:54:15,,1324215977,7/16/2014 11:53:05,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prominent associated,N/A,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384181,7/16/2014 12:53:48,,1324238668,7/16/2014 12:52:34,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],generalized histiocytic proliferation with prominent,n/a,124,2,139,49,1,RO-disease_has_finding,901971-FS1,"A VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS) is a non neoplastic, generalized histiocytic proliferation with prominent HEMOPHAGOCYTOSIS associated with a systemic viral infection.",HEMOPHAGOCYTOSIS,VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME (VAHS)
503384182,7/15/2014 23:40:43,,1323913127,7/15/2014 23:38:17,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",higher risk for the development of,N/A,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/15/2014 23:52:39,,1323919293,7/15/2014 23:51:53,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[SYMPTOM],[SYMPTOM],following factors place,Na,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 00:18:32,,1323935491,7/16/2014 00:18:10,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],Development,n/a,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 00:20:26,,1323936494,7/16/2014 00:19:22,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[SYMPTOM],[SYMPTOM],Development of,[SYMPTOM],337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 00:36:23,,1323944211,7/16/2014 00:36:05,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[IS_A],[IS_A],COMPLEX FEBRILE SEIZURES Development of EPILEPSY,N/A,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 02:18:23,,1323996488,7/16/2014 02:18:08,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],developing,Na,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 07:03:41,,1324097359,7/16/2014 07:02:56,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],risk of developing epilepsy after,N/a,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 09:17:59,,1324138730,7/16/2014 09:16:40,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],risk of developing,N/A,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 11:53:37,,1324215745,7/16/2014 11:53:11,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 11:55:06,,1324216189,7/16/2014 11:54:18,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],Recurrent Development,N/A,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 12:49:49,,1324236850,7/16/2014 12:49:22,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[MANIFESTATION],[MANIFESTATION],Development of,n/a,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 12:52:25,,1324238020,7/16/2014 12:51:54,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],developing epilepsy after simple febrile seizure,n/a,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 13:00:22,,1324241555,7/16/2014 13:00:00,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",higher the FEBRILE febrile Rationale: assess,These are the factors,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 13:12:41,,1324246392,7/16/2014 13:12:16,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],the risk of epilepsy,na,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384182,7/16/2014 13:29:51,,1324253422,7/16/2014 13:27:35,tremorgames,1.0,18832393,GBR,C5,Runcorn,90.195.197.162,[MANIFESTATION],[MANIFESTATION],COMPLEX FEBRILE SEIZURES EPILEPSY,N/A,337,449,360,457,-1,RO-has_definitional_manifestation,904843-FS1,"B]  Specific recommendation: ? Tell parents and caretakers that: ? The risk of developing epilepsy after a simple febrile seizure is small and is only slightly greater than the background risk in the population ? The following factors place the child at a higher risk for the development of epilepsy: ? Previous neurologic abnormality ? COMPLEX FEBRILE SEIZURES ? Family history of epilepsy ? Recurrent febrile seizures  Rationale: ? Development of EPILEPSY is another major concern that families often have, and it can be difficult to assess the risk of epilepsy on an.",COMPLEX FEBRILE SEIZURES,EPILEPSY
503384183,7/15/2014 23:10:02,,1323896659,7/15/2014 23:09:34,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES],[CAUSES],showing MARKED HEPATOMEGALY in patient with AL AMYLOIDOSIS,N/A,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/15/2014 23:15:25,,1323899545,7/15/2014 23:15:04,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[SYMPTOM],[SYMPTOM],showing in a patient,N/A,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/15/2014 23:19:27,,1323901867,7/15/2014 23:19:21,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],HEPATOMEGALY,n/a,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/15/2014 23:21:02,,1323902751,7/15/2014 23:20:07,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION] [SYMPTOM],"[LOCATION]
[SYMPTOM]",showing in,N/A,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/15/2014 23:22:37,,1323903486,7/15/2014 23:22:02,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],showing,N/A,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/15/2014 23:33:46,,1323909642,7/15/2014 23:32:54,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Nuclear Liver Spleen Scan showing MARKED HEPATOMEGALY patient with AL AMYLOIDOSIS,Diagnosed by test or drug,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/16/2014 00:06:16,,1323927096,7/16/2014 00:05:16,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[TREATS],[TREATS],Scan,asd,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/16/2014 00:13:27,,1323932030,7/16/2014 00:13:09,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],showing,n/a,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/16/2014 00:19:05,,1323935860,7/16/2014 00:18:45,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in a patient,I did not select none.,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/16/2014 04:01:34,,1324035443,7/16/2014 04:00:47,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],MARKED HEPATOMEGALY AMYLOIDOSIS,n/a,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/16/2014 04:20:17,,1324044380,7/16/2014 04:20:01,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],spleen scan,N/A,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/16/2014 05:12:29,,1324062215,7/16/2014 05:11:54,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in a patient with,N/A,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/16/2014 05:55:00,,1324074645,7/16/2014 05:54:34,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[MANIFESTATION],[MANIFESTATION],in a patient with,N/A,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/16/2014 07:08:30,,1324099742,7/16/2014 07:08:10,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],scan showing MARKED HEPATOMEGALY in patient with AL AMYLOIDOSIS,N/a,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384183,7/16/2014 07:56:11,,1324113922,7/16/2014 07:55:40,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[SYMPTOM],[SYMPTOM],showing in,n/a,61,99,79,113,-1,RO-disease_may_have_finding,902820-FS1,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing MARKED HEPATOMEGALY in a patient with AL AMYLOIDOSIS of the liver and spleen.,MARKED HEPATOMEGALY,AL AMYLOIDOSIS
503384184,7/15/2014 23:11:11,,1323897308,7/15/2014 23:11:02,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SIDE_EFFECT],[SIDE_EFFECT],in,N/A,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/15/2014 23:13:12,,1323898369,7/15/2014 23:12:49,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[CAUSES],[CAUSES],revealed live,N/A,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/15/2014 23:14:27,,1323899078,7/15/2014 23:14:16,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],revealed,n/a,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/15/2014 23:20:06,,1323902255,7/15/2014 23:19:10,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],revealed,N/A,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/15/2014 23:23:39,,1323904180,7/15/2014 23:23:06,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",prevalence of mites in,N/A,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/15/2014 23:25:07,,1323905049,7/15/2014 23:24:57,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],revealed live,N/A,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/15/2014 23:29:26,,1323907294,7/15/2014 23:28:54,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],live,N/A,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/15/2014 23:44:05,,1323914688,7/15/2014 23:43:38,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[CAUSES],[CAUSES],prevalence of,Na,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/15/2014 23:57:11,,1323921561,7/15/2014 23:56:26,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],cases of normal SCABIES revealed live MITES in all 37 cases,N/A,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/16/2014 00:38:06,,1323944876,7/16/2014 00:37:19,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",Investigations of the prevalence of,N/A,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/16/2014 00:58:51,,1323955857,7/16/2014 00:58:19,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION],[MANIFESTATION],SCABIES revealed live MITES,N/A,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/16/2014 02:03:28,,1323988489,7/16/2014 02:03:00,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[CAUSES],[CAUSES],revealed,none,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/16/2014 04:19:10,,1324043964,7/16/2014 04:18:27,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],Investigations,N/A,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/16/2014 08:16:19,,1324120347,7/16/2014 08:15:18,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[CAUSES],[CAUSES],revealed live,"because this:

 normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches",116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384184,7/16/2014 10:35:40,,1324186462,7/16/2014 10:34:06,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the environment of,n/a,116,94,120,101,-1,RO-has_causative_agent,903877-FS1,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
503384185,7/15/2014 23:11:53,,1323897709,7/15/2014 23:11:43,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],significantly,N/A,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/15/2014 23:13:55,,1323898808,7/15/2014 23:13:38,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared,N/A,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/15/2014 23:19:35,,1323901953,7/15/2014 23:19:28,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],lower,n/a,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/15/2014 23:26:57,,1323906025,7/15/2014 23:26:43,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared to,N/A,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/15/2014 23:59:00,,1323922625,7/15/2014 23:57:42,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],NEPHROTIC,N/A,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/16/2014 00:20:38,,1323936567,7/16/2014 00:20:06,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared to the,I did not select none,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/16/2014 00:43:46,,1323947579,7/16/2014 00:41:24,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER],[OTHER],compared to,N/A,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/16/2014 00:52:35,,1323951990,7/16/2014 00:52:12,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/16/2014 00:56:04,,1323954429,7/16/2014 00:55:41,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],compared to the,N/A,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/16/2014 01:13:56,,1323964998,7/16/2014 01:13:46,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NEPHROTIC NEPHROTICS.,N/A,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/16/2014 04:20:56,,1324044568,7/16/2014 04:18:58,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[NONE],[NONE],N/A,for some reason tested together,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/16/2014 05:16:55,,1324063685,7/16/2014 05:16:02,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],compared to,N/A,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/16/2014 05:42:44,,1324070967,7/16/2014 05:42:18,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared to,N/A,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/16/2014 05:54:33,,1324074548,7/16/2014 05:53:47,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,separate conditions,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384185,7/16/2014 06:13:32,,1324080486,7/16/2014 06:11:23,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[OTHER],[OTHER],compared,n/a,139,98,157,113,-1,RO-cause_of,900403-FS1,The serum triglycerides and serum cholesterol levels were not significantly lower in the group of LUPUS NEPHROTIC patients compared to the NONLUPUS NEPHROTICS.,NONLUPUS NEPHROTICS,LUPUS NEPHROTIC
503384186,7/15/2014 23:08:31,,1323895718,7/15/2014 23:08:18,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],years,N/A,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/15/2014 23:18:12,,1323901050,7/15/2014 23:17:34,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Severe HYPERTENSION and HYPERTENSIVE CRISIS,Associated With,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 00:09:55,,1323929681,7/16/2014 00:09:15,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",333 Severe,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 00:13:13,,1323931887,7/16/2014 00:12:25,prodege,1.0,15287417,CAN,ON,North York,24.114.67.233,[OTHER],[OTHER],and,N/A,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 00:31:07,,1323941673,7/16/2014 00:28:35,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERTENSION and HYPERTENSIVE CRISIS,.,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 01:12:21,,1323964197,7/16/2014 01:11:47,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Severe HYPERTENSION and HYPERTENSIVE CRISIS,N/A,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 05:10:46,,1324061650,7/16/2014 05:10:08,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],HYPERTENSION HYPERTENSIVE,N/A,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 05:27:41,,1324066900,7/16/2014 05:27:20,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],and,N/A,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 06:16:47,,1324081725,7/16/2014 06:16:03,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Severe HYPERTENSION and HYPERTENSIVE CRISIS,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 06:33:42,,1324087306,7/16/2014 06:33:29,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],HYPERTENSIVE,n/a,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 07:54:35,,1324113437,7/16/2014 07:54:22,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 09:13:37,,1324136813,7/16/2014 09:13:25,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 12:14:00,,1324222721,7/16/2014 12:13:27,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[PART_OF],[PART_OF],and,N/A,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 12:52:08,,1324237897,7/16/2014 12:50:51,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],and,N/A,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384186,7/16/2014 12:59:52,,1324241251,7/16/2014 12:59:18,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,12,29,23,48,-1,RO-disease_has_finding,901613-FS1,333  Severe HYPERTENSION and HYPERTENSIVE CRISIS   +  >     IV Injection  Children 1 17 years of age: Maximum 40 mg per dose.,HYPERTENSION,HYPERTENSIVE CRISIS
503384187,7/15/2014 23:18:36,,1323901357,7/15/2014 23:18:30,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],oculogyric,n/a,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/15/2014 23:22:51,,1323903663,7/15/2014 23:22:29,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/15/2014 23:41:11,,1323913347,7/15/2014 23:40:14,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/15/2014 23:48:20,,1323917016,7/15/2014 23:47:00,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Attacks of,Na,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/16/2014 00:30:16,,1323941177,7/16/2014 00:29:17,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,na,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/16/2014 00:37:17,,1323944547,7/16/2014 00:37:03,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[PART_OF],[PART_OF],GELASTIC SEIZURE with,N/A,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/16/2014 00:41:21,,1323946430,7/16/2014 00:40:01,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Attacks horizontal epileptic nystagmus,n/a,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/16/2014 00:45:15,,1323948211,7/16/2014 00:44:56,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/16/2014 03:50:04,,1324030060,7/16/2014 03:49:39,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GELASTIC SEIZURE IPSILATERAL ADVERSIVE SEIZURES,n/a,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/16/2014 04:18:26,,1324043639,7/16/2014 04:18:07,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],were observed,N/A,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/16/2014 04:51:13,,1324053133,7/16/2014 04:49:58,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES,N/A,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/16/2014 09:13:10,,1324136694,7/16/2014 09:13:00,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/16/2014 09:16:39,,1324138099,7/16/2014 09:15:25,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],with,N/A,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/16/2014 10:09:50,,1324176638,7/16/2014 10:09:24,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384187,7/16/2014 11:34:16,,1324208996,7/16/2014 11:33:29,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[SYMPTOM],[SYMPTOM],with,"I think because of:

Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis",33,11,62,27,-1,RO-has_definitional_manifestation,904849-FS1,"Attacks of GELASTIC SEIZURE with IPSILATERAL ADVERSIVE SEIZURES ipsilateral oculogyric crisis, and horizontal epileptic nystagmus were observed until her death at age 29.",IPSILATERAL ADVERSIVE SEIZURES,GELASTIC SEIZURE
503384188,7/15/2014 23:08:17,,1323895552,7/15/2014 23:08:00,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[LOCATION],[LOCATION],consisting of,N/A,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/15/2014 23:11:55,,1323897713,7/15/2014 23:11:16,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],NERVOUS SYSTEM,N/A,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 02:49:18,,1324007634,7/16/2014 02:47:47,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",CENTRAL NERVOUS SYSTEM consisting of MEDULLOBLASTOMAS,N/A,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 05:13:43,,1324062623,7/16/2014 05:13:14,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],consisting of,N/A,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 06:05:15,,1324077782,7/16/2014 06:04:52,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[LOCATION],[LOCATION],consisting of,N/A,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 07:46:49,,1324111556,7/16/2014 07:46:28,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[SYMPTOM],[SYMPTOM],consisting of,n/a,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 09:25:14,,1324144854,7/16/2014 09:24:02,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[LOCATION],[LOCATION],"in children,",N/A,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 10:37:10,,1324186876,7/16/2014 10:35:42,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[LOCATION],[LOCATION],cancers consisting of,n/a,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 11:02:10,,1324197860,7/16/2014 11:01:33,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],"tumors are devastating cancers children, consisting",N/A,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 11:57:26,,1324217033,7/16/2014 11:56:39,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],consisting of,N/A,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 11:59:38,,1324217697,7/16/2014 11:58:29,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[LOCATION],[LOCATION],(CNS),N/A,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 12:58:57,,1324241002,7/16/2014 12:58:10,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],"children, consisting of",n/a,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 12:59:17,,1324241136,7/16/2014 12:58:36,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[MANIFESTATION],[MANIFESTATION],consisting of,n/a,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 13:02:59,,1324242450,7/16/2014 13:02:36,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[CAUSES] [LOCATION],"[CAUSES]
[LOCATION]","embryonal tumors in children, consisting",The tumors affect it,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384188,7/16/2014 13:11:41,,1324245964,7/16/2014 13:11:14,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],"in children,",na,0,97,21,113,1,RO-disease_has_primary_anatomic_site,902273-FS1,"CENTRAL NERVOUS SYSTEM (CNS) embryonal tumors are devastating cancers in children, consisting of MEDULLOBLASTOMAS CNS primitive neuroectodermal tumors, and atypical teratoid/rhabdoid tumors.",CENTRAL NERVOUS SYSTEM,MEDULLOBLASTOMAS
503384189,7/15/2014 23:08:33,,1323895741,7/15/2014 23:07:39,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],modelling VIRUS dynamics to the study of chronic,N/A,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/15/2014 23:39:22,,1323912551,7/15/2014 23:39:05,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the study of,N/A,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/15/2014 23:43:37,,1323914466,7/15/2014 23:41:42,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[ASSOCIATED_WITH],[ASSOCIATED_WITH],demonstrating a model,Na,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/15/2014 23:52:38,,1323919290,7/15/2014 23:51:34,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],dynamics to the study of,n/a,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/16/2014 00:24:00,,1323938093,7/16/2014 00:23:37,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[SYMPTOM],[SYMPTOM],dynamics to the study of chronic,n/a,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/16/2014 00:48:24,,1323949741,7/16/2014 00:47:39,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],to the study of,N/A,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/16/2014 00:49:23,,1323950345,7/16/2014 00:48:08,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,VIRUS dynamics to the study of chronic VIRAL INFECTION,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/16/2014 00:50:04,,1323950740,7/16/2014 00:49:38,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SIDE_EFFECT],[SIDE_EFFECT],to,N/A,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/16/2014 01:13:48,,1323964925,7/16/2014 01:13:12,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],principles of modelling VIRUS dynamics to VIRAL INFECTION,N/A,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/16/2014 02:07:10,,1323990213,7/16/2014 02:06:38,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],dynamics to the study,n/a,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/16/2014 02:13:28,,1323993702,7/16/2014 02:12:31,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two different terms,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/16/2014 02:24:34,,1323999097,7/16/2014 02:24:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],production.,Na,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/16/2014 02:59:56,,1324010988,7/16/2014 02:58:43,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],VIRUS dynamics to study chronic VIRAL INFECTION,N/A,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/16/2014 03:52:14,,1324031009,7/16/2014 03:51:46,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[LOCATION],[LOCATION],VIRUS VIRAL INFECTION,n/a,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384189,7/16/2014 04:32:41,,1324047864,7/16/2014 04:30:43,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[SYMPTOM] [ASSOCIATED_WITH] [PART_OF],"[SYMPTOM]
[ASSOCIATED_WITH]
[PART_OF]",apply principles of modelling VIRUS dynamics to study chronic VIRAL INFECTION,N/A,50,89,54,104,-1,RO-has_causative_agent,903880-FS1,We apply well established principles of modelling VIRUS dynamics to the study of chronic VIRAL INFECTION demonstrating that a model which incorporates the distinct contributions of cytotoxic T lymphocytes (CTLs) and antibodies exhibits long periods of quiescence followed by brief bursts of viral production.,VIRUS,VIRAL INFECTION
503384190,7/15/2014 23:12:30,,1323897963,7/15/2014 23:11:56,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in individuals with,N/A,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/15/2014 23:14:02,,1323898857,7/15/2014 23:13:55,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],EPILEPSY,n/a,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/15/2014 23:22:47,,1323903616,7/15/2014 23:22:26,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in individuals with CRANIOCEREBRAL TRAUMA in the past.,N/A,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/15/2014 23:31:54,,1323908707,7/15/2014 23:31:30,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],predict,N/A,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/15/2014 23:36:51,,1323911092,7/15/2014 23:36:27,clixsense,1.0,15189335,GBR,H9,London,188.29.165.200,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],predict development,Na,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/16/2014 00:09:53,,1323929635,7/16/2014 00:09:35,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],in individuals with,n/a,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/16/2014 00:27:52,,1323939920,7/16/2014 00:27:04,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],in individuals with,N/A,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/16/2014 00:31:27,,1323941840,7/16/2014 00:30:49,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",in individuals with,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/16/2014 01:06:54,,1323960595,7/16/2014 01:05:20,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",development of POSTTRAUMATIC EPILEPSY with CRANIOCEREBRAL TRAUMA,N/A,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/16/2014 05:25:54,,1324066472,7/16/2014 05:25:33,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],in individuals with,N/A,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/16/2014 05:42:11,,1324070817,7/16/2014 05:41:50,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],in individuals with,N/A,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/16/2014 05:53:01,,1324073981,7/16/2014 05:52:30,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[MANIFESTATION],[MANIFESTATION],individuals with in the past.,N/A,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/16/2014 06:21:54,,1324083501,7/16/2014 06:21:06,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[SYMPTOM],[SYMPTOM],development of,"because of "" the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA""",46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/16/2014 06:42:41,,1324090109,7/16/2014 06:42:19,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],the development of,n/a,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384190,7/16/2014 07:38:17,,1324109274,7/16/2014 07:37:09,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[ASSOCIATED_WITH],[ASSOCIATED_WITH],development with,N/A,46,89,67,110,1,RO-cause_of,900492-FS1,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
503384191,7/15/2014 23:10:09,,1323896734,7/15/2014 23:08:27,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER liver cirrhosis),",Associated With,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/15/2014 23:22:14,,1323903276,7/15/2014 23:21:59,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],"(ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis),",N/A,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/15/2014 23:25:28,,1323905223,7/15/2014 23:24:53,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],have been studied compared,N/A,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/15/2014 23:42:03,,1323913716,7/15/2014 23:41:48,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],alcoholic fatty,N/A,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/15/2014 23:51:51,,1323918961,7/15/2014 23:48:51,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[ASSOCIATED_WITH],[ASSOCIATED_WITH],alcoholic fatty,Na,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/16/2014 00:08:00,,1323928388,7/16/2014 00:07:40,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],alcoholic fatty,n/a,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/16/2014 00:21:08,,1323936856,7/16/2014 00:20:29,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],alcoholic fatty have been studied,[DIAGNOSE_BY_TEST_OR_DRUG],60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/16/2014 00:33:24,,1323942722,7/16/2014 00:33:11,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[LOCATION],[LOCATION],alcoholic fatty,N/A,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/16/2014 01:15:30,,1323965967,7/16/2014 01:14:55,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[LOCATION],[LOCATION],liver patients,N/A,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/16/2014 02:07:27,,1323990384,7/16/2014 02:06:46,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/16/2014 03:11:17,,1324015074,7/16/2014 03:10:39,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(ACUTE HEPATITIS LIVER,n/a,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/16/2014 07:56:49,,1324114101,7/16/2014 07:55:24,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[OTHER],[OTHER],liver patients,Is a disease of the liver.,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/16/2014 08:10:42,,1324118540,7/16/2014 08:09:55,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[SYMPTOM],[SYMPTOM],alcoholic fatty,I think because of s (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis),60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/16/2014 09:08:07,,1324134975,7/16/2014 09:07:28,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(ACUTE VIRAL HEPATITIS LIVER,n/a,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384191,7/16/2014 10:14:20,,1324178606,7/16/2014 10:12:51,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,60,22,64,43,1,RO-has_finding_site,905028-FS1,"Sixty liver patients (ACUTE VIRAL HEPATITIS alcoholic fatty LIVER and liver cirrhosis), without overt renal disease, have been studied and compared to controls.",LIVER,ACUTE VIRAL HEPATITIS
503384192,7/15/2014 23:10:10,,1323896748,7/15/2014 23:09:45,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[CAUSES],[CAUSES],a common,N/A,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/15/2014 23:32:39,,1323909071,7/15/2014 23:32:19,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],common,N/A,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/15/2014 23:39:54,,1323912756,7/15/2014 23:38:45,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[ASSOCIATED_WITH],[ASSOCIATED_WITH],common,Na,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/15/2014 23:46:21,,1323916000,7/15/2014 23:46:03,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/15/2014 23:59:32,,1323922898,7/15/2014 23:58:04,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,[IS_A],[IS_A],a common,na,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/16/2014 00:02:06,,1323924363,7/16/2014 00:01:49,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],a common COMPLICATION,N/A,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/16/2014 00:14:19,,1323932645,7/16/2014 00:13:41,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],PREECLAMPSIA common COMPLICATION OF PREGNANCY,Manifestation,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/16/2014 00:21:55,,1323937184,7/16/2014 00:21:30,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[SIDE_EFFECT],[SIDE_EFFECT],a common,n/a,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/16/2014 00:28:06,,1323940066,7/16/2014 00:25:05,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[IS_A],[IS_A],a common is,N/A,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/16/2014 00:58:49,,1323955828,7/16/2014 00:57:45,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[MANIFESTATION],[MANIFESTATION],COMPLICATION OF PREGNANCY is associated with,na,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/16/2014 01:11:40,,1323963735,7/16/2014 01:11:20,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SIDE_EFFECT],[SIDE_EFFECT],COMPLICATION,N/A,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/16/2014 01:46:39,,1323980597,7/16/2014 01:46:12,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",associated with,none,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/16/2014 05:19:32,,1324064574,7/16/2014 05:19:01,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",common COMPLICATION OF,N/A,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/16/2014 05:25:43,,1324066431,7/16/2014 05:25:13,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[SYMPTOM],[SYMPTOM],a common COMPLICATION,N/A,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384192,7/16/2014 06:00:09,,1324076300,7/16/2014 05:59:46,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[CAUSES],[CAUSES],a common,N/A,22,0,46,12,-1,RO-disease_has_finding,901620-FS1,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
503384193,7/15/2014 23:08:10,,1323895505,7/15/2014 23:08:00,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[TREATS],[TREATS],PROPRANOLOL treatment ANGINA PECTORIS,N/A,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/15/2014 23:11:01,,1323897215,7/15/2014 23:10:53,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],tolerated,N/A,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/15/2014 23:13:56,,1323898823,7/15/2014 23:11:25,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/15/2014 23:17:09,,1323900451,7/15/2014 23:16:45,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in the treatment of patients with,N/A,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/15/2014 23:21:36,,1323903052,7/15/2014 23:21:04,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],treatment of patients,N/A,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/15/2014 23:23:55,,1323904368,7/15/2014 23:23:21,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/15/2014 23:24:33,,1323904745,7/15/2014 23:24:26,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],in the treatment,N/A,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/15/2014 23:48:39,,1323917161,7/15/2014 23:48:09,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],in the treatment of,N/A,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/16/2014 00:15:58,,1323933897,7/16/2014 00:15:25,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[TREATS],[TREATS],in the treatment of,[TREATS],162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/16/2014 02:02:19,,1323987924,7/16/2014 02:02:03,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],treatment,none,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/16/2014 03:03:12,,1324012284,7/16/2014 03:02:47,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],PROPRANOLOL treatment ANGINA PECTORIS,N/A,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/16/2014 05:41:12,,1324070571,7/16/2014 05:40:55,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],in the treatment of,N/A,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/16/2014 06:04:51,,1324077650,7/16/2014 06:04:05,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],in the treatment of,N/A,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/16/2014 06:40:47,,1324089494,7/16/2014 06:38:31,clixsense,1,23233834,GBR,N6,Sunderland,86.17.58.181,[TREATS],[TREATS],PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,N/A,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384193,7/16/2014 06:41:44,,1324089803,7/16/2014 06:41:29,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],the treatment of,n/a,162,116,176,127,1,RO-may_treat,907967-FS1,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
503384194,7/15/2014 23:20:35,,1323902505,7/15/2014 23:20:29,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],frequently,n/a,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/15/2014 23:28:28,,1323906808,7/15/2014 23:28:04,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[NONE],[NONE],N/A,There is no link between the two words. It's not mentionned which ''GROUP'' we are talking about.,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/15/2014 23:31:32,,1323908489,7/15/2014 23:31:07,instagc,1.0,13763729,USA,"","",75.182.89.225,[NONE],[NONE],N/A,Group is quantitative.,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/15/2014 23:41:46,,1323913625,7/15/2014 23:41:33,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,N/A,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/16/2014 00:04:41,,1323926107,7/16/2014 00:04:27,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],of,n/a,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/16/2014 00:26:39,,1323939388,7/16/2014 00:25:52,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[MANIFESTATION],[MANIFESTATION],developed twice as frequently,[MANIFESTATION],7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/16/2014 00:47:16,,1323949132,7/16/2014 00:46:50,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[PART_OF],[PART_OF],of,N/A,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/16/2014 01:15:55,,1323966165,7/16/2014 01:15:44,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[NONE],[NONE],N/A,No relation,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/16/2014 02:14:02,,1323994044,7/16/2014 02:11:24,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],of,none,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/16/2014 03:20:11,,1324018105,7/16/2014 03:17:42,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GROUP POST TRAUMATIC EPILEPSY SEIZURES,n/a,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/16/2014 05:32:15,,1324068229,7/16/2014 05:31:29,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[PART_OF],[PART_OF],In the of,N/A,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/16/2014 06:20:30,,1324083037,7/16/2014 06:19:49,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[PART_OF],[PART_OF],of,because of In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/16/2014 07:42:18,,1324110273,7/16/2014 07:41:55,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[OTHER],[OTHER],of,n/a,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/16/2014 09:14:00,,1324136979,7/16/2014 09:13:49,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,n/a,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384194,7/16/2014 10:49:42,,1324194225,7/16/2014 10:48:54,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],GROUP of SEIZURES,N/A,7,16,11,48,-1,RO-has_definitional_manifestation,904975-FS1,In the GROUP of POST TRAUMATIC EPILEPSY SEIZURES developed twice as frequently after severe trauma than after light trauma.,GROUP,POST TRAUMATIC EPILEPSY SEIZURES
503384195,7/15/2014 23:09:48,,1323896573,7/15/2014 23:09:40,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],bone,N/A,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/15/2014 23:50:40,,1323918240,7/15/2014 23:49:55,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[PART_OF],[PART_OF],with normal,n/a,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 00:49:00,,1323950159,7/16/2014 00:48:45,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],with,N/A,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 00:59:06,,1323956010,7/16/2014 00:58:43,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,BONE PAIN with normal LAMELAR BONE,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 01:04:15,,1323959090,7/16/2014 01:03:29,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]","patient with HCAO, characterized BONE PAIN with LAMELAR BONE",N/A,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 02:58:42,,1324010494,7/16/2014 02:57:58,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],BONE PAIN with LAMELAR BONE,N/A,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 05:07:42,,1324060636,7/16/2014 05:06:09,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",bone thickening BONE PAIN normal LAMELAR BONE,N/A,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 05:30:43,,1324067757,7/16/2014 05:27:43,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized by,N/A,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 05:36:48,,1324069365,7/16/2014 05:35:34,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],with normal,N/A,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 06:57:49,,1324095082,7/16/2014 06:57:25,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],with normal,N/a,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 07:41:33,,1324110102,7/16/2014 07:40:47,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[OTHER],[OTHER],with normal,n/a,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 10:15:05,,1324178920,7/16/2014 10:14:21,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[LOCATION],[LOCATION],with,n/a,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 11:55:42,,1324216388,7/16/2014 11:55:08,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[CAUSES],[CAUSES],with normal,N/A,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 12:02:24,,1324218872,7/16/2014 12:02:13,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[SYMPTOM],[SYMPTOM],characterized by,N/A,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384195,7/16/2014 12:55:43,,1324239467,7/16/2014 12:53:50,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[NONE],[NONE],N/A,No connection between bone pain and lamelar bone is specified.,113,91,124,100,1,RO-has_finding_site,905427-FS1,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
503384196,7/15/2014 23:12:38,,1323898038,7/15/2014 23:12:30,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],factor,N/A,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/15/2014 23:27:32,,1323906311,7/15/2014 23:27:21,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and that,N/A,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/15/2014 23:29:59,,1323907598,7/15/2014 23:29:36,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],aggravating factor for and relapsed,N/A,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/15/2014 23:59:35,,1323922920,7/15/2014 23:59:05,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and that THYROTOXICOSIS relapsed,n/a,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/16/2014 00:09:15,,1323929190,7/16/2014 00:08:01,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and that,n/a,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/16/2014 00:35:53,,1323944058,7/16/2014 00:35:21,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/16/2014 05:14:58,,1324063044,7/16/2014 05:13:45,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],N/A,Relationship not obvious from statement - could be a symptom or something entirely different.,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/16/2014 07:57:18,,1324114233,7/16/2014 07:56:50,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[MANIFESTATION],[MANIFESTATION],aggravating factor,N/A,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/16/2014 10:11:12,,1324177387,7/16/2014 10:10:27,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and that,n/a,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/16/2014 12:02:38,,1324218936,7/16/2014 12:02:25,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,unclear,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/16/2014 12:12:19,,1324222105,7/16/2014 12:10:29,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[CAUSES],[CAUSES],and that,N/A,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/16/2014 12:54:55,,1324239120,7/16/2014 12:54:22,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],aggravating factor relapsed 2 months after allergic attack.,n/a,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/16/2014 12:57:24,,1324240291,7/16/2014 12:56:34,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[ASSOCIATED_WITH] [SIDE_EFFECT] [PART_OF],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]",aggravating factor GRAVES' DISEASE THYROTOXICOSIS relapsed 2 months,They are related due to the 2 month period,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/16/2014 12:58:35,,1324240842,7/16/2014 12:57:37,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[MANIFESTATION],[MANIFESTATION],relapsed,n/a,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384196,7/16/2014 13:00:25,,1324241564,7/16/2014 12:58:18,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[NONE],[NONE],N/A,No relationship between Graves disease and thyrotoxicosis is secified.,76,101,90,115,-1,RO-cause_of,900139-FS1,We previously reported that allergic rhinitis was an aggravating factor for GRAVES' DISEASE and that THYROTOXICOSIS relapsed 2 months after an allergic attack.,GRAVES' DISEASE,THYROTOXICOSIS
503384197,7/15/2014 23:05:35,,1323894045,7/15/2014 23:05:22,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES],[CAUSES],causes of HYPERTENSION such as PHEOCHROMOCYTOMA,N/A,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/15/2014 23:41:41,,1323913588,7/15/2014 23:40:19,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[CAUSES],[CAUSES],causes such as,Na,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/15/2014 23:46:17,,1323915956,7/15/2014 23:45:39,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],causes of HYPERTENSION such as,n/a,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/16/2014 00:20:11,,1323936366,7/16/2014 00:19:55,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",such as,n/a,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/16/2014 00:43:25,,1323947384,7/16/2014 00:42:51,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,of HYPERTENSION such as PHEOCHROMOCYTOMA,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/16/2014 01:16:31,,1323966562,7/16/2014 01:16:24,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],such as,N/A,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/16/2014 02:11:04,,1323992314,7/16/2014 02:10:32,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],causes of such as,na,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/16/2014 03:37:51,,1324024203,7/16/2014 03:37:13,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],HYPERTENSION PHEOCHROMOCYTOMA,n/a,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/16/2014 05:41:49,,1324070733,7/16/2014 05:41:30,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],identifiable causes of such as,N/A,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/16/2014 06:01:04,,1324076609,7/16/2014 06:00:37,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[MANIFESTATION],[MANIFESTATION],causes of such as,N/A,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/16/2014 07:42:23,,1324110303,7/16/2014 07:41:16,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],causes,N/A,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/16/2014 09:10:48,,1324135856,7/16/2014 09:10:30,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",such as,n/a,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/16/2014 11:56:51,,1324216843,7/16/2014 11:56:28,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such as,N/A,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/16/2014 12:15:07,,1324223073,7/16/2014 12:14:02,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[CAUSES],[CAUSES],such as,N/A,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384197,7/16/2014 12:57:35,,1324240377,7/16/2014 12:56:10,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],identifiable causes,n/a,49,70,60,86,1,RO-disease_may_have_finding,902958-FS1,Evidence: ? Patients with identifiable causes of HYPERTENSION such as PHEOCHROMOCYTOMA and renal disease have unique perioperative considerations ( 12.,HYPERTENSION,PHEOCHROMOCYTOMA
503384198,7/15/2014 23:23:04,,1323903799,7/15/2014 23:22:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],GROUP,N/A,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/15/2014 23:33:46,,1323909644,7/15/2014 23:33:19,instagc,1.0,13763729,USA,"","",75.182.89.225,[NONE],[NONE],N/A,Group is quantitative.,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/15/2014 23:35:15,,1323910360,7/15/2014 23:33:47,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[OTHER],[OTHER],GROUP POOR PROGNOSIS BREAST CANCER,HOw they are studied,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/15/2014 23:48:25,,1323917034,7/15/2014 23:47:44,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SIDE_EFFECT],[SIDE_EFFECT],presence,asd,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/16/2014 00:35:45,,1323944012,7/16/2014 00:35:18,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH] [LOCATION] [PART_OF],"[LOCATION]
[ASSOCIATED_WITH]
[PART_OF]",GROUP of,N/A,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/16/2014 03:16:18,,1324016827,7/16/2014 03:15:16,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GROUP POOR PROGNOSIS BREAST CANCER,n/a,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/16/2014 03:45:30,,1324027882,7/16/2014 03:44:40,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GROUP POOR PROGNOSIS BREAST CANCER,n/a,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/16/2014 06:40:54,,1324089531,7/16/2014 06:40:29,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],of,n/a,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/16/2014 08:17:08,,1324120582,7/16/2014 08:16:21,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in this GROUP of,"because:

in this GROUP of POOR PROGNOSIS BREAST CANCER",166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/16/2014 09:26:07,,1324145760,7/16/2014 09:25:15,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],in,N/A,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/16/2014 10:12:07,,1324177796,7/16/2014 10:11:13,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[PART_OF],[PART_OF],GROUP of,n/a,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/16/2014 11:01:33,,1324197679,7/16/2014 11:00:57,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],in this GROUP of POOR PROGNOSIS BREAST CANCER,N/A,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/16/2014 12:01:54,,1324218669,7/16/2014 12:01:40,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,separate,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/16/2014 12:02:43,,1324218956,7/16/2014 12:02:01,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in this,N/A,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384198,7/16/2014 12:56:33,,1324239895,7/16/2014 12:54:22,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[ASSOCIATED_WITH] [PART_OF] [LOCATION],"[LOCATION]
[ASSOCIATED_WITH]
[PART_OF]",No difference found between presence absence circulating tumor cells previous chemotherapy treatment,it states that no difference was found,166,157,193,162,-1,RO-has_manifestation,906080-FS1,No difference was found between presence or absence of circulating tumor cells and previous chemotherapy treatment (p = 0.5) or stage TNM (p = 0.13) in this GROUP of POOR PROGNOSIS BREAST CANCER,POOR PROGNOSIS BREAST CANCER,GROUP
503384199,7/15/2014 23:09:36,,1323896399,7/15/2014 23:09:12,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis includes,N/A,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/15/2014 23:11:49,,1323897661,7/15/2014 23:11:29,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such as,N/A,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/15/2014 23:20:10,,1323902282,7/15/2014 23:19:30,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],ACTINIC KERATOSIS VERRUCA VULGARIS,N/A,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/15/2014 23:26:07,,1323905597,7/15/2014 23:25:50,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[OTHER],[OTHER],ACTINIC KERATOSIS VERRUCA VULGARIS,N/A,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/15/2014 23:31:24,,1323908411,7/15/2014 23:30:51,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],"types of benign malignant lesions,",N/A,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/15/2014 23:52:40,,1323919298,7/15/2014 23:51:40,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[TREATS],[TREATS],many types,asd,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/16/2014 00:18:10,,1323935287,7/16/2014 00:17:19,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[ASSOCIATED_WITH],[ASSOCIATED_WITH],types,I did not select none.,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/16/2014 00:30:10,,1323941129,7/16/2014 00:29:22,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ACTINIC KERATOSIS VERRUCA VULGARIS,n/a,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/16/2014 00:36:04,,1323944126,7/16/2014 00:35:46,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",N/A,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/16/2014 00:45:34,,1323948338,7/16/2014 00:44:44,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[NONE],[NONE],na,there is no relation mentioned,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/16/2014 01:17:38,,1323967293,7/16/2014 01:16:37,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[IS_A],[IS_A],ACTINIC KERATOSIS VERRUCA VULGARIS,N/A,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/16/2014 02:12:30,,1323993149,7/16/2014 02:11:30,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two different terms,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/16/2014 03:08:14,,1324014067,7/16/2014 03:07:35,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[PART_OF],[PART_OF],ACTINIC KERATOSIS VERRUCA VULGARIS,N/A,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/16/2014 03:36:16,,1324023586,7/16/2014 03:35:36,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[PART_OF],[PART_OF],ACTINIC KERATOSIS VERRUCA VULGARIS,n/a,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384199,7/16/2014 06:01:40,,1324076744,7/16/2014 06:01:05,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,different consitions,123,141,139,157,-1,RO-disease_has_finding,901592-FS1,"Differential diagnosis includes many types of benign and malignant lesions, such as basal cell carcinoma, keratoacanthoma, ACTINIC KERATOSIS VERRUCA VULGARIS and seborrheic keratosis.",ACTINIC KERATOSIS,VERRUCA VULGARIS
503384200,7/15/2014 23:05:47,,1323894170,7/15/2014 23:05:37,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[IS_A],[IS_A],VARICELLA also known as CHICKENPOX,N/A,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/15/2014 23:08:05,,1323895438,7/15/2014 23:07:55,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],herpesvirus,N/A,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/15/2014 23:14:36,,1323899166,7/15/2014 23:13:10,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],causes the,N/A,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/15/2014 23:31:28,,1323908440,7/15/2014 23:29:37,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],also known as,N/A,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/16/2014 00:48:47,,1323949943,7/16/2014 00:46:08,prodege,1,22360212,GBR,I1,Luton,82.6.41.191,[NONE],[NONE],N/a,The relationship is that they are two alternative names for the same disease - an relationship option which is not provided.,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/16/2014 00:49:58,,1323950703,7/16/2014 00:49:23,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A] [OTHER],"[IS_A]
[OTHER]",also known as,N/A,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/16/2014 00:52:12,,1323951772,7/16/2014 00:51:50,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[IS_A],[IS_A],also known as,N/A,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/16/2014 01:21:51,,1323969887,7/16/2014 01:21:03,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES] [IS_A],"[CAUSES]
[IS_A]",disease VARICELLA also known as CHICKENPOX,N/A,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/16/2014 02:16:59,,1323995792,7/16/2014 02:16:28,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[IS_A],[IS_A],also known,Na,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/16/2014 05:42:17,,1324070869,7/16/2014 05:41:19,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[PART_OF],[PART_OF],also known as,N/A,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/16/2014 06:34:19,,1324087468,7/16/2014 06:34:02,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[IS_A],[IS_A],also known as,n/a,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/16/2014 07:45:24,,1324111056,7/16/2014 07:45:00,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[CAUSES],[CAUSES],which causes the disease,n/a,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/16/2014 08:05:22,,1324117069,7/16/2014 08:05:02,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[CAUSES],[CAUSES],causes,N/A,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/16/2014 09:07:27,,1324134783,7/16/2014 09:07:03,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],causes,n/a,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384200,7/16/2014 11:03:15,,1324198164,7/16/2014 11:02:46,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CAUSES],[CAUSES],is the herpesvirus which causes the childhood disease,N/A,83,107,91,117,-1,RO-has_causative_agent,903771-FS1,"Varicella zoster virus (VZV) is the herpesvirus which causes the childhood disease VARICELLA also known as CHICKENPOX and the adult disease herpes zoster, also known as shingles.",VARICELLA,CHICKENPOX
503384201,7/15/2014 23:03:10,,1323892343,7/15/2014 23:01:26,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],characterized by,N/A,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/15/2014 23:09:29,,1323896298,7/15/2014 23:09:21,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],BILATERAL,N/A,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/15/2014 23:11:15,,1323897335,7/15/2014 23:11:01,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[LOCATION],[LOCATION],BILATERAL INTERNAL CAROTID ARTERIES in ARTERIAL OCCLUSION,N/A,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/15/2014 23:14:13,,1323898925,7/15/2014 23:13:56,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[LOCATION],[LOCATION],vicinity,N/A,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/15/2014 23:21:13,,1323902829,7/15/2014 23:20:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],ARTERIAL,N/A,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/16/2014 00:46:08,,1323948549,7/16/2014 00:45:31,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is characterized by,N/A,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/16/2014 00:56:02,,1323954404,7/16/2014 00:54:53,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,n/a,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/16/2014 03:04:24,,1324012713,7/16/2014 03:03:49,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],BILATERAL INTERNAL CAROTID ARTERIES vicinity ARTERIAL OCCLUSION,N/A,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/16/2014 05:13:12,,1324062394,7/16/2014 05:12:31,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],characterized by and,N/A,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/16/2014 08:00:38,,1324115548,7/16/2014 08:00:05,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the vicinity of,N/A,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/16/2014 08:11:21,,1324118723,7/16/2014 08:10:44,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[LOCATION],[LOCATION],in the vicinity of the ARTERIAL OCCLUSION,I think: of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/16/2014 09:09:30,,1324135399,7/16/2014 09:09:19,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/16/2014 10:18:55,,1324180594,7/16/2014 10:18:06,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[LOCATION],[LOCATION],portions of,n/a,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/16/2014 10:46:40,,1324192956,7/16/2014 10:46:00,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],the vicinity of the,N/A,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384201,7/16/2014 11:48:15,,1324213923,7/16/2014 11:47:40,clixsense,1.0,6621167,USA,IL,Round Lake,24.12.122.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,86,175,120,193,1,RO-has_finding_site,905037-FS1,The disease is characterized by stenosis or occlusion of the terminal portions of the BILATERAL INTERNAL CAROTID ARTERIES and abnormal vascular network in the vicinity of the ARTERIAL OCCLUSION,BILATERAL INTERNAL CAROTID ARTERIES,ARTERIAL OCCLUSION
503384202,7/15/2014 23:09:02,,1323896028,7/15/2014 23:08:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],for patients with,N/A,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/15/2014 23:22:45,,1323903601,7/15/2014 23:22:13,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],collected data,N/A,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/15/2014 23:28:53,,1323906995,7/15/2014 23:28:40,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],versus pamidronate for patients with,N/A,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/15/2014 23:51:33,,1323918777,7/15/2014 23:51:06,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],versus pamidronate for patients with,n/a,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/15/2014 23:55:14,,1323920440,7/15/2014 23:54:45,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[TREATS],[TREATS],trial of,Na,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/16/2014 00:06:33,,1323927261,7/16/2014 00:06:21,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],MULTIPLE,asd,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/16/2014 00:44:53,,1323948016,7/16/2014 00:44:23,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/16/2014 00:52:08,,1323951718,7/16/2014 00:50:39,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],for patients with,N/A,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/16/2014 01:17:19,,1323967058,7/16/2014 01:17:10,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],trial,N/A,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/16/2014 02:18:01,,1323996335,7/16/2014 02:17:05,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],multinational trial of versus pamidronate for patients with,na,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/16/2014 02:19:15,,1323996928,7/16/2014 02:18:57,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],multinational trial,Na,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/16/2014 04:18:06,,1324043501,7/16/2014 04:17:42,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],collected,N/A,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/16/2014 04:46:49,,1324051640,7/16/2014 04:44:39,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[NONE],[NONE],N/A,patients were tested for both,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/16/2014 05:31:11,,1324067905,7/16/2014 05:30:44,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],for patients with,N/A,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384202,7/16/2014 05:34:40,,1324068827,7/16/2014 05:33:31,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],trial of for patients with,N/A,150,97,176,112,1,RO-may_treat,908304-FS1,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
503384203,7/15/2014 23:11:24,,1323897369,7/15/2014 23:11:12,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],resulting,N/A,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/15/2014 23:16:41,,1323900152,7/15/2014 23:16:23,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[SYMPTOM],[SYMPTOM],hallmark,N/A,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/15/2014 23:18:57,,1323901622,7/15/2014 23:18:31,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],calcifications occurred,N/A,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/15/2014 23:24:00,,1323904386,7/15/2014 23:23:33,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],hallmark,N/A,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/15/2014 23:30:37,,1323907938,7/15/2014 23:30:11,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],resulting,N/A,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/15/2014 23:39:55,,1323912790,7/15/2014 23:39:11,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[MANIFESTATION] [CAUSES],"[CAUSES]
[MANIFESTATION]",hallmark of high grade,n/a,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/16/2014 00:00:14,,1323923248,7/15/2014 23:59:36,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],resulting in,n/a,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/16/2014 00:03:39,,1323925361,7/16/2014 00:03:13,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],resulting,n/a,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/16/2014 00:31:19,,1323941786,7/16/2014 00:30:36,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],resulting in linear and a hallmark of high grade,n/a,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/16/2014 00:35:21,,1323943741,7/16/2014 00:33:30,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,[CAUSES],[CAUSES],DCIS resulting in BRANCHING (CASTING TYPE CALCIFICATIONS,N/A,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/16/2014 00:37:20,,1323944598,7/16/2014 00:36:30,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/16/2014 05:40:36,,1324070428,7/16/2014 05:40:08,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],a hallmark of,N/A,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/16/2014 06:30:21,,1324086357,7/16/2014 06:29:58,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],a hallmark of,n/a,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/16/2014 06:58:39,,1324095411,7/16/2014 06:58:12,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],in the necrotic core,N/a,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384203,7/16/2014 08:03:06,,1324116406,7/16/2014 08:02:37,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],a hallmark of,N/A,101,72,138,76,-1,RO-disease_may_have_finding,902562-FS1,Multiple calcifications occurred in the necrotic core of the continuous DCIS resulting in linear and BRANCHING (CASTING TYPE CALCIFICATIONS a hallmark of high grade DCIS on mammograms.,BRANCHING (CASTING TYPE CALCIFICATIONS,DCIS
503384204,7/15/2014 23:07:59,,1323895380,7/15/2014 23:07:31,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[LOCATION],[LOCATION],in the,N/A,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/15/2014 23:10:44,,1323897055,7/15/2014 23:10:19,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[CAUSES] [NONE],"[CAUSES]
[NONE]",N/A,Different conditions,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/15/2014 23:17:32,,1323900676,7/15/2014 23:16:32,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION] [LOCATION],"[LOCATION]
[MANIFESTATION]",changes seen LENS CATARACT FORMATION.,Manifestation / Location,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/15/2014 23:23:45,,1323904263,7/15/2014 23:23:22,clixsense,1.0,15189335,GBR,H9,London,188.29.165.232,[SYMPTOM],[SYMPTOM],and in,Na,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/15/2014 23:24:52,,1323904934,7/15/2014 23:24:16,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],reactions occur,N/A,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/15/2014 23:33:53,,1323909723,7/15/2014 23:33:27,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],in,N/A,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/15/2014 23:39:40,,1323912678,7/15/2014 23:39:23,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/16/2014 00:36:28,,1323944223,7/16/2014 00:35:55,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,LENS with age and in CATARACT FORMATION.,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/16/2014 00:55:34,,1323954001,7/16/2014 00:55:18,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],seen,N/A,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/16/2014 01:03:27,,1323958686,7/16/2014 01:02:39,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],seen in LENS with age and in CATARACT FORMATION.,N/A,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/16/2014 04:41:47,,1324050189,7/16/2014 04:41:17,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],seen in the LENS with age and in CATARACT FORMATION.,N/A,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/16/2014 06:22:06,,1324083538,7/16/2014 06:21:42,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],in the LENS,n/a,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/16/2014 09:11:54,,1324136207,7/16/2014 09:11:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/16/2014 09:27:32,,1324147418,7/16/2014 09:26:08,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],metal catalyzed oxidation reactions,N/A,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384204,7/16/2014 10:10:26,,1324177044,7/16/2014 10:09:51,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[PART_OF],[PART_OF],and in,n/a,177,198,180,216,1,RO-has_finding_site,905038-FS1,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
503384205,7/15/2014 23:17:58,,1323900907,7/15/2014 23:14:57,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],carcinomatous,n/a,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/15/2014 23:26:02,,1323905546,7/15/2014 23:25:20,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],cases,N/A,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/15/2014 23:48:08,,1323916890,7/15/2014 23:47:29,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[PART_OF],[PART_OF],having a carcinomatous and a,n/a,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/16/2014 00:10:14,,1323929892,7/16/2014 00:09:55,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],having a carcinomatous,n/a,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/16/2014 00:45:30,,1323948311,7/16/2014 00:44:51,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM],[SYMPTOM],in having a,N/A,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/16/2014 00:53:00,,1323952299,7/16/2014 00:52:36,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/16/2014 01:59:58,,1323986565,7/16/2014 01:58:46,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[MANIFESTATION],[MANIFESTATION],in having a carcinomatous and a,na,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/16/2014 03:17:36,,1324017267,7/16/2014 03:16:23,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MMMT SARCOMATOUS COMPONENT,n/a,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/16/2014 07:40:32,,1324109878,7/16/2014 07:38:56,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[PART_OF],[PART_OF],having,N/A,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/16/2014 11:32:30,,1324208432,7/16/2014 11:31:26,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[PART_OF],[PART_OF],in having a carcinomatous and a,"because of:

This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT",79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/16/2014 11:50:31,,1324214758,7/16/2014 11:50:17,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in having,N/A,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/16/2014 12:10:23,,1324221491,7/16/2014 12:09:32,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],having a,N/A,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/16/2014 12:51:15,,1324237450,7/16/2014 12:50:35,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MMMT in having carcinomatous and SARCOMATOUS COMPONENT,n/a,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/16/2014 12:59:08,,1324241049,7/16/2014 12:58:38,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[SYMPTOM] [CONTRAINDICATES] [ASSOCIATED_WITH],"[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]",carcinomatous SARCOMATOUS COMPONENT differs MMMT,They differ due to the gender.,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384205,7/16/2014 13:00:36,,1324241622,7/16/2014 12:59:56,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",differs from cases of,n/a,79,42,99,46,1,RO-disease_has_finding,901872-FS1,This case fulfills all the criteria of an MMMT in having a carcinomatous and a SARCOMATOUS COMPONENT but differs from cases of MMMT in women in that the sarcomatous component had decidualized.,SARCOMATOUS COMPONENT,MMMT
503384206,7/15/2014 23:06:11,,1323894356,7/15/2014 23:05:48,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[IS_A],[IS_A],patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,N/A,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/15/2014 23:07:38,,1323895172,7/15/2014 23:07:05,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],more sustained,N/A,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/15/2014 23:08:41,,1323895802,7/15/2014 23:08:32,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SYMPTOM],[SYMPTOM],differentiation,N/A,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/15/2014 23:16:21,,1323899959,7/15/2014 23:15:57,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],differentiation,N/A,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/15/2014 23:22:38,,1323903484,7/15/2014 23:21:41,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/15/2014 23:27:36,,1323906335,7/15/2014 23:26:46,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],sustained,N/A,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/15/2014 23:54:51,,1323920275,7/15/2014 23:54:31,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[CONTRAINDICATES],[CONTRAINDICATES],differentiation of patients with,n/a,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/15/2014 23:57:34,,1323921783,7/15/2014 23:57:00,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],might allow for differentiation,Na,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/16/2014 00:01:49,,1323924224,7/16/2014 00:01:01,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[NONE],[NONE],N/A,They are two separate issues that have similar signs.,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/16/2014 00:18:44,,1323935660,7/16/2014 00:18:11,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[ASSOCIATED_WITH],[ASSOCIATED_WITH],those with more sustained,I did not select none,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/16/2014 00:29:53,,1323941005,7/16/2014 00:27:57,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER] [IS_A],"[IS_A]
[OTHER]",from those with more sustained,N/A,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/16/2014 00:34:55,,1323943518,7/16/2014 00:34:26,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH] [PART_OF] [OTHER],"[ASSOCIATED_WITH]
[PART_OF]
[OTHER]",from those with more sustained,N/A,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/16/2014 01:36:41,,1323977131,7/16/2014 01:36:13,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with more sustained,na,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/16/2014 03:15:11,,1324016463,7/16/2014 03:14:24,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],TRANSIENT ELEVATED BLOOD PRESSURE HYPERTENSION,n/a,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384206,7/16/2014 06:35:24,,1324087759,7/16/2014 06:35:07,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],differentiation,n/a,89,154,121,166,-1,RO-has_definitional_manifestation,904985-FS1,Ambulatory monitoring of blood pressure might allow for differentiation of patients with TRANSIENT ELEVATED BLOOD PRESSURE from those with more sustained HYPERTENSION,TRANSIENT ELEVATED BLOOD PRESSURE,HYPERTENSION
503384207,7/15/2014 23:24:26,,1323904653,7/15/2014 23:24:13,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],DEPRESSION (TRICYCLIC ANTIDEPRESSANTS,N/A,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/15/2014 23:47:07,,1323916384,7/15/2014 23:46:18,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],"(TRICYCLIC ANTIDEPRESSANTS venlafaxine),",n/a,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 00:16:46,,1323934425,7/16/2014 00:15:59,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",bipolar disorder,[ASSOCIATED_WITH] [MANIFESTATION],185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 00:20:05,,1323936345,7/16/2014 00:19:40,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[TREATS],[TREATS],"effective against them,",I didn't select none,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 00:40:55,,1323946268,7/16/2014 00:40:11,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]","may be effective against them,",N/A,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 00:50:24,,1323950917,7/16/2014 00:49:24,elite,1.0,27788262,USA,"","",172.163.6.138,[TREATS],[TREATS],that may be effective against,N/A,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 00:54:45,,1323953531,7/16/2014 00:54:31,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[OTHER],[OTHER],(TRICYCLIC ANTIDEPRESSANTS,N/A,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 00:57:06,,1323954912,7/16/2014 00:56:06,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],migraine medications,N\A,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 00:59:28,,1323956253,7/16/2014 00:58:51,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[TREATS],[TREATS],(TRICYCLIC ANTIDEPRESSANTS,na,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 02:04:04,,1323988750,7/16/2014 02:03:28,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],against,none,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 05:37:25,,1324069518,7/16/2014 05:36:49,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],medications that may be effective against,N/A,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 06:24:02,,1324084160,7/16/2014 06:23:13,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine),","because of ), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine),",185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 07:39:30,,1324109626,7/16/2014 07:38:55,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[PART_OF],[PART_OF],"DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine),",n/a,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 08:02:36,,1324116213,7/16/2014 08:01:58,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],medications,N/A,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384207,7/16/2014 10:27:09,,1324183501,7/16/2014 10:25:47,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[TREATS],[TREATS],medications,n/a,185,197,194,222,1,RO-may_treat,907737-FS1,"Other disorders, along with the migraine medications that may be effective against them, include epilepsy (divalproex sodium, topiramate, and gabapentin), hypertension (beta blockers), DEPRESSION (TRICYCLIC ANTIDEPRESSANTS venlafaxine), bipolar disorder (divalproex sodium), insomnia (tricyclic antidepressants), essential tremor (beta blockers and topiramate), and overweight or obesity (topiramate.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
503384208,7/15/2014 23:21:59,,1323903202,7/15/2014 23:21:19,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],DRUG,N/A,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/15/2014 23:32:52,,1323909196,7/15/2014 23:31:56,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]","include isoimmune neonatal neutropenia,",N/A,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/15/2014 23:33:18,,1323909420,7/15/2014 23:32:56,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],selective neutropenia,N/A,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/15/2014 23:46:58,,1323916303,7/15/2014 23:46:06,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[IS_A],[IS_A],and,Na,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/16/2014 00:01:22,,1323923875,7/16/2014 00:00:14,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They are two kinds of neutropenia but don't seem to be caused by or always associated with each other.,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/16/2014 00:04:26,,1323925955,7/16/2014 00:04:01,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA,n/a,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/16/2014 00:57:12,,1323954982,7/16/2014 00:55:40,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/16/2014 01:11:47,,1323963784,7/16/2014 01:09:22,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [PREVENTS] [PART_OF],"[TREATS]
[PREVENTS]
[PART_OF]",AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA,N/A,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/16/2014 01:16:51,,1323966772,7/16/2014 01:16:32,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NEUTROPENIA NEUTROPENIA,N/A,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/16/2014 02:03:20,,1323988403,7/16/2014 02:01:26,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA,na,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/16/2014 05:27:42,,1324066905,7/16/2014 05:26:58,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],selective neutropenia include,N/A,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/16/2014 07:55:40,,1324113775,7/16/2014 07:55:10,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[SYMPTOM],[SYMPTOM],syndromes include,n/a,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/16/2014 07:59:41,,1324115104,7/16/2014 07:59:11,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DRUG INDUCED,N/A,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/16/2014 09:12:21,,1324136358,7/16/2014 09:11:56,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA,n/a,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384208,7/16/2014 10:58:23,,1324196753,7/16/2014 10:57:24,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],immune clinical syndromes,N/A,131,108,154,130,-1,RO-has_definitional_manifestation,904866-FS1,"The immune clinical syndromes predisposing to selective neutropenia include isoimmune neonatal neutropenia, AUTOIMMUNE NEUTROPENIA DRUG INDUCED NEUTROPENIA and complement mediated neutropenia.",DRUG INDUCED NEUTROPENIA,AUTOIMMUNE NEUTROPENIA
503384209,7/15/2014 23:26:43,,1323905924,7/15/2014 23:26:06,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/15/2014 23:28:05,,1323906590,7/15/2014 23:27:47,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Two complications noticed:,N/A,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/15/2014 23:42:19,,1323913840,7/15/2014 23:41:45,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,"Different patients had each condition, so they do not appear to be related.",62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/15/2014 23:48:50,,1323917247,7/15/2014 23:47:38,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES],[CAUSES],and pancreatic pseudocyst and a late development of a hepatic nodule,n/a,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/16/2014 00:25:10,,1323938668,7/16/2014 00:24:19,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],complications were noticed:,N/A,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/16/2014 00:25:55,,1323939035,7/16/2014 00:25:33,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[SIDE_EFFECT],[SIDE_EFFECT],and pancreatic pseudocyst and a late development of a hepatic nodule (probably,n/a,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/16/2014 01:13:33,,1323964781,7/16/2014 01:13:24,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],(probably,N/A,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/16/2014 02:23:38,,1323998698,7/16/2014 02:23:26,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],development,Na,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/16/2014 03:11:06,,1324015009,7/16/2014 03:10:35,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],ASCITES and HEPATOMA,N/A,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/16/2014 03:44:00,,1324027138,7/16/2014 03:43:15,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[CAUSES],[CAUSES],ASCITES HEPATOMA,n/a,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/16/2014 05:10:08,,1324061438,7/16/2014 05:09:31,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],complications,N/A,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/16/2014 05:33:37,,1324068552,7/16/2014 05:32:34,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Two early postoperative complications,N/A,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/16/2014 06:32:41,,1324087036,7/16/2014 06:31:45,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],Two early postoperative complications,n/a,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/16/2014 07:43:50,,1324110682,7/16/2014 07:43:12,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[SYMPTOM],[SYMPTOM],and a late development of,n/a,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384209,7/16/2014 07:55:23,,1324113703,7/16/2014 07:54:46,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[MANIFESTATION],[MANIFESTATION],complications,N/A,62,149,68,157,-1,RO-disease_may_have_finding,902723-FS1,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
503384210,7/15/2014 23:11:41,,1323897584,7/15/2014 23:11:09,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,N/A,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/15/2014 23:21:39,,1323903065,7/15/2014 23:21:14,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],disorder with an,N/A,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/15/2014 23:21:47,,1323903115,7/15/2014 23:21:32,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],a rare disorder with an,N/A,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/15/2014 23:49:54,,1323917895,7/15/2014 23:48:09,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],a rare disorder with an AGGRESSIVE CLINICAL COURSE,n/a,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/16/2014 00:24:18,,1323938263,7/16/2014 00:22:02,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],with an,N/A,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/16/2014 00:34:12,,1323943129,7/16/2014 00:33:48,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[IS_A],[IS_A],a rare disorder with an,N/A,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/16/2014 01:49:39,,1323981698,7/16/2014 01:48:57,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],with,none,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/16/2014 03:00:41,,1324011288,7/16/2014 02:59:57,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A],[IS_A],PLASMA CELL LEUKAEMIA with AGGRESSIVE CLINICAL COURSE,N/A,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/16/2014 04:21:50,,1324044826,7/16/2014 04:20:57,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[TREATS] [OTHER],"[TREATS]
[OTHER]",diagnosis PLASMA CELL LEUKAEMIA rare disorder AGGRESSIVE CLINICAL COURSE,N/A,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/16/2014 05:20:39,,1324064923,7/16/2014 05:19:59,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],with an,N/A,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/16/2014 05:31:28,,1324067995,7/16/2014 05:31:09,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[SYMPTOM],[SYMPTOM],a rare disorder with an,N/A,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/16/2014 05:44:09,,1324071361,7/16/2014 05:43:37,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[MANIFESTATION],[MANIFESTATION],rare disorder with an,N/A,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/16/2014 06:02:10,,1324076878,7/16/2014 06:01:41,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[ASSOCIATED_WITH],[ASSOCIATED_WITH],a rare disorder with an,N/A,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/16/2014 06:59:15,,1324095608,7/16/2014 06:59:01,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],with an,N/a,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384210,7/16/2014 09:13:48,,1324136885,7/16/2014 09:13:38,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with an,n/a,63,17,88,38,1,RO-disease_may_have_finding,902607-FS1,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
503384211,7/15/2014 23:01:24,,1323891140,7/15/2014 23:00:41,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],responses to,N/A,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/15/2014 23:07:16,,1323895017,7/15/2014 23:06:50,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[OTHER],[OTHER],PLASMA GLUCOSE HYPOGLYCEMIA,Unclear,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/15/2014 23:11:42,,1323897593,7/15/2014 23:11:35,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],induced,N/A,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/15/2014 23:15:15,,1323899473,7/15/2014 23:13:30,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],restoring,N/A,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/15/2014 23:32:45,,1323909119,7/15/2014 23:32:16,clixsense,1.0,15189335,GBR,H9,London,188.29.165.200,[ASSOCIATED_WITH],[ASSOCIATED_WITH],responses,Na,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/16/2014 00:12:09,,1323931240,7/16/2014 00:11:46,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],but little is known about,n/a,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/16/2014 00:55:08,,1323953780,7/16/2014 00:54:47,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],to,N/A,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/16/2014 01:34:17,,1323976216,7/16/2014 01:33:26,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[TREATS],[TREATS],induced by hypoglycemia restoring,na,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/16/2014 02:17:04,,1323995840,7/16/2014 02:16:20,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],protect the brain by restoring,na,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/16/2014 04:04:49,,1324037012,7/16/2014 04:03:57,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PLASMA GLUCOSE HYPOGLYCEMIA,n/a,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/16/2014 04:40:18,,1324049790,7/16/2014 04:37:29,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[SYMPTOM],[SYMPTOM],restoring GLUCOSE HYPOGLYCEMIA,N/A,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/16/2014 05:00:43,,1324057921,7/16/2014 05:00:08,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],may also be neuroprotective.,N/A,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/16/2014 05:26:57,,1324066760,7/16/2014 05:26:20,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[CAUSES],[CAUSES],protect the brain by restoring,N/A,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/16/2014 05:31:07,,1324067881,7/16/2014 05:30:07,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",by restoring,N/A,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384211,7/16/2014 05:56:56,,1324075284,7/16/2014 05:56:26,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],protect the brain by restoring,N/A,173,109,184,123,1,RO-may_treat,908276-FS1,The robust neuroendocrine counterregulatory responses induced by hypoglycemia protect the brain by restoring PLASMA GLUCOSE but little is known about molecular responses to HYPOGLYCEMIA that may also be neuroprotective.,HYPOGLYCEMIA,PLASMA GLUCOSE
503384212,7/15/2014 23:14:55,,1323899288,7/15/2014 23:14:49,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],safe,n/a,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 00:08:08,,1323928465,7/16/2014 00:07:14,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[SIDE_EFFECT] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SIDE_EFFECT]",effective means of,[SIDE_EFFECT] [DIAGNOSE_BY_TEST_OR_DRUG],104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 00:17:18,,1323934725,7/16/2014 00:16:47,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],Treatment TYPE A BOTULINUM TOXIN relieving BLEPHAROSPASM,Treats,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 00:25:06,,1323938646,7/16/2014 00:23:13,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],appears to be a safe and effective means of temporarily relieving,N/A,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 00:33:29,,1323942777,7/16/2014 00:32:13,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,[OTHER],[OTHER],TYPE A BOTULINUM TOXIN relieving BLEPHAROSPASM,N/A,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 00:46:05,,1323948536,7/16/2014 00:45:17,elite,1.0,27788262,USA,"","",172.163.6.138,[TREATS],[TREATS],appears to be a safe and effective means of temporarily relieving,N/A,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 01:34:46,,1323976380,7/16/2014 01:34:21,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[TREATS],[TREATS],temporarily relieving,na,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 02:06:45,,1323989960,7/16/2014 02:06:21,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],Treatment,none,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 02:21:18,,1323997709,7/16/2014 02:21:00,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],safe effective means relieving,Na,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 03:25:33,,1324019655,7/16/2014 03:24:27,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],TYPE BOTULINUM TOXIN BLEPHAROSPASM,n/a,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 03:48:42,,1324029398,7/16/2014 03:48:07,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[TREATS],[TREATS],TYPE A BOTULINUM TOXIN BLEPHAROSPASM,n/a,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 05:03:03,,1324058906,7/16/2014 05:02:32,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[TREATS],[TREATS],Treatment TYPE BOTULINUM TOXIN temporarily relieving BLEPHAROSPASM,N/A,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 05:35:30,,1324069030,7/16/2014 05:34:21,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],safe and effective means of temporarily relieving,N/A,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 07:54:55,,1324113531,7/16/2014 07:54:36,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[TREATS],[TREATS],Treatment with,n/a,104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384212,7/16/2014 11:33:28,,1324208725,7/16/2014 11:32:31,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[TREATS],[TREATS],Treatment appears to be of temporarily relieving,"because of:

appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM",104,15,116,37,1,RO-may_treat,908035-FS1,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
503384213,7/15/2014 23:01:31,,1323891186,7/15/2014 23:00:57,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],in the inhibition,N/A,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/15/2014 23:03:12,,1323892358,7/15/2014 23:02:55,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[TREATS],[TREATS],DENTAL CARIES FLUORIDE inhibition,N/A,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/15/2014 23:27:53,,1323906495,7/15/2014 23:27:43,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],role of FLUORIDE in the inhibition,N/A,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/15/2014 23:31:55,,1323908668,7/15/2014 23:31:25,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],inhibition or reversal,N/A,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/15/2014 23:53:19,,1323919613,7/15/2014 23:52:42,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",inhibition or reversal,Na,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/16/2014 00:11:14,,1323930666,7/16/2014 00:10:12,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],DENTAL CARIES role of FLUORIDE inhibition reversal,Treats,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/16/2014 00:54:18,,1323953271,7/16/2014 00:53:52,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],and the role,N/A,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/16/2014 01:16:58,,1323966837,7/16/2014 01:16:51,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],FLUORIDE,N/A,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/16/2014 02:01:24,,1323987483,7/16/2014 02:00:36,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[PREVENTS],[PREVENTS],in the inhibition,na,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/16/2014 02:18:06,,1323996360,7/16/2014 02:17:53,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",role inhibition,Na,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/16/2014 03:08:59,,1324014258,7/16/2014 03:08:09,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DENTAL CARIES FLUORIDE,n/a,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/16/2014 03:10:33,,1324014839,7/16/2014 03:10:06,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",DENTAL CARIES FLUORIDE inhibition,N/A,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/16/2014 05:09:30,,1324061170,7/16/2014 05:08:55,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",the role in the inhibition or,N/A,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/16/2014 05:19:57,,1324064694,7/16/2014 05:19:14,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],the inhibition or reversal of that process.,N/A,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384213,7/16/2014 06:09:44,,1324079213,7/16/2014 06:08:27,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",inhibition reversal,n/a,45,75,57,83,1,RO-may_prevent,907223-FS1,This paper reviews the probable mechanism of DENTAL CARIES and the role of FLUORIDE in the inhibition or reversal of that process.,DENTAL CARIES,FLUORIDE
503384214,7/15/2014 23:27:19,,1323906177,7/15/2014 23:26:58,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],IVIG were IDIOPATHIC THROMBOCYTOPENIC PURPURA,N/A,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/15/2014 23:37:55,,1323911686,7/15/2014 23:37:19,clixsense,1.0,15189335,GBR,H9,London,188.29.165.200,[SYMPTOM],[SYMPTOM],Indications,Na,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/15/2014 23:38:11,,1323911835,7/15/2014 23:37:22,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],therapy,N/A,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/15/2014 23:47:37,,1323916649,7/15/2014 23:46:42,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",were,n/a,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/16/2014 00:50:38,,1323951001,7/16/2014 00:48:25,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],Indications for,N/A,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/16/2014 01:17:09,,1323966969,7/16/2014 01:16:59,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],therapy,N/A,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/16/2014 01:21:02,,1323969397,7/16/2014 01:20:29,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA,N/A,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/16/2014 01:29:06,,1323974042,7/16/2014 01:28:33,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[TREATS],[TREATS],therapy,na,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/16/2014 01:48:57,,1323981353,7/16/2014 01:48:25,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],therapy,none,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/16/2014 02:51:54,,1324008338,7/16/2014 02:51:14,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],Indications IVIG therapy IDIOPATHIC THROMBOCYTOPENIC PURPURA,N/A,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/16/2014 04:05:39,,1324037455,7/16/2014 04:04:52,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],IVIG IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),n/a,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/16/2014 06:17:52,,1324082115,7/16/2014 06:16:49,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[TREATS],[TREATS],Indications for therapy,Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/16/2014 10:15:56,,1324179237,7/16/2014 10:15:06,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[IS_A],[IS_A],were,n/a,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/16/2014 11:50:07,,1324214612,7/16/2014 11:49:14,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],therapy,N/A,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384214,7/16/2014 11:58:27,,1324217360,7/16/2014 11:57:45,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],therapy,N/A,34,16,68,20,1,RO-may_treat,908158-FS1,"Indications for IVIG therapy were IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID.",IDIOPATHIC THROMBOCYTOPENIC PURPURA,IVIG
503384215,7/15/2014 23:19:25,,1323901861,7/15/2014 23:17:45,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/15/2014 23:35:57,,1323910679,7/15/2014 23:35:36,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/15/2014 23:55:13,,1323920454,7/15/2014 23:53:26,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],Dopa,ASd,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/16/2014 00:21:12,,1323936875,7/16/2014 00:20:39,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[TREATS],[TREATS],patients often experience fluctuations in performance after a period of time,n/a,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/16/2014 00:32:12,,1323942185,7/16/2014 00:31:08,prodege,1.0,22360212,GBR,I1,Luton,82.6.41.191,[TREATS],[TREATS],L Dopa is used in the treatment of PARKINSON'S DISEASE,N/A,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/16/2014 03:01:20,,1324011568,7/16/2014 03:00:41,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],treatment of PARKINSON'S DISEASE L DOPA.,N/A,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/16/2014 03:46:04,,1324028104,7/16/2014 03:45:34,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[TREATS],[TREATS],"L Dopa PARKINSON'S DISEASE (PD),",n/a,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/16/2014 09:14:14,,1324137054,7/16/2014 09:14:02,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],treatment of,n/a,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/16/2014 10:25:47,,1324183075,7/16/2014 10:25:17,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[TREATS],[TREATS],used in the treatment,n/a,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/16/2014 10:55:35,,1324195793,7/16/2014 10:54:53,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],patients often experience fluctuations in performance after taking,n/a,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/16/2014 11:35:46,,1324209428,7/16/2014 11:35:05,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[SYMPTOM],[SYMPTOM],often experience fluctuations,"because of:

and patients often experience fluctuations in performance after a period of time taking L DOPA.",44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/16/2014 11:56:27,,1324216714,7/16/2014 11:55:52,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],treatment,N/A,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/16/2014 12:07:05,,1324220528,7/16/2014 12:06:11,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[TREATS],[TREATS],treatment of,N/A,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/16/2014 12:53:25,,1324238473,7/16/2014 12:53:12,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],used in the treatment of,n/a,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384215,7/16/2014 12:53:48,,1324238658,7/16/2014 12:53:10,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],used in the treatment,N/A,44,158,62,164,1,RO-may_treat,908159-FS1,"The drug L Dopa is used in the treatment of PARKINSON'S DISEASE (PD), and patients often experience fluctuations in performance after a period of time taking L DOPA.",PARKINSON'S DISEASE,L DOPA
503384216,7/15/2014 23:02:48,,1323892097,7/15/2014 23:02:07,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],"involving the mucosal tissue,",N/A,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/15/2014 23:23:05,,1323903809,7/15/2014 23:22:52,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],involving the SKIN,N/A,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/15/2014 23:27:06,,1323906067,7/15/2014 23:25:42,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/15/2014 23:33:26,,1323909513,7/15/2014 23:32:40,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],"tissue,",N/A,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/15/2014 23:38:15,,1323911874,7/15/2014 23:37:00,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],involving the,N/A,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/15/2014 23:56:50,,1323921271,7/15/2014 23:55:27,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],"the SKIN mucosal tissue, or both",n/a,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/16/2014 00:36:46,,1323944313,7/16/2014 00:36:36,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[LOCATION],[LOCATION],"(e.g.,",N/A,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/16/2014 00:57:06,,1323954894,7/16/2014 00:56:56,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],involving,N/A,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/16/2014 01:48:25,,1323981144,7/16/2014 01:47:47,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",both,none,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/16/2014 02:17:52,,1323996256,7/16/2014 02:17:26,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],"mucosal tissue,",Na,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/16/2014 03:34:48,,1324023010,7/16/2014 03:33:51,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[LOCATION],[LOCATION],SKIN GENERALIZED HIVES;,n/a,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/16/2014 05:01:33,,1324058327,7/16/2014 05:00:44,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],involving the,N/A,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/16/2014 06:34:41,,1324087555,7/16/2014 06:34:20,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],involving the SKIN,n/a,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/16/2014 07:07:14,,1324099102,7/16/2014 07:06:54,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],"Acute onset of an illness involving the SKIN (e.g., GENERALIZED HIVES;",N/a,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384216,7/16/2014 07:34:35,,1324108329,7/16/2014 07:34:01,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[LOCATION],[LOCATION],involving,N/A,72,108,75,125,1,RO-disease_has_primary_anatomic_site,902176-FS1,"Acute onset of an illness (over minutes to several hours) involving the SKIN mucosal tissue, or both (e.g., GENERALIZED HIVES; pruritus or flushing; swollen lips, tongue, or uvula) and at least one of the following:  a.",SKIN,GENERALIZED HIVES
503384217,7/15/2014 23:09:58,,1323896625,7/15/2014 23:09:49,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],interleukin,N/A,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/15/2014 23:20:27,,1323902437,7/15/2014 23:20:22,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],(rhIL)3,n/a,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/15/2014 23:24:49,,1323904889,7/15/2014 23:24:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],cells of MYELOGENOUS LEUKEMIA,N/A,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/15/2014 23:28:53,,1323907002,7/15/2014 23:28:30,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],proliferation,N/A,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/15/2014 23:51:04,,1323918505,7/15/2014 23:50:40,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],cells of,n/a,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/16/2014 00:07:38,,1323928085,7/16/2014 00:05:59,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],cells of,n/a,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/16/2014 00:26:41,,1323939399,7/16/2014 00:26:25,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[PART_OF],[PART_OF],cells of,n/a,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/16/2014 00:38:03,,1323944863,7/16/2014 00:37:22,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/16/2014 02:18:56,,1323996774,7/16/2014 02:18:39,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],cells,Na,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/16/2014 03:31:54,,1324021903,7/16/2014 03:30:58,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[LOCATION],[LOCATION],BONE MARROW (BM) cells MYELOGENOUS LEUKEMIA,n/a,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/16/2014 07:04:05,,1324097588,7/16/2014 07:03:42,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA,N/a,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/16/2014 09:14:36,,1324137158,7/16/2014 09:14:26,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],cells of,n/a,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/16/2014 10:12:50,,1324178121,7/16/2014 10:12:08,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[LOCATION],[LOCATION],cells of,n/a,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/16/2014 11:52:46,,1324215440,7/16/2014 11:52:31,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[LOCATION],[LOCATION],cells,N/A,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384217,7/16/2014 12:22:52,,1324225710,7/16/2014 12:21:47,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[PART_OF],[PART_OF],proliferation in,N/A,100,126,110,146,1,RO-disease_has_primary_anatomic_site,902331-FS1,This study shows that both recombinant human interleukin (rhIL)3 and rhIL4 induced proliferation in BONE MARROW (BM) cells of MYELOGENOUS LEUKEMIA patients in a manner similar to that reported using normal BM cells.,BONE MARROW,MYELOGENOUS LEUKEMIA
503384218,7/15/2014 23:13:09,,1323898313,7/15/2014 23:12:27,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM] [LOCATION],"[LOCATION]
[SYMPTOM]",Look for presence,N/A,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/15/2014 23:31:53,,1323908698,7/15/2014 23:31:30,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],medications,N/A,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/15/2014 23:55:26,,1323920558,7/15/2014 23:54:52,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Look for,n/a,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/16/2014 00:27:44,,1323939859,7/16/2014 00:26:42,prodege,1.0,9636318,USA,HI,Wailuku,72.234.78.171,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],exam,n/a,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/16/2014 00:28:29,,1323940239,7/16/2014 00:28:08,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH],[ASSOCIATED_WITH],exam Look for,N/A,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/16/2014 01:00:52,,1323957205,7/16/2014 01:00:25,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[NONE],[NONE],na,there is no relation mentioned,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/16/2014 01:58:44,,1323985770,7/16/2014 01:57:53,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated things,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/16/2014 04:06:25,,1324037974,7/16/2014 04:05:41,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SKIN PETECHIAE,n/a,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/16/2014 04:37:27,,1324049113,7/16/2014 04:35:02,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[OTHER],[OTHER],SKIN Look ecchymosis and PETECHIAE Differential Diagnosis,N/A,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/16/2014 06:19:03,,1324082529,7/16/2014 06:17:53,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[NONE],[NONE],N/A,N/A,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/16/2014 06:27:14,,1324085361,7/16/2014 06:25:19,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],Physical exam SKIN exam,n/a,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/16/2014 07:47:18,,1324111626,7/16/2014 07:46:50,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[MANIFESTATION],[MANIFESTATION],exam Look for,n/a,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/16/2014 07:58:56,,1324114764,7/16/2014 07:58:32,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[SYMPTOM],[SYMPTOM],Look for,N/A,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/16/2014 11:00:19,,1324197323,7/16/2014 10:59:37,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],exam Look for PETECHIAE,N/A,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384218,7/16/2014 11:51:09,,1324214910,7/16/2014 11:50:08,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[LOCATION],[LOCATION],presence Look for,N/A,337,372,340,381,1,RO-has_finding_site,905203-FS1,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
503384219,7/15/2014 23:18:07,,1323901013,7/15/2014 23:17:34,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],consist of,N/A,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/15/2014 23:23:07,,1323903846,7/15/2014 23:22:35,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",consist of,N/A,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/15/2014 23:36:58,,1323911187,7/15/2014 23:34:46,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER],[OTHER],consist of the triad of,N/A,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/15/2014 23:46:35,,1323916132,7/15/2014 23:46:05,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[TREATS],[TREATS],childhood,asd,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/15/2014 23:48:49,,1323917238,7/15/2014 23:48:21,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/16/2014 00:10:36,,1323930179,7/16/2014 00:09:56,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],consist of the triad,[DIAGNOSE_BY_TEST_OR_DRUG],57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/16/2014 00:35:54,,1323944065,7/16/2014 00:35:23,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[OTHER],[OTHER],and,N/A,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/16/2014 01:23:11,,1323970907,7/16/2014 01:22:46,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],diseases consist of ASTHMA and ATOPIC DERMATITIS,N/A,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/16/2014 01:24:53,,1323971880,7/16/2014 01:24:05,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[OTHER],[OTHER],atopic diseases,na,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/16/2014 02:07:31,,1323990410,7/16/2014 02:07:11,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"allergic rhinitis,",n/a,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/16/2014 02:08:34,,1323990971,7/16/2014 02:08:04,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/16/2014 05:25:05,,1324066239,7/16/2014 05:24:25,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],The atopic diseases of childhood consist of,N/A,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/16/2014 05:52:30,,1324073845,7/16/2014 05:52:06,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,different conditions,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/16/2014 06:21:05,,1324083223,7/16/2014 06:20:31,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[PART_OF],[PART_OF],and,"because of the following""  the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384219,7/16/2014 11:04:58,,1324198778,7/16/2014 11:04:06,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],consist of triad and,N/A,57,87,62,104,-1,RO-has_manifestation,906019-FS1,"The atopic diseases of childhood consist of the triad of ASTHMA allergic rhinitis, and ATOPIC DERMATITIS",ASTHMA,ATOPIC DERMATITIS
503384220,7/15/2014 23:07:04,,1323894912,7/15/2014 23:06:18,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],lesions of the,N/A,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/15/2014 23:07:40,,1323895193,7/15/2014 23:07:17,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[NONE],[NONE],N/A,Different conditions,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/15/2014 23:15:56,,1323899788,7/15/2014 23:15:26,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[PART_OF],[PART_OF],SKIN SKIN,N/A,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/15/2014 23:56:39,,1323921202,7/15/2014 23:56:22,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CONTRAINDICATES],[CONTRAINDICATES],observed,asd,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/16/2014 00:16:46,,1323934424,7/16/2014 00:16:03,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],SKIN WOUNDS lesions BLISTERING SKIN DISEASE PEMPHIGUS,Manifestation,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/16/2014 00:32:24,,1323942294,7/16/2014 00:31:29,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],has been observed during,[DIAGNOSE_BY_TEST_OR_DRUG],88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/16/2014 00:43:48,,1323947595,7/16/2014 00:43:27,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/16/2014 02:10:23,,1323991976,7/16/2014 02:09:02,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/16/2014 02:15:52,,1323995096,7/16/2014 02:15:20,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/16/2014 03:12:55,,1324015712,7/16/2014 03:12:01,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],SKIN WOUNDS BLISTERING SKIN DISEASE PEMPHIGUS,n/a,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/16/2014 04:03:17,,1324036216,7/16/2014 04:02:50,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[CAUSES],[CAUSES],SKIN BLISTERING SKIN DISEASE PEMPHIGUS,n/a,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/16/2014 05:02:42,,1324058784,7/16/2014 05:02:08,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],and in,N/A,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/16/2014 05:32:32,,1324068294,7/16/2014 05:32:05,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[PART_OF],[PART_OF],and in lesions of,N/A,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/16/2014 06:23:12,,1324083921,7/16/2014 06:22:30,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[SIDE_EFFECT],[SIDE_EFFECT],and in lesions of,"this is why i think ""SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS""",88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384220,7/16/2014 06:40:02,,1324089205,7/16/2014 06:39:26,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],SKIN,n/a,88,133,98,166,1,RO-disease_has_primary_anatomic_site,902059-FS1,The activation of the urokinase system has been observed during re epithelialization of SKIN WOUNDS and in lesions of the autoimmune BLISTERING SKIN DISEASE PEMPHIGUS,SKIN WOUNDS,BLISTERING SKIN DISEASE PEMPHIGUS
503384221,7/15/2014 23:06:34,,1323894610,7/15/2014 23:06:12,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[OTHER],[OTHER],REFRACTORY STATUS EPILEPTICUS PROPOFOL or,"""or"" relationship",13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/15/2014 23:09:19,,1323896237,7/15/2014 23:09:10,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],with,N/A,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/15/2014 23:31:03,,1323908243,7/15/2014 23:30:40,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],Treatment,N/A,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/15/2014 23:49:06,,1323917425,7/15/2014 23:48:41,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],Treatment of,N/A,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/15/2014 23:54:30,,1323920126,7/15/2014 23:54:09,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],Treatment of with,n/a,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/16/2014 01:14:19,,1323965173,7/16/2014 01:13:49,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],Treatment of REFRACTORY STATUS EPILEPTICUS with PROPOFOL,N/A,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/16/2014 01:31:24,,1323975107,7/16/2014 01:30:57,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[TREATS],[TREATS],Treatment,na,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/16/2014 02:24:04,,1323998873,7/16/2014 02:23:54,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],Treatment,Na,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/16/2014 03:27:46,,1324020510,7/16/2014 03:26:38,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],REFRACTORY STATUS EPILEPTICUS PROPOFOL,n/a,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/16/2014 04:41:15,,1324050080,7/16/2014 04:40:19,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[TREATS],[TREATS],Treatment REFRACTORY STATUS EPILEPTICUS with PROPOFOL,N/A,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/16/2014 05:00:07,,1324057657,7/16/2014 04:59:30,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],Treatment with,N/A,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/16/2014 05:08:52,,1324061039,7/16/2014 05:05:51,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[OTHER],[OTHER],"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL",Propofol is the one treating,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/16/2014 05:17:12,,1324063820,7/16/2014 05:16:40,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],Treatment of with,N/A,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/16/2014 05:40:07,,1324070242,7/16/2014 05:39:52,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],Treatment of,N/A,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384221,7/16/2014 05:56:24,,1324075099,7/16/2014 05:56:03,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],Treatment of,N/A,13,63,41,71,1,RO-may_treat,907626-FS1,"Treatment of REFRACTORY STATUS EPILEPTICUS with pentobarbital, PROPOFOL or midazolam: a systematic review.",REFRACTORY STATUS EPILEPTICUS,PROPOFOL
503384222,7/15/2014 23:12:07,,1323897792,7/15/2014 23:11:50,elite,1.0,28503042,USA,OK,Watonga,65.255.78.241,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CEREBELLAR ATAXIA correlated with AI in CEREBELLUM,N/A,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/15/2014 23:14:40,,1323899188,7/15/2014 23:13:58,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlated,N/A,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/15/2014 23:19:08,,1323901705,7/15/2014 23:18:08,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CONTRAINDICATES],[CONTRAINDICATES],was correlated,N/A,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/15/2014 23:27:41,,1323906398,7/15/2014 23:27:33,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],correlated with,N/A,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/16/2014 00:10:34,,1323930135,7/16/2014 00:10:16,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlated,n/a,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/16/2014 00:28:54,,1323940455,7/16/2014 00:28:30,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was significantly correlated with,N/A,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/16/2014 00:51:33,,1323951393,7/16/2014 00:50:26,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/16/2014 00:55:40,,1323954078,7/16/2014 00:54:34,prodege,1.0,15287417,CAN,ON,Maple,99.248.137.57,[PART_OF],[PART_OF],was significantly correlated with,N/A,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/16/2014 00:58:04,,1323955330,7/16/2014 00:57:53,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],in the,N/A,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/16/2014 01:14:52,,1323965620,7/16/2014 01:14:44,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],CEREBELLUM,N/A,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/16/2014 01:54:25,,1323983741,7/16/2014 01:53:12,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],correlated with AI in the,na,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/16/2014 02:19:42,,1323997097,7/16/2014 02:19:16,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],correlated,Na,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/16/2014 02:51:12,,1324008214,7/16/2014 02:50:25,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],CEREBELLAR ATAXIA in CEREBELLUM,N/A,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/16/2014 05:27:20,,1324066828,7/16/2014 05:26:55,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],in the,N/A,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384222,7/16/2014 07:06:53,,1324098980,7/16/2014 07:06:36,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],CEREBELLAR ATAXIA was significantly correlated in the CEREBELLUM,N/a,80,18,89,35,1,RO-has_finding_site,905449-FS1,The laterality of CEREBELLAR ATAXIA was significantly correlated with AI in the CEREBELLUM in patients with sOPCA.,CEREBELLUM,CEREBELLAR ATAXIA
503384223,7/15/2014 23:09:01,,1323896045,7/15/2014 23:08:40,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[SYMPTOM],[SYMPTOM],defined,N/A,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/15/2014 23:09:09,,1323896117,7/15/2014 23:09:01,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],than,N/A,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/15/2014 23:20:21,,1323902379,7/15/2014 23:19:28,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],defined,N/A,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/15/2014 23:25:10,,1323905083,7/15/2014 23:24:34,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],can be defined as,N/A,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/15/2014 23:26:59,,1323906027,7/15/2014 23:26:01,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],passage more than,N/A,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/15/2014 23:29:20,,1323907230,7/15/2014 23:29:08,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],defined,N/A,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/15/2014 23:57:18,,1323921644,7/15/2014 23:57:02,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[TREATS],[TREATS],DIARRHEA be,asds,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/16/2014 00:01:01,,1323923648,7/15/2014 23:59:01,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[SYMPTOM],[SYMPTOM],can be defined as,N/A,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/16/2014 00:46:38,,1323948839,7/16/2014 00:46:06,elite,1.0,27788262,USA,"","",172.163.6.138,[IS_A],[IS_A],can be defined as,N/A,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/16/2014 00:59:42,,1323956430,7/16/2014 00:58:52,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[LOCATION],[LOCATION],CHRONIC DIARRHEA defined as passage 3 LOOSE STOOLS,N/A,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/16/2014 01:32:00,,1323975343,7/16/2014 01:31:31,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[IS_A],[IS_A],defined as,na,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/16/2014 01:50:54,,1323982284,7/16/2014 01:49:39,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],defined,none,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/16/2014 02:20:18,,1323997338,7/16/2014 02:20:04,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],defined as,Na,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/16/2014 02:41:40,,1324005217,7/16/2014 02:41:16,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",passage of more than 3 LOOSE STOOLS,n/a,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384223,7/16/2014 03:10:33,,1324014834,7/16/2014 03:09:04,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",CHRONIC DIARRHEA LOOSE STOOLS,n/a,62,0,73,16,1,RO-has_definitional_manifestation,904910-FS1,CHRONIC DIARRHEA can be defined as the passage of more than 3 LOOSE STOOLS per day during more than 4 weeks.,LOOSE STOOLS,CHRONIC DIARRHEA
503384224,7/15/2014 23:15:27,,1323899560,7/15/2014 23:14:45,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],Long term efficacy tolerability CANDESARTAN CILEXETIL patients moderate HYPERTENSION,Treats,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/15/2014 23:16:48,,1323900238,7/15/2014 23:15:52,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],efficacy tolerability,N/A,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/15/2014 23:19:29,,1323901895,7/15/2014 23:19:08,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],efficacy and tolerability of,N/A,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/15/2014 23:41:45,,1323913610,7/15/2014 23:41:10,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with mild to moderate,n/a,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/15/2014 23:57:42,,1323921818,7/15/2014 23:57:12,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[TREATS],[TREATS],efficacy and tolerability of CANDESARTAN CILEXETIL in patients,N/A,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/16/2014 01:14:43,,1323965543,7/16/2014 01:14:35,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],mild to moderate,N/A,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/16/2014 02:14:11,,1323994129,7/16/2014 02:13:28,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],Long term efficacy and tolerability of in patients with mild to moderate,na,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/16/2014 02:29:16,,1324001083,7/16/2014 02:28:54,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES],[CAUSES],mild to moderate,n/a,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/16/2014 04:47:34,,1324051918,7/16/2014 04:46:50,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",tolerability CANDESARTAN CILEXETIL patients with HYPERTENSION,N/A,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/16/2014 05:11:53,,1324061952,7/16/2014 05:11:13,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",Long term efficacy and tolerability of,N/A,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/16/2014 05:25:12,,1324066256,7/16/2014 05:24:35,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],Long term efficacy and tolerability of in patients with mild to moderate,N/A,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/16/2014 06:34:00,,1324087406,7/16/2014 06:33:43,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],Long term efficacy and tolerability,n/a,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/16/2014 07:38:55,,1324109473,7/16/2014 07:38:18,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.7,[OTHER],[OTHER],efficacy and tolerability,N/A,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/16/2014 09:12:59,,1324136608,7/16/2014 09:12:37,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CANDESARTAN CILEXETIL HYPERTENSION,n/a,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384224,7/16/2014 10:02:37,,1324170320,7/16/2014 10:00:27,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[TREATS],[TREATS],efficacy tolerability,n/A,117,61,128,82,1,RO-may_treat,907902-FS1,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
503384225,7/15/2014 23:08:20,,1323895585,7/15/2014 23:07:35,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],present,N/A,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/15/2014 23:18:29,,1323901212,7/15/2014 23:17:59,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],unusual,n/a,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/15/2014 23:24:50,,1323904905,7/15/2014 23:24:23,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],with an unusual pattern,N/A,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/16/2014 00:19:27,,1323936026,7/16/2014 00:19:04,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],with an unusual pattern of,n/a,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/16/2014 00:42:50,,1323947104,7/16/2014 00:42:17,elite,1.0,27788262,USA,"","",172.163.6.138,[NONE],[NONE],N/A,ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/16/2014 00:53:24,,1323952557,7/16/2014 00:52:13,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],pattern,N/A,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/16/2014 01:22:50,,1323970561,7/16/2014 01:22:16,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,na,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/16/2014 02:18:38,,1323996585,7/16/2014 02:18:23,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],unusual pattern,Na,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/16/2014 03:21:24,,1324018426,7/16/2014 03:20:16,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],ADRENAL PHEOCHROMOCYTOMA PERIODIC ALTERNATING HYPERTENSION,n/a,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/16/2014 07:07:36,,1324099318,7/16/2014 07:07:16,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],a patient with an ADRENAL PHEOCHROMOCYTOMA with PERIODIC ALTERNATING HYPERTENSION,N/a,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/16/2014 07:43:11,,1324110543,7/16/2014 07:42:47,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with an unusual pattern of,n/a,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/16/2014 08:03:58,,1324116688,7/16/2014 08:03:38,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[SYMPTOM],[SYMPTOM],unusual pattern,N/A,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/16/2014 08:12:16,,1324118956,7/16/2014 08:11:21,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[MANIFESTATION],[MANIFESTATION],with an unusual pattern of,"because of ""a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION""",81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/16/2014 09:10:15,,1324135624,7/16/2014 09:09:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",with,n/a,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384225,7/16/2014 10:56:05,,1324196049,7/16/2014 10:55:36,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with an unusual pattern of,N/A,81,29,113,53,1,RO-disease_may_have_finding,902699-FS1,We present a patient with an ADRENAL PHEOCHROMOCYTOMA with an unusual pattern of PERIODIC ALTERNATING HYPERTENSION and hypotension.,PERIODIC ALTERNATING HYPERTENSION,ADRENAL PHEOCHROMOCYTOMA
503384226,7/15/2014 23:10:28,,1323896946,7/15/2014 23:10:20,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],presenting,N/A,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/15/2014 23:11:30,,1323897486,7/15/2014 23:10:10,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],CHRONIC MIGRAINE common form HEADACHE,Is A,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/15/2014 23:15:33,,1323899573,7/15/2014 23:14:37,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",is presenting in,N/A,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/15/2014 23:24:01,,1323904391,7/15/2014 23:23:40,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],common form of,N/A,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/15/2014 23:35:07,,1323910283,7/15/2014 23:34:44,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],common,N/A,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/15/2014 23:51:06,,1323918527,7/15/2014 23:50:42,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[MANIFESTATION],[MANIFESTATION],common disabling,asd,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/16/2014 00:12:47,,1323931607,7/16/2014 00:12:30,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],common form,n/a,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/16/2014 00:21:45,,1323937113,7/16/2014 00:21:11,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",form of disabling headache,[PREVENTS] [TREATS],70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/16/2014 00:41:22,,1323946446,7/16/2014 00:40:56,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],is a common form of,N/A,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/16/2014 01:27:09,,1323973131,7/16/2014 01:26:42,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[IS_A],[IS_A],is,na,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/16/2014 02:21:04,,1323997638,7/16/2014 02:20:31,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[IS_A],[IS_A],is a common form of disabling headache presenting in,na,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/16/2014 04:08:36,,1324039257,7/16/2014 04:07:59,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHRONIC MIGRAINE HEADACHE,n/a,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/16/2014 04:17:41,,1324043421,7/16/2014 04:17:08,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[PART_OF],[PART_OF],common form of disabling headache,N/A,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/16/2014 04:53:22,,1324054074,7/16/2014 04:51:14,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[LOCATION] [MANIFESTATION] [PART_OF] [IS_A],"[LOCATION]
[MANIFESTATION]
[IS_A]
[PART_OF]",CHRONIC MIGRAINE common form disabling headache presenting in HEADACHE subspecialty practice.,N/A,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384226,7/16/2014 05:02:06,,1324058593,7/16/2014 05:01:34,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],subspecialty,N/A,70,0,77,16,1,RO-has_definitional_manifestation,904636-FS1,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
503384227,7/15/2014 23:29:55,,1323907569,7/15/2014 23:29:34,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with acute illnesses,N/A,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/15/2014 23:30:10,,1323907700,7/15/2014 23:29:29,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],associated,N/A,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/15/2014 23:40:08,,1323912885,7/15/2014 23:39:33,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],HEADACHES associated acute illnesses precursor MIGRAINE,Is A,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/16/2014 03:35:31,,1324023225,7/16/2014 03:34:53,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHES MIGRAINE,n/a,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/16/2014 04:59:50,,1324057508,7/16/2014 04:57:00,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[SIDE_EFFECT] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",HEADACHES associated acute illnesses precursor later MIGRAINE,N/A,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/16/2014 07:41:54,,1324110202,7/16/2014 07:41:34,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,[SYMPTOM],[SYMPTOM],may be a precursor to,n/a,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/16/2014 08:06:32,,1324117372,7/16/2014 08:06:17,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/16/2014 11:54:44,,1324216095,7/16/2014 11:53:38,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[IS_A],[IS_A],associated,N/A,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/16/2014 12:21:05,,1324225064,7/16/2014 12:19:49,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[CAUSES],[CAUSES],to later,N/A,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/16/2014 12:53:44,,1324238617,7/16/2014 12:53:25,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],may be precursor to later,n/a,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/16/2014 12:54:57,,1324239130,7/16/2014 12:54:38,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],precursor to,n/a,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/16/2014 13:02:02,,1324242114,7/16/2014 13:01:34,instagc,1.0,14378608,USA,NY,Brooklyn,24.189.101.95,[CAUSES] [SYMPTOM] [ASSOCIATED_WITH],"[CAUSES]
[SYMPTOM]
[ASSOCIATED_WITH]",HEADACHES acute illnesses MIGRAINE,They may later cause migraines,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/16/2014 13:13:13,,1324246607,7/16/2014 13:12:43,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],precursor to later,na,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/16/2014 13:27:33,,1324252510,7/16/2014 13:25:07,tremorgames,1,18832393,GBR,C5,Runcorn,90.195.197.162,[IS_A] [TREATS],"[TREATS]
[IS_A]",HEADACHES MIGRAINE,N/A,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384227,7/16/2014 14:18:30,,1324272930,7/16/2014 14:18:18,zoombucks,1,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],precursor,N/A,0,70,8,78,-1,RO-has_definitional_manifestation,904999-FS1,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
503384228,7/15/2014 23:13:54,,1323898781,7/15/2014 23:13:48,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],enhance,n/a,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/15/2014 23:16:25,,1323899969,7/15/2014 23:15:34,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],can be divided,N/A,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/15/2014 23:27:20,,1323906187,7/15/2014 23:26:50,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[NONE],[NONE],N/A,Medication and Tolerance are two words that have no direct link between each other.,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/15/2014 23:33:36,,1323909575,7/15/2014 23:31:55,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],enhance,N/A,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/16/2014 00:12:00,,1323931122,7/16/2014 00:11:15,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],MEDICATIONS that enhance metabolic TOLERANCE,Treats,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/16/2014 00:17:25,,1323934798,7/16/2014 00:16:49,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],that enhance metabolic,[CAUSES],185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/16/2014 00:41:08,,1323946375,7/16/2014 00:39:51,elite,1.0,27788262,USA,"","",172.163.6.138,[TREATS],[TREATS],that enhance,N/A,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/16/2014 01:30:52,,1323974853,7/16/2014 01:30:23,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[TREATS],[TREATS],enhance,na,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/16/2014 02:15:20,,1323994806,7/16/2014 02:14:38,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],enhance,none,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/16/2014 03:22:27,,1324018714,7/16/2014 03:21:29,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MEDICATIONS TOLERANCE,n/a,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/16/2014 03:48:04,,1324029059,7/16/2014 03:47:34,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MEDICATIONS TOLERANCE,n/a,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/16/2014 07:01:03,,1324096334,7/16/2014 07:00:46,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],MEDICATIONS that enhance metabolic,N/a,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/16/2014 08:15:16,,1324119963,7/16/2014 08:14:33,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[TREATS],[TREATS],MEDICATIONS that enhance metabolic,"because of:

MEDICATIONS that enhance metabolic TOLERANCE",185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/16/2014 11:02:44,,1324198042,7/16/2014 11:02:11,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],MEDICATIONS that enhance metabolic TOLERANCE,N/A,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384228,7/16/2014 11:47:22,,1324213572,7/16/2014 11:46:18,clixsense,1.0,6621167,USA,IL,Round Lake,24.12.122.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,185,220,195,229,1,RO-has_causative_agent,903789-FS1,"Overall, they can be divided into: a) medications that act on the inflammatory response triggered by ischemia/reperfusion, such as anti CD11/CD18 antibodies and anti complement, and b) MEDICATIONS that enhance metabolic TOLERANCE such as glucose insulin potassium solution and inhibitors of the Na+/H+ ion exchange system.",MEDICATIONS,TOLERANCE
503384229,7/15/2014 23:10:40,,1323897017,7/15/2014 23:10:30,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],the,N/A,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/15/2014 23:59:56,,1323923075,7/15/2014 23:59:43,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],established recording,asd,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 00:34:25,,1323943234,7/16/2014 00:34:13,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[CAUSES],[CAUSES],TOLERANCE,N/A,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 01:17:43,,1323967317,7/16/2014 01:15:35,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[OTHER],[OTHER],development of TOLERANCE,N/A,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 01:45:49,,1323980387,7/16/2014 01:45:10,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],action,none,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 02:05:37,,1323989425,7/16/2014 02:03:21,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated things,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 06:11:21,,1324079729,7/16/2014 06:10:21,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[MANIFESTATION],[MANIFESTATION],action of,n/a,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 06:19:48,,1324082792,7/16/2014 06:19:04,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[CAUSES],[CAUSES],to the analgesic action,because of TOLERANCE to the analgesic action of the DRUG,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 07:00:30,,1324096138,7/16/2014 07:00:08,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],recording the development of TOLERANCE to,N/a,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 09:15:40,,1324137612,7/16/2014 09:15:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TOLERANCE DRUG,n/a,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 10:04:27,,1324171750,7/16/2014 10:02:38,bitcoinget,1.0,28222930,USA,IL,Charleston,67.58.235.205,[SIDE_EFFECT],[SIDE_EFFECT],development of,N/A,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 10:54:12,,1324195431,7/16/2014 10:53:26,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],TOLERANCE to the analgesic action of the DRUG,N/A,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 12:02:52,,1324218992,7/16/2014 12:02:38,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,talking about drug tolerance,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 12:09:27,,1324221234,7/16/2014 12:08:22,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],action of the,N/A,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384229,7/16/2014 12:49:21,,1324236608,7/16/2014 12:48:58,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],analgesic action of,n/a,113,72,116,81,1,RO-has_causative_agent,903548-FS1,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
503384230,7/15/2014 23:13:29,,1323898543,7/15/2014 23:12:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",reveals,N/A,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/15/2014 23:17:21,,1323900560,7/15/2014 23:16:42,instagc,1.0,28301350,GBR,O4,Torquay,89.241.101.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reveals,N/A,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/15/2014 23:19:12,,1323901717,7/15/2014 23:19:06,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],DCIS,n/a,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/15/2014 23:20:15,,1323902315,7/15/2014 23:19:42,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],reveals,N/A,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/15/2014 23:31:45,,1323908583,7/15/2014 23:31:33,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reveals,N/A,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/15/2014 23:35:35,,1323910512,7/15/2014 23:35:08,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],reveals,N/A,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/15/2014 23:46:04,,1323915819,7/15/2014 23:45:26,clixsense,1.0,15189335,GBR,H9,London,188.29.164.122,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reveals,Na,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/15/2014 23:46:41,,1323916182,7/15/2014 23:46:22,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES],[CAUSES],reveals,n/a,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/15/2014 23:53:23,,1323919624,7/15/2014 23:52:45,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],remaining,asd,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/16/2014 00:09:33,,1323929365,7/16/2014 00:09:17,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],reveals,n/a,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/16/2014 01:14:07,,1323965096,7/16/2014 01:13:58,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reveals,N/A,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/16/2014 01:25:33,,1323972364,7/16/2014 01:24:58,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.160,[SYMPTOM],[SYMPTOM],reveals,na,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/16/2014 04:17:07,,1324043200,7/16/2014 04:16:42,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reveals,N/A,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/16/2014 04:56:58,,1324056065,7/16/2014 04:56:06,neodev,1.0,20929875,USA,MA,Allston,71.174.190.73,[MANIFESTATION],[MANIFESTATION],biopsy remaining CALCIFICATIONS reveals DCIS,N/A,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
503384230,7/16/2014 05:17:23,,1324063863,7/16/2014 05:16:56,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],reveals,N/A,38,61,51,65,1,RO-disease_may_have_finding,902978-FS1,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
